<?xml version="1.0" encoding="UTF-8"?>
<!--Arbortext, Inc., 1988-2012, v.4002-->
<article xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:noNamespaceSchemaLocation="http://internal.acs.org/ACSJournal/JATS-archive-oasis-article1-mathml3.xsd"
         article-type="research-article"
         dtd-version="1.1d1">
   <front>
      <journal-meta>
         <journal-id journal-id-type="acspubs">jm</journal-id>
         <journal-id journal-id-type="coden">jmcmar</journal-id>
         <journal-title-group>
            <journal-title>Journal of Medicinal Chemistry</journal-title>
            <abbrev-journal-title>J. Med. Chem.</abbrev-journal-title>
         </journal-title-group>
         <issn pub-type="ppub">0022-2623</issn>
         <issn pub-type="epub">1520-4804</issn>
         <publisher>
            <publisher-name>American Chemical
Society</publisher-name>
         </publisher>
         <self-uri>pubs.acs.org/jmc</self-uri>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1021/jm501212r</article-id>
         <article-categories>
            <subj-group subj-group-type="document-type-name">
               <subject>Perspective</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Inhibitors of c‑Jun N‑Terminal Kinases:
An Update</article-title>
         </title-group>
         <contrib-group id="CONTRIB-GROUP-d2969e28-autogenerated">
            <contrib contrib-type="author" corresp="yes" id="ath1">
               <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>Pierre</given-names>
               </name>
               <xref rid="cor1"/>
               <xref rid="notes-1"/>
            </contrib>
            <contrib contrib-type="author" id="ath2">
               <name name-style="western">
                  <surname>Gehringer</surname>
                  <given-names>Matthias</given-names>
               </name>
               <xref rid="notes-1"/>
            </contrib>
            <contrib contrib-type="author" corresp="yes" id="ath3">
               <name name-style="western">
                  <surname>Laufer</surname>
                  <given-names>Stefan A.</given-names>
               </name>
               <xref rid="cor2"/>
            </contrib>
            <aff id="aff1"><institution id="d16e55" content-type="dept">Department
of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences</institution>, <institution>Eberhard Karls Universität Tübingen</institution>, <addr-line content-type="street-address">Auf der Morgenstelle 8</addr-line>, <addr-line content-type="postal-code">72076</addr-line> <addr-line content-type="city">Tübingen</addr-line>, <country>Germany</country></aff>
         </contrib-group>
         <author-notes>
            <corresp id="cor1"><label>*</label>P.K.: phone, <phone>+49 7071 29-74579</phone>; e-mail, <email>pierre.koch@uni-tuebingen.de</email>.</corresp>
            <corresp id="cor2"><label>*</label>S.A.L.: phone, <phone>+49 7071
29-72459</phone>; e-mail, <email>stefan.laufer@uni-tuebingen.de</email>.</corresp>
         </author-notes>
         <pub-date pub-type="epub">
            <day>21</day>
            <month>11</month>
            <year>2014</year>
         </pub-date>
         <pub-date pub-type="ppub">
            <day>08</day>
            <month>01</month>
            <year>2015</year>
         </pub-date>
         <volume>58</volume>
         <issue>1</issue>
         <issue-title>New Frontiers in Kinases</issue-title>
         <fpage>72</fpage>
         <lpage>95</lpage>
         <history><date date-type="received"><day>06</day><month>08</month><year>2014</year></date><date date-type="asap"><day>08</day><month>12</month><year>2014</year></date><date date-type="issue-pub"><day>08</day><month>01</month><year>2015</year></date><date date-type="just-accepted"><day>21</day><month>11</month><year>2014</year></date></history>
         <permissions>
            <copyright-statement>Copyright © 2014 American Chemical Society</copyright-statement>
            <copyright-year>2014</copyright-year>
            <copyright-holder>American Chemical Society</copyright-holder>
         </permissions>
         <abstract>
            <p content-type="toc-graphic"><graphic xlink:href="jm-2014-01212r_0032.tif" id="tgr1" orientation="portrait" position="float"/></p>
            <p content-type="abstract-graphic"><graphic xlink:href="jm-2014-01212r_0033.tif" orientation="portrait" position="float"/></p>
            <p>The
c-Jun N-terminal kinases (JNKs) are serine/threonine kinases
implicated in the pathogenesis of various diseases. Recent advances
in the development of novel inhibitors of JNKs will be reviewed. Significant
progress in the design of JNK inhibitors displaying selectivity versus
other kinases has been achieved within the past 4 years. However,
the development of isoform selective JNK inhibitors is still an open
task.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>document-id-old-9</meta-name>
               <meta-value>jm501212r</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>document-id-new-14</meta-name>
               <meta-value>jm-2014-01212r</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="sec1">
         <title>Introduction</title>
         <p>Protein kinases are a large and diverse
multigene family of enzymes,
which represent about 1.7% of the human genome and mediate most of
the signal transduction events in eukaryotic cells by phosphorylating
target proteins. The c-Jun N-terminal kinases (JNKs, also known as
stress-activated protein kinases) phosphorylate different substrates
in response to cellular stress stimuli and proinflammatory cytokines
such as tumor necrosis factor α (TNF-α) and interleukin
1β (IL-1β). Several proteins have been identified as JNK
substrates including c-Jun, activating transcription factor 2 (ATF-2),
and the JNK-interacting protein 1 (JIP-1).<xref rid="ref1" ref-type="bibr"/> JNKs are serine/threonine kinases belonging to the family of mitogen-activated
protein (MAP) kinases. Three genes, namely, <italic toggle="yes">jnk1</italic> (<italic toggle="yes">MAPK8</italic>), <italic toggle="yes">jnk2</italic> (<italic toggle="yes">MAPK9</italic>),
and <italic toggle="yes">jnk3</italic> (<italic toggle="yes">MAPK10</italic>), encode for 10
different splice variants with molecular weights of 46 and 55 kDa.<named-content content-type="bibref-group"><xref rid="ref2" ref-type="bibr"/>−<xref rid="ref3" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref4" ref-type="bibr"/></named-content> While JNK1 and JNK2 are spliced into four variants (JNK1/2-α1,-α2,
-β1, and -β2), only two splice isoforms of JNK3 (JNK3-α1
and -α2) are known. Those splice variants differ in the amino
acid sequence of the subdomains IX and X<xref rid="ref5" ref-type="bibr"/> (α and β), while α2 and β2 variants have
a C-terminus, which is extended by 43 amino acids compared to α1
and β1 variants.<named-content content-type="bibref-group"><xref rid="ref6" ref-type="bibr"/>,<xref rid="ref7" ref-type="bibr"/></named-content> The JNKs are activated by two
different upstream kinases, MAP kinase kinase (MKK) 4 and MKK7, by
phosphorylation of the Thr183 and Tyr185 (JNK1/JNK2 numbering) residues
present in a conserved Thr-Pro-Tyr motif located in the activation
loop.<xref rid="ref3" ref-type="bibr"/> JNK1 and JNK2 are ubiquitously expressed,
while the expression of JNK3 is mainly restricted to the brain and,
to a less extent, to the heart and testis.<xref rid="ref8" ref-type="bibr"/></p>
         <p>Among all JNKs, the ATP-binding site is highly conserved (Figure <xref rid="fig1"/>). Moreover, the JNKs are closely related to other
members of the mitogen-activate protein (MAP) kinase family, especially
the p38α and p38β MAP kinases and the extracellular-regulated
kinase (ERK) 2. Thus, the design of JNK-selective and especially of
JNK isoform-selective inhibitors is a considerable challenge.</p>
         <fig id="fig1" position="float" orientation="portrait">
            <label>1</label>
            <caption>
               <p>(a) General
structure of the JNKs (generated from the PDB structure <ext-link ext-link-type="pdb" xlink:href="3TTJ"/>) and the p38 MAP
kinases. Residues contributing to the binding cleft are depicted as
spheres, and the colors were chosen according to the sequence alignment
below. (b) Differences in the ATP binding site of JNK3 and the p38α
MAP kinase. Residues discriminating between the two kinases and their
contribution to the binding pocket are depicted in red. The key difference
between JNKs and p38α MAP kinase is found in the gatekeeper
residue (Met vs Thr, highlighted in magenta) and the cysteine flanking
the solvent exposed front region (Cys vs Asn, highlighted in yellow).
The latter serves as a target for covalent inhibitors. The images
were generated with PyMOL.<xref rid="ref9" ref-type="bibr"/> (c) Sequence
alignment of the residues surrounding the ATP binding site in the
JNKs and p38α MAP kinase. Differing amino acids are highlighted
with darker colors.</p>
            </caption>
            <graphic xlink:href="jm-2014-01212r_0001.tif"
                     id="gr1"
                     position="float"
                     orientation="portrait"/>
         </fig>
      </sec>
      <sec id="sec2">
         <title>JNKs as Therapeutic Targets</title>
         <p>Studies using knockout mice lacking one or more specific JNK isoforms
revealed the role of each isoform in the development and progression
of various disorders.<xref rid="ref10" ref-type="bibr"/> The JNKs are implicated
in numerous diseases ranging from central nervous system (CNS) disorders
to inflammation and cancer.</p>
         <sec id="sec2.1">
            <title>CNS Disorders</title>
            <p>Neurodegenerative
diseases, like Parkinson’s
disease (PD), Alzheimer’s disease (AD), Huntington’s
disease (HD), and multiple sclerosis (MS), are complex disorders,
and distinct targets involved in the progression of these diseases
have been identified. Because of the restricted expression pattern
of JNK3, the role of this kinase in various CNS disorders has been
evaluated in numerous knockout studies. JNK3 activity is typically
low in the brain but increases when abnormalities in the cerebral
metabolism occur.</p>
            <p>Increased JNK activity has been detected in
the post-mortem analysis of brains from AD patients.<named-content content-type="bibref-group"><xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/></named-content> Amyloid-β deposits (plaques) are a central pathological feature
of AD. A study of Yoon et al. showed that JNK3 modifies the amyloid
precursor protein (APP), which results in a stimulation of amyloid-β
42 (Aβ42) peptide production.<xref rid="ref13" ref-type="bibr"/> Genetic
depletion of JNK3 in familial AD (FAD) mice resulted in a dramatic
reduction in Aβ42 peptide levels and overall plaque loads as
well as in an increased number of neurons and improved cognition providing
a rational for JNK3 inhibition in the treatment of AD.</p>
            <p>JNK3
is also associated with PD, a chronic, progressive neurodegenerative
disorder characterized by motor dysfunctions that are caused by the
loss of dopaminergic neurons. The post-mortem analysis of PD patient
brains revealed that JNK activity was increased resulting in higher
levels of phosphorylated c-Jun compared to matched control patients.<named-content content-type="bibref-group"><xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/></named-content> A study by Hunot et al. showed
that JNK3, JNK2, and especially JNK3/2 knockout mice, but not JNK1
knockout and wild type mice, were resistant to acute 1-methyl-4-phenyltetrahydropyridine
(MPTP) intoxication, a common model of PD.<xref rid="ref14" ref-type="bibr"/> Moreover, double JNK3/JNK2 knockout mice showed a significantly
decreased loss of dopaminergic neurons in the substantia nigra pars
compacta (SNpc) and increased levels of striatal dopamine compared
to wild type mice treated with MPTP.</p>
            <p>The survival of dopaminergic
neurons in the SNpc after injection
of 6-hydroxydopamine (6-OHDA), another common model of PD,<named-content content-type="bibref-group"><xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/></named-content> was significantly higher in JNK3 knockout compared to wild-type
mice.<xref rid="ref17" ref-type="bibr"/> A nonsignificant protective effect
on these neurons was observed in the same study using JNK2 knockout
mice, whereas JNK1 knockout had no effect on neuronal survival. These
data raise the question of whether a JNK3 selective or a dual JNK2/JNK3
selective inhibitor might be preferable for the treatment of PD.</p>
         </sec>
         <sec id="sec2.2">
            <title>Inflammation</title>
            <p>The phosphorylation of the transcription
factor ATF-2 by JNKs triggers the release of proinflammatory cytokines,
like TNF-α and IL-1β.<xref rid="ref18" ref-type="bibr"/> JNK
inhibition might therefore be a promising strategy for the treatment
of cytokine driven diseases like rheumatoid arthritis (RA), inflammatory
bowel disease (IBD), and psoriasis.</p>
            <p>Although JNK2 was revealed
as the key determinant of matrix degradation in a model of passive
murine collagen induced arthritis using JNK2-knockout mice, the absence
of this isoform had little influence on inflammation and paw swelling.<xref rid="ref19" ref-type="bibr"/> In a recent study analyzing the impact of JNK1
and JNK2 on antigen-induced arthritis, JNK-1-deficient, but not JNK-2-deficient
mice showed a reduction in inflammatory cell infiltration and joint
damage.<xref rid="ref20" ref-type="bibr"/></p>
         </sec>
         <sec id="sec2.3">
            <title>Cancer</title>
            <p>Upstream
enzymes and downstream substrates of
JNKs are involved in the development and progression of different
cancer types.<named-content content-type="bibref-group"><xref rid="ref21" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/></named-content> Members of the activation protein
1 (AP1) group of transcription factors, like ATF-2 and c-Jun, are
implicated in deregulation of growth and tumor progression.<xref rid="ref23" ref-type="bibr"/></p>
            <p>Investigation of the particular role of
JNK1 or JNK2 in different knockout models of cancer led to contradictory
findings. In some cases, JNKs acted as a tumor suppressor, whereas
other studies support a pro-oncogenic function of JNKs.<named-content content-type="bibref-group"><xref rid="ref21" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/></named-content> For example, JNK1 knockout mice were more susceptible to skin tumors
induced by the tumor promoter 12-<italic toggle="yes">O</italic>-tetradecanoylphorbol
13-acetate (TPA) than wild-type mice.<xref rid="ref24" ref-type="bibr"/> On the other side, JNK2 knockout mice had a lower papilloma multiplicity
induced by TPA than wild-type mice.<xref rid="ref25" ref-type="bibr"/> Papillomas
on wild-type mice grew rapidly and were well vascularized compared
with JNK2-deficient mice.<xref rid="ref25" ref-type="bibr"/></p>
            <p>In contrast,
in a diethylnitrosamine-phenobarbital-induced mouse
liver cancer model, JNK1-knockout mice developed fewer and smaller
liver tumors than JNK2-knockout and wild-type mice.<xref rid="ref26" ref-type="bibr"/></p>
            <p>These findings underline the need for the development
of isoform
selective JNK inhibitors in order to define the specific role of the
particular isoforms in both inhibition and promotion of cancer.</p>
         </sec>
         <sec id="sec2.4">
            <title>Other Diseases</title>
            <p>Besides the above-mentioned diseases,
JNK family kinases are implicated in various other pathological processes
and have been investigated as targets for cardiovascular diseases
and metabolic disorders.<named-content content-type="bibref-group"><xref rid="ref27" ref-type="bibr"/>,<xref rid="ref28" ref-type="bibr"/></named-content></p>
            <p>It has been shown
that <italic toggle="yes">jnk3</italic> depletion protects from brain injury after
cerebral ischemia/hypoxia, suggesting JNK3 as a target for neuroprotective
therapies in stroke.<named-content content-type="bibref-group"><xref rid="ref29" ref-type="bibr"/>,<xref rid="ref30" ref-type="bibr"/></named-content> A more recent study proved that <italic toggle="yes">jnk1</italic><sup>–/–</sup> and <italic toggle="yes">jnk2</italic><sup>–/–</sup> mice are less prone to cellular apoptosis
in vivo following ischemia/reperfusion injury,<xref rid="ref31" ref-type="bibr"/> while a similar study paradoxically concluded that JNK1
inactivation was protective against apoptosis and infarction caused
by extended but not by short-term ischemia.<xref rid="ref32" ref-type="bibr"/> Furthermore, it was recently shown that inhibiting the mitochondrial
localization and signaling of JNKs protects against ischemia/reperfusion
injury in rats and may thus be an effective treatment to prevent ischemia/reperfusion-induced
cardiomyocyte death.<xref rid="ref33" ref-type="bibr"/> As a consequence
of those and other studies, JNK inhibitors have been developed for
the treatment of ischemia/reperfusion injury in humans and one compound,
discussed later in this review, was tested in early clinical trials.<xref rid="ref8" ref-type="bibr"/></p>
            <p>Early reports on JNK signaling in metabolic
disorders highlighted
the potential role of JNKs as targets for diabetes therapy.<named-content content-type="bibref-group"><xref rid="ref34" ref-type="bibr"/>,<xref rid="ref35" ref-type="bibr"/></named-content> Knockout studies linking JNK1 to diabetes mellitus type 2 revealed
that JNK1-deficient mice are protected from developing high-fat diet-induced
obesity, glucose intolerance, and insulin resistance.<xref rid="ref36" ref-type="bibr"/> In contrast, JNK2 is believed to play a central role in
type 1 diabetes.<xref rid="ref37" ref-type="bibr"/> Several compound series
were developed to address those disorders; however, no clinical studies
have been initiated to date.<named-content content-type="bibref-group"><xref rid="ref38" ref-type="bibr"/>−<xref rid="ref39" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref40" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref41" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref42" ref-type="bibr"/></named-content></p>
            <p>JNK1 and JNK2 were also demonstrated to play an important
role
in liver physiology and pathogenesis, as they regulate the accumulation
of reactive oxygen species (ROS), insulin signaling, and carcinogenesis
via multiple pathways.<xref rid="ref1" ref-type="bibr"/> There is evidence
that TNF-induced hepatocyte cell death is prevented by JNK1 disruption<xref rid="ref43" ref-type="bibr"/> while JNK2, but not JNK1 disruption prevents
acetaminophen induced liver injury.<xref rid="ref44" ref-type="bibr"/> A
central role of JNKs in ischemia/reperfusion liver injury, liver fibrosis,
and liver regeneration is also discussed.<xref rid="ref1" ref-type="bibr"/></p>
            <p>The implication of JNK family kinases in sensory hair cell
death
led to the development of JNK inhibitors for the treatment of hearing
loss.<xref rid="ref45" ref-type="bibr"/> The peptidic JNK inhibitor XG-102
(AM-111, <sc>d</sc>-JNKI-1) from Xigen containing 31 <sc>d</sc>-configured
amino acids was extensively characterized in animal models.<named-content content-type="bibref-group"><xref rid="ref46" ref-type="bibr"/>,<xref rid="ref47" ref-type="bibr"/></named-content></p>
            <p>Further indications involving JNKs as potential targets include
pulmonary fibrosis,<xref rid="ref48" ref-type="bibr"/> arteriosclerosis<xref rid="ref49" ref-type="bibr"/> and neuroprotection after spinal cord injury.<xref rid="ref50" ref-type="bibr"/></p>
            <p>However, in all the pathologies discussed
above, the distinct role
of each JNK isoform is vague and studies sometimes come to conflicting
conclusions. Consequently, there is an urgent need for isoform selective
inhibitors with a favorable in vivo profile as molecular probes to
complement knockout animal studies.</p>
         </sec>
      </sec>
      <sec id="sec3">
         <title>JNK Inhibitors</title>
         <p>Protein kinases have become attractive targets within the past
2 decades. Currently, more than 25 kinase inhibitors were introduced
to the market. Except the Janus kinase inhibitor tofacitinib, all
inhibitors were launched for the treatment of cancer. Most of them
are poorly selective within the kinome, leading to side effects, which
might be tolerable in terms of treating cancer but not for chronic
application.</p>
         <p>The design of selective kinase inhibitors is challenging
because
of structural similarity in the ATP binding site, which is the target
of most kinase inhibitors. When aiming for chronic treatment, e.g.,
of inflammation, metabolic, or CNS disorders, those compounds require
a clean and safe profile. For compounds targeting CNS disorders, there
is the added challenge of penetrating the blood–brain barrier,
a property that remained largely unexplored in kinase drug discovery
during the previous decades.</p>
         <p>Inhibition of JNKs is an attractive
therapeutic strategy that has
been investigated with considerable recent effort from both the pharmaceutical
industry and academia. The development of JNK inhibitors prior to
2010 has been extensively reviewed by Siddiqui and Reddy in this journal.<xref rid="ref51" ref-type="bibr"/> The current review provides an update to this
account from a medicinal chemist’s perspective covering the
design and discovery of novel JNK inhibitors with details about structure–activity
relationships and the hit-to-lead optimization. Finally, an outlook
discussing the future directions and unaddressed challenges is provided.
Other recent overviews of JNK inhibitors have been published by Graczyk<xref rid="ref10" ref-type="bibr"/> in 2013 and by Bogoyevitch et al.<xref rid="ref52" ref-type="bibr"/> in 2010.</p>
         <p>Within the past years, few small
molecule inhibitors of JNKs have
entered clinical trials for different indications. Recently, a phase
IIa proof of concept study of the pan-JNK inhibitor bentamapimod (PGL5001,
AS602801)<named-content content-type="bibref-group"><xref rid="ref53" ref-type="bibr"/>,<xref rid="ref54" ref-type="bibr"/></named-content> for the treatment of inflammatory endometriosis
has been terminated.<xref rid="ref55" ref-type="bibr"/> A second JNK inhibitor, <bold>1</bold> (CC-930, tanzisertib, Figure <xref rid="fig3"/>),<xref rid="ref56" ref-type="bibr"/> has reached phase II clinical trials for the
treatment of idiopathic pulmonary fibrosis and discoid lupus erythematosus.<xref rid="ref57" ref-type="bibr"/> Inhibitor <bold>1</bold> will be discussed in
the section <xref rid="sec3.2">Diaminopurines</xref> below. The peptidic
JNK inhibitor XG-102 has recently completed a phase II clinical trial
in patients with acute sensorineural hearing loss and has also been
investigated in clinical trials for the treatment of inflammation
and stroke.<named-content content-type="bibref-group"><xref rid="ref58" ref-type="bibr"/>−<xref rid="ref59" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref60" ref-type="bibr"/></named-content> In contrast to ATP-competitive inhibitors, the peptide-based
inhibitor XG-102 targets a docking site of downstream substrates or
scaffolding proteins. Xigen announced that a phase II study of XG-102
in the field of ophthalmology is currently ongoing.<xref rid="ref61" ref-type="bibr"/></p>
         <sec id="sec3.1">
            <title>SP600125: An Early JNK Inhibitor</title>
            <p>The ATP competitive
pan-JNK inhibitor SP600125 (<bold>2</bold>) from Celgene was one of
the first small molecule inhibitors reported for this target class
(Figure <xref rid="fig2"/>).<xref rid="ref62" ref-type="bibr"/> Compound <bold>2</bold> has been investigated in various studies aiming to clarify
the particular role of JNKs in different diseases.<named-content content-type="bibref-group"><xref rid="ref63" ref-type="bibr"/>−<xref rid="ref64" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref65" ref-type="bibr"/></named-content> Despite the
fact that anthrapyrazolone <bold>2</bold> inhibits multiple kinases,<xref rid="ref66" ref-type="bibr"/> this inhibitor is worth mentioning, since it
still serves as the reference compound in biological JNK assays.<named-content content-type="bibref-group"><xref rid="ref67" ref-type="bibr"/>−<xref rid="ref68" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref69" ref-type="bibr"/></named-content></p>
            <fig id="fig2" position="float" orientation="portrait">
               <label>2</label>
               <caption>
                  <p>Structure
and IC<sub>50</sub> values of pan-JNK inhibitor SP600125.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0002.tif"
                        id="gr2"
                        position="float"
                        orientation="portrait"/>
            </fig>
         </sec>
         <sec id="sec3.2">
            <title>Diaminopurines</title>
            <p>A more recent class
of JNK inhibitors
was reported in 2012 by researchers from Celgene. In two studies,
Krenitsky et al. developed trisubstituted 2,8-diaminopurines as JNK
inhibitors for the prevention of ischemia/reperfusion injury and for
the treatment of idiopathic pulmonary fibrosis (IPF).<named-content content-type="bibref-group"><xref rid="ref56" ref-type="bibr"/>,<xref rid="ref70" ref-type="bibr"/></named-content> Notably, similar structures have also been reported to inhibit wild
type EGFR and its T790M drug resistance mutant.<xref rid="ref71" ref-type="bibr"/> Starting from high throughput screening (HTS) hit <bold>3</bold>, which displayed poor kinase selectivity, the residues in
the C<sup>2</sup>, C<sup>8</sup>, and N<sup>9</sup> position of the
9<italic toggle="yes">H</italic>-purine scaffold were optimized to obtain several
potent JNK inhibitors with up to 500-fold selectivity against p38α
MAP kinase (Figure <xref rid="fig3"/>).<xref rid="ref70" ref-type="bibr"/></p>
            <fig id="fig3" position="float" orientation="portrait">
               <label>3</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values
of diaminopurine JNK inhibitors.
Footnote is the following: <sup><italic toggle="yes">a</italic></sup>Inhibition
of c-Jun phosphorylation in Jurkat T cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0003.tif"
                        id="gr3"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Screening hit <bold>3</bold> was cocrystallized with JNK3
to gain
further insight into the binding mode of this substance class (PDB
code <ext-link ext-link-type="pdb" xlink:href="3TTJ"/>, Figure <xref rid="fig4"/>a). The heteroaryl scaffold binds to the hinge region
of the kinase via a bidentate hydrogen bond involving the purine N<sup>3</sup> and the Leu148 backbone NH function as well as the secondary
purine C<sup>2</sup> amino substituent and the backbone carbonyl of
Met149. The cyclopentyl moiety occupies the ribose pocket, while the
C<sup>2</sup> anilino residue fills the solvent exposed front region
(hydrophobic region II)<xref rid="ref72" ref-type="bibr"/> with the <italic toggle="yes">p</italic>-methoxy substituent pointing toward the solvent. The C<sup>8</sup> anilino fragment is buried in the hydrophobic back pocket
(hydrophobic region I), forming a water-mediated hydrogen bond toward
the Lys93 side chain amino function. Interestingly, the Met146 gatekeeper
residue is shifted 2.3 Å from its position in the JNK3 apo-structure
(PDB code <ext-link ext-link-type="pdb" xlink:href="4KKG"/>), allowing the C<sup>8</sup> anilino moiety to penetrate the hydrophobic
region I. This back pocket is often termed “selectivity pocket”
because it significantly differs between kinases (even within the
highly conserved JNK family, Figure <xref rid="fig1"/>) and
thus was systematically explored by the authors. Despite those efforts,
the key modification to increase kinome selectivity was replacing
the C<sup>2</sup> anilino substituent with a cycloalkylamine. Metabolic
stability could be increased by introducing additional fluorine substituents
to the C<sup>8</sup> anilino residue, which did not have a major impact
on the potency and intra-JNK selectivity. Additional SAR studies on
the N<sup>9</sup> substituent revealed that cyclic alkyl substituents
were best suited at this position.</p>
            <p>In the report focusing on
prevention of ischemia/reperfusion injury,
compound <bold>4</bold> (CC-359) was further profiled.<xref rid="ref70" ref-type="bibr"/> It potently inhibited all JNK isoforms while
being approximately 10-fold selective against p38α (Figure <xref rid="fig3"/>). Kinome selectivity was assessed at 10 μM
against a panel of 75 kinases and a GINI selectivity score<xref rid="ref73" ref-type="bibr"/> of 0.82 was found for <bold>3</bold>, indicating
good selectivity within this subset of the kinome. The compound inhibited
cellular c-Jun phosphorylation and LPS-induced TNF-α release
in rat whole blood (IC<sub>50</sub> = 1.5 μM). Dosed iv at 3
and 10 mg/kg, <bold>4</bold> demonstrated efficacy in a rat ischemia/reperfusion
model. While the PK profile of <bold>4</bold> in dogs and rats was
poor, it proved to be appropriate in monkeys with a slow iv clearance
of 5 mL min<sup>–1</sup> kg<sup>–1</sup> and a half-life
of 37 min at a 1 mg/kg dose. Showing no CYP inhibition at 30 μM
while moderately inhibiting the hERG channel (59% at 10 μM), <bold>4</bold> was well tolerated in vivo (rat) and claimed as a clinical
candidate. However, none of the announced studies have been published
to date.</p>
            <p>The second study from the same authors focused on the
development
of antifibrotic JNK inhibitors. The key compound <bold>1</bold> (CC-930)
comprises a metabolically stable 2,4,6-trifluoroanilino substituent
at the purine C<sup>8</sup> position and a <italic toggle="yes">trans</italic>-4-hydroxycyclohexyl­amino
substituent at the C<sup>2</sup>-position.<xref rid="ref56" ref-type="bibr"/> The N<sup>9</sup> cyclopentyl moiety contained in <bold>3</bold> was replaced by a chiral 3-tetrahydrofuranyl residue. The <italic toggle="yes">S</italic>-enantiomer was identified as the eutomer with higher affinity
for JNK2/3, moderate selectivity against JNK1, and excellent selectivity
against p38α MAP kinase.</p>
            <fig id="fig4" position="float" orientation="portrait">
               <label>4</label>
               <caption>
                  <p>(a) Superimposition of the X-ray crystal
structure of compound <bold>3</bold> in complex with JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="3TTJ"/>, pale green) and
apo-JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="4KKG"/>, blue). (b) Superimposition
of the X-ray crystal structure of compound <bold>1</bold> in complex
with JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="3TTI"/>, salmon) and the JNK3-AMP complex (PDB code <ext-link ext-link-type="pdb" xlink:href="4KKE"/>, blue). Both structures
feature an induced fit of the Met146 gatekeeper residue. The sulfur
atom is shifted 2.1/2.4 Å from its position in the AMP-bound/apo-structure,
opening up the hydrophobic region I to host the fluorinated anilino
moiety. The image was generated using PyMOL and the AMP ligand of <ext-link ext-link-type="pdb" xlink:href="4KKE"/> was omitted for
clarity.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0004.tif"
                        id="gr4"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Inhibitor <bold>1</bold> was crystallized
in complex with JNK3
(PDB code <ext-link ext-link-type="pdb" xlink:href="3TTI"/>) and displayed a similar binding mode as observed in the <bold>3</bold>/JNK3 crystal structure (Figure <xref rid="fig4"/>). According
to this crystal structure, the difference in potency and selectivity
between the two enantiomers is predominantly caused by electrostatic
interactions. The tetrahydrofuranyl moiety altered the physicochemical
properties of the compound, leading to improved cellular potency.
Despite the high clearance in rats, compound <bold>1</bold> was slowly
metabolized in dogs and monkeys and displayed a favorable overall
PK profile. Selectivity within a panel of 240 kinases was remarkable,
as EGFR (IC<sub>50</sub> = 0.38 μM) and ERK1 (IC<sub>50</sub> = 0.48 μM) were the only kinases impacted at an IC<sub>50</sub> value below 3 μM. Furthermore, no targets were significantly
hit in a screen against 75 receptors and 22 diverse non-kinase enzymes.
CYPs were hardly influenced; <bold>4</bold> was AMES-negative and
marginally inhibited hERG channels in vitro. Two phase II clinical
trials initiated in 2011 in patients with IPF and discoid lupus erythematosus
(DLE) were terminated because of an inappropriate benefit/risk profile.<xref rid="ref55" ref-type="bibr"/> The compounds developed by Celgene were not
intended to target the CNS, and consequently, blood–brain barrier
penetration was not assessed. Although meeting the Lipinski rule of
five,<xref rid="ref74" ref-type="bibr"/> the physicochemical properties
of those molecules suggest negligible CNS penetration.<xref rid="ref75" ref-type="bibr"/> However, it cannot be ruled out that central
JNK inhibition might partially be responsible for the unfavorable
side effect profile leading to the discontinuation of those clinical
trials.</p>
         </sec>
         <sec id="sec3.3">
            <title>Azaindoles</title>
            <p>A series of 7-azaindole-derived pan-JNK
inhibitors was reported from Graczyk et al. from Eisai in a recent
review and several preceding patent applications.<named-content content-type="bibref-group"><xref rid="ref10" ref-type="bibr"/>,<xref rid="ref76" ref-type="bibr"/>,<xref rid="ref77" ref-type="bibr"/></named-content> The prototype inhibitor <bold>5</bold> (ER-358063)<xref rid="ref76" ref-type="bibr"/> was potent but moderately selective across the
kinome with a GINI selectivity score of 0.34 (Figure <xref rid="fig5"/>). A significant improvement of clinical symptoms was observed
in an experimental autoimmune encephalomyelitis (EAE) mouse model,
a murine in vivo model for MS,<xref rid="ref78" ref-type="bibr"/> when <bold>5</bold> was dosed at 20 mg kg<sup>–1</sup> day<sup>–1</sup>. It was also observed that compound <bold>5</bold> protected against
the loss of white matter and neurons in the lumbar spinal cord. However,
side effects associated with <bold>5</bold> led to the further assessment
of less potent but more selective compounds <bold>6</bold> (ER-409903)
and <bold>7</bold> (ER-417258) with GINI scores of 0.72 and 0.77,
respectively.<xref rid="ref77" ref-type="bibr"/></p>
            <fig id="fig5" position="float" orientation="portrait">
               <label>5</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of 7-azaindole JNK inhibitors.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0005.tif"
                        id="gr5"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Compounds <bold>6</bold> and <bold>7</bold> were claimed
to possess
a favorable overall PK profile, good oral bioavailability and brain
penetration, and high selectivity in a screen against 270 receptor
proteins. In mice, compounds <bold>6</bold> and <bold>7</bold> had
similar efficiency as <bold>5</bold> and an improved side effect profile.
Unfortunately, no additional numerical data were provided in the peer
reviewed literature, complicating the comparison of those compounds
with other JNK inhibitors.<xref rid="ref10" ref-type="bibr"/></p>
         </sec>
         <sec id="sec3.4">
            <title>Pyrazolylureas</title>
            <p>A substantial body of work in the field
of JNK inhibitors has been contributed by the research groups of LoGrasso
and Kamenecka at the Scripps Research Institute. In joint efforts,
these academic groups developed several series of JNK inhibitors with
varying selectivity profiles primarily focusing on CNS applications.
Many of the compounds were able to penetrate the blood–brain
barrier, and one compound, SR-3306, was preclinically characterized
using different animal models for PD and ischemia/reperfusion injury.<named-content content-type="bibref-group"><xref rid="ref33" ref-type="bibr"/>,<xref rid="ref79" ref-type="bibr"/>−<xref rid="ref80" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref81" ref-type="bibr"/></named-content> Earlier work of those groups on bicyclic bis-arylimidazoles<xref rid="ref82" ref-type="bibr"/> as well as on 3,5-disubstituted quinolones<xref rid="ref83" ref-type="bibr"/> will not be discussed in this review.</p>
            <p>Very potent inhibitors based on a pyrazol-4-ylurea scaffold were
identified in the laboratories of those two groups. Initial work has
been focused on the development of indazole-derived inhibitors exemplified
by the previously published compound <bold>8</bold> (SR-3737, Figure <xref rid="fig6"/>).<xref rid="ref84" ref-type="bibr"/> Compound <bold>8</bold> inhibits JNK1 and JNK3 with IC<sub>50</sub> values of 73 and 9 nM,
respectively, but suffers from poor penetration of the blood–brain
barrier.<xref rid="ref85" ref-type="bibr"/> Modifications were carried out
at the anilide as well as the aniline portion of the molecule. In
general, examples bearing <italic toggle="yes">N</italic>-arylamides poorly penetrated
into the CNS, while the introduction of aliphatic amide side chains,
e.g., <bold>9</bold> and <bold>10</bold>, resulted in a decreased
inhibitory activity compared to <bold>8</bold>.<xref rid="ref85" ref-type="bibr"/> These modifications nevertheless improved CNS penetration
and resulted in higher drug concentrations in the brain than in plasma
(determined at <italic toggle="yes">t</italic> = 2 h after ip administration).</p>
            <fig id="fig6" position="float" orientation="portrait">
               <label>6</label>
               <caption>
                  <p>Structures
and IC<sub>50</sub> values of 1-aryl-5-anilinoindazoles.
Footnote is the following: <sup><italic toggle="yes">a</italic></sup>p38 isoform
not reported. <sup><italic toggle="yes">b</italic></sup>Inhibition of c-Jun phosphorylation
in INS-1 cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0006.tif"
                        id="gr6"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Select compounds were
further tested in a cell-based in vitro assay
(INS-1 cells) for their ability to inhibit JNK3. These compounds showed
a considerable decrease in potency in the cellular setting (e.g., <bold>9</bold>, IC<sub>50</sub> = 5.3 μM). In this series, compound <bold>10</bold> showed the best pharmacokinetic (PK) profile in rat, having
a moderate oral absorption (<italic toggle="yes">F</italic> = 27%), a short half-life
of 3.3 min, and a clearance of 25 mL min<sup>–1</sup> kg<sup>–1</sup> (dosed at 1 mg/kg, iv, and 2 mg/kg po).</p>
            <p>Because
none of the compounds shown in Figure <xref rid="fig6"/> provided
sufficient selectivity against p38 MAP kinase (isoform
not reported), the indazole core was exchanged by a pyrazol-4-ylurea
system allowing for specific tuning of selectivity (Figure <xref rid="fig7"/>).</p>
            <fig id="fig7" position="float" orientation="portrait">
               <label>7</label>
               <caption>
                  <p>Scaffold hopping from indazole to pyrazolylurea JNK inhibitors:
structures and IC<sub>50</sub> values of <bold>8</bold>, <bold>11</bold>, and <bold>12</bold>. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>The p38 isoform was not reported. <sup><italic toggle="yes">b</italic></sup>Inhibition of c-Jun phosphorylation in INS-1 cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0007.tif"
                        id="gr7"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>The rationale behind this replacement strategy
was the assumption
that the sp<sup>2</sup>-like nature of the urea would maintain a planar
arrangement similar to the indazoles leading to comparable binding
modes and affinities. Within this pyrazol-4-ylurea series, compound <bold>11</bold> (SR-3576) was particularly potent and exhibited more than
2800-fold selectivity against p38 MAP kinase.<xref rid="ref84" ref-type="bibr"/> Despite the excellent biochemical potency, the compound was a moderate
inhibitor of c-Jun phosphorylation in INS-1 cells (IC<sub>50</sub> = 1.3 μM), presumably because of insufficient cell penetration.
To rationalize the gain in selectivity against p38 MAP kinase, <bold>8</bold> and <bold>12</bold> (SR-3451) were soaked on JNK3 crystals
and the X-ray crystal structure was determined (PDB codes <ext-link ext-link-type="pdb" xlink:href="3FI3"/> and <ext-link ext-link-type="pdb" xlink:href="3FI2"/>).<xref rid="ref84" ref-type="bibr"/> Both inhibitors were anchored to the hinge region via two
hydrogen bonds and displayed a similar type I binding mode.<xref rid="ref86" ref-type="bibr"/> Similar to the cocrystal structure of the aforementioned
trisubstituted diaminopurines, a movement of the gatekeeper Met146
enables the anilino residue to occupy the hydrophobic back pocket.
The authors claim that this induced fit binding mode is responsible
for the moderate JNK3 selectivity of both inhibitors, since the hydrophobic
region I is lined with slightly different amino acids in JNK1 versus
JNK3 (compare to Figure <xref rid="fig1">1</xref>; Ile106 vs Leu144).
However, no strong rationale is provided explaining the selectivity
against p38 MAP kinase.</p>
         </sec>
         <sec id="sec3.5">
            <title>Aminopyrimidines and Related Scaffolds</title>
            <p>The largest
group of JNK inhibitors established by Kamenecka et al. was derived
from a 2-aminopyrimidine scaffold<xref rid="ref87" ref-type="bibr"/> and
is structurally related to the approved kinase inhibitor imatinib.<xref rid="ref88" ref-type="bibr"/> Preliminary studies describing the use of aminopyrimidines
with distinct substitution patterns as potent JNK inhibitors to treat
inflammatory disorders and diabetes mellitus type 2 have been reported
by researchers from UCB Celltech<xref rid="ref89" ref-type="bibr"/> and
Pfizer.<xref rid="ref38" ref-type="bibr"/> Although highly potent against
JNK family kinases, these early compounds mainly suffered from poor
selectivity against CDK2 as well as other kinases or from poor cellular
potency. As the compounds were developed for peripheral applications,
the ability to penetrate the CNS was not investigated. In contrast,
the studies from Kamenecka et al. focused on achieving brain penetration
and cellular potency while maintaining a clean selectivity profile.
In an initial report, weakly active 2-aminopyrimidine <bold>13</bold> was used to evaluate the kinetic mechanism of ATF-2 phosphorylation
by JNK3 (Figure <xref rid="fig8"/>).<xref rid="ref90" ref-type="bibr"/> From a subsequent extensive SAR study comprising about 500 2-aminopyrimidine
derivatives, 12 selected examples with high selectivity against p38
MAP kinase were further profiled.<xref rid="ref87" ref-type="bibr"/> The
most potent compound <bold>14</bold> exhibited IC<sub>50</sub> values
in the low nanomolar range against JNK1 and JNK3 while being virtually
inactive on p38 MAP kinase (JNK2 was not assessed).<xref rid="ref87" ref-type="bibr"/> Despite being reasonably potent in INS-1 cells, <bold>14</bold> suffered from poor brain penetration probably because of its high
polar surface area (PSA calcd: 123 Å<sup>2</sup>).<xref rid="ref91" ref-type="bibr"/></p>
            <fig id="fig8" position="float" orientation="portrait">
               <label>8</label>
               <caption>
                  <p>Structures and biological data of aminopyrimidine-derived
JNK inhibitors
from Kamenecka et al. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup><italic toggle="yes">K</italic><sub>i</sub> value. <sup><italic toggle="yes">b</italic></sup>IC<sub>50</sub> value. <sup><italic toggle="yes">c</italic></sup>The p38
isoform was not reported. <sup><italic toggle="yes">d</italic></sup>Inhibition
of c-Jun phosphorylation in INS-1 cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0008.tif"
                        id="gr8"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Compound <bold>15</bold> (SR-3562) was less potent in the
in vitro
enzyme assay but exhibited increased cell penetration leading to the
strongest inhibition of cellular c-Jun phosphorylation within this
series.<xref rid="ref87" ref-type="bibr"/> The compound showed good oral
bioavailability in rats (<italic toggle="yes">F</italic> = 45%) and was able to
penetrate the blood–brain barrier as indicated by a brain/plasma
ratio of 75%. (Remark: The exclusive use of the brain/plasma ratio
as a measure for CNS availability has been questioned and might be
misleading.<xref rid="ref92" ref-type="bibr"/>) Plasma protein binding in
mouse, rat, dog, monkey, and human was high (92–98%), and the
compound showed reasonable stability in liver microsomes. In vivo
studies in rats indicated a favorable PK profile with a half-life
of 2.4 h and a clearance of 20 mL min<sup>–1</sup> kg<sup>–1</sup> (1 mg/kg dose, iv). Furthermore, compound <bold>15</bold> proved
to be a subnanomolar inhibitor of ROS generation in INS-1 cells. The
major liability of <bold>15</bold> was the inhibition of several CYP450
enzymes; e.g., CYP450 2C9, 3A4, and 1A2 were inhibited between 70%
and 90% at 10 μM inhibitor concentration.</p>
            <fig id="fig9" position="float" orientation="portrait">
               <label>9</label>
               <caption>
                  <p>(a) Overlay of the X-ray
crystal structures of <bold>15</bold> bound
to JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="3KVX"/>, cyan) and the JNK3 crystal structures from Scarpin et al. (PDB
code <ext-link ext-link-type="pdb" xlink:href="1PMN"/>, magenta)
and Alam et al. (PDB code <ext-link ext-link-type="pdb" xlink:href="2P33"/>, gray) generated with PyMOL. The induced fit of the
gatekeeper residue and the glycine-rich loop is highlighted, and the
ligand from Scarpin et al. has been omitted for clarity. (b, c) Comparison
of the 3D-pharmacophores of <bold>15</bold> and the structurally related
inhibitor from Alam et al. While <bold>15</bold> exclusively binds
via hydrophobic interactions, the compound from Alam et al. is anchored
to the kinase by four hydrogen bonds, two of them involving the aminopyrimidine
scaffold. 3D pharmacophores were extracted from the respective crystal
structures using LigandScout.<xref rid="ref93" ref-type="bibr"/> Hydrophobic
interactions are displayed as yellow spheres, and hydrogen bonds are
depicted as red (acceptor) and green (donor) arrows.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0009.tif"
                        id="gr9"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>The X-ray crystal structure of <bold>15</bold> bound
to JNK3 (PDB
code <ext-link ext-link-type="pdb" xlink:href="3KVX"/>)<xref rid="ref94" ref-type="bibr"/> revealed an unexpected binding mode exclusively
relying on hydrophobic interactions (Figure <xref rid="fig9"/>a). The compound bound JNK3 with a highly planar arrangement of the
aromatic cycles, and remarkably, it did not form any hydrogen bonds
with the enzyme. The inhibitor did not induce a displacement of the
Met146 gatekeeper side chain as observed in other JNK crystal structures.<named-content content-type="bibref-group"><xref rid="ref56" ref-type="bibr"/>,<xref rid="ref70" ref-type="bibr"/>,<xref rid="ref95" ref-type="bibr"/>−<xref rid="ref96" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref97" ref-type="bibr"/></named-content> Instead, the
glycine-rich loop was collapsed toward the active site by 2.5 Å
compared to a structure published by Scarpin et al. (PDB code <ext-link ext-link-type="pdb" xlink:href="1PMN"/>).<xref rid="ref97" ref-type="bibr"/> The compression of the binding pocket is discussed as the
driver of selectivity. In contrast, related aminopyrimidines released
by Alam et al. formed a bidentate hydrogen bond between the 2-aminopyrimidine
core and the hinge region of the kinase (Figure <xref rid="fig9"/>c).<xref rid="ref89" ref-type="bibr"/> In addition, another hydrogen bond
is formed from the Asn152 backbone NH function to the urea carbonyl
of the compound supplemented by one water-mediated hydrogen bond between
the compounds indole NH and the Lys93 side chain. Unlike the series
from Kamenecka et al., those 2-aminopyridines caused a movement of
the gatekeeper residue while not dropping the glycine rich loop toward
the ATP binding cleft (PDB code <ext-link ext-link-type="pdb" xlink:href="2P33"/>).<xref rid="ref89" ref-type="bibr"/></p>
            <fig id="fig10" position="float" orientation="portrait">
               <label>10</label>
               <caption>
                  <p>Structures
and IC<sub>50</sub> values of aminopyrimidine JNK inhibitors
evaluated in animal models for neurodegeneration and ischemia/reperfusion
injury. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>The p38 isoform was not reported. <sup><italic toggle="yes">b</italic></sup>Inhibition
of c-Jun phosphorylation in INS-1 cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0010.tif"
                        id="gr10"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>In two follow-up studies, Chambers
and Crocker et al. characterized <bold>16</bold> (SR-3306), a compound
from the 2-aminopyrimidine series
not included in the previous publication, in several in vitro an in
vivo models for PD (Figure <xref rid="fig10"/>).<named-content content-type="bibref-group"><xref rid="ref79" ref-type="bibr"/>,<xref rid="ref80" ref-type="bibr"/></named-content> Compound <bold>16</bold> inhibited the JNKs in vitro with potencies
similar to <bold>15</bold> and retained the high selectivity against
p38 MAP kinase but was approximately 4 times less potent in a cellular
setting. According to the authors, an X-ray crystal structure of <bold>16</bold> in complex with JNK3 has been determined; however, it has
not yet been published. Inhibitor <bold>16</bold> was profiled at
3 μM against a panel of 347 kinases<xref rid="ref98" ref-type="bibr"/> and proved to be moderately selective. Thirty-five out of the tested
kinases were hit (no other member of the MAP kinase family except
JNK1 and JNK3), and four of the kinases tested (KIT, KIT V559D, PDGFR-β,
TYK2) suggested <italic toggle="yes">K</italic><sub>D</sub> values below 1 μM.
The compound possessed IC<sub>50</sub> values of &gt;30 μM for
the hERG channel and &gt;50 μM against nine CYP enzymes tested
(1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), making it superior
to <bold>15</bold> for in vivo studies. Testing close analogue <bold>17</bold> (SR-2502)<xref rid="ref87" ref-type="bibr"/> with similar potency
and p38 MAP kinase selectivity against a panel of 67 receptors, ion
channels, and transporters (MDS Pharma Lead Profiling Screen) proved
that this compound class is highly selective against non-kinase targets.
Only the adenosine A<sub>2A</sub> and A<sub>3</sub> receptors showed
significant inhibition at 10 μM (55% and 93%). However, the
authors did not state why they used <bold>17</bold> instead of <bold>16</bold> in this off-target screen. With a brain/plasma ratio of
30–40% and an overall PK profile very similar to <bold>17</bold>, compound <bold>16</bold> was promoted as a development candidate.
It exhibited a neuroprotective effect against MPP<sup>+</sup>-induced
cell death<xref rid="ref99" ref-type="bibr"/> in primary dopaminergic neurons,
and greater than 90% neuroprotection was observed in this model at
a concentration of 300 nM (the number of TH-positive neurons was reduced
in the presence of 10 μM MPP<sup>+</sup> and absence of the
inhibitor by approximately 50%). After application of a single oral
dose (30 mg/kg) to mice, the inhibitor concentration remained above
the cell based &gt;90% neuroprotective concentration for more than
8
h.<xref rid="ref79" ref-type="bibr"/> Furthermore, inhibitor <bold>16</bold> (30 mg/kg, oral) protected dopaminergic neurons in the SNpc of mice
intoxicated with MPTP.</p>
            <p>A second in vivo study using <bold>16</bold> focused on behavioral
improvement in a rat 6-OHDA model of PD.<named-content content-type="bibref-group"><xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/></named-content> While no protection of dopamine terminals in the striatum was detected
using the MPTP rat model, protection of both dopaminergic neurons
in the SNpc and their projections to the striatum was observed in
the 6-OHDA model (10 mg kg<sup>–1</sup> day<sup>–1</sup>, sc).<xref rid="ref80" ref-type="bibr"/> Furthermore, protection of about
30% of the dopaminergic neurons in the SNpc caused a 90% reduction
of behavioral deficits as assessed by <sc>d</sc>-amphetamine induced
circling.<xref rid="ref100" ref-type="bibr"/> Recently, a third in vivo
study demonstrated <bold>16</bold> to protect effectively against
ischemia/reperfusion injury in rats, reducing the infarct volume by
34% at a moderate dose of 5 mg/kg.<xref rid="ref33" ref-type="bibr"/></p>
            <p>The 2-aminopyrimidine series was complemented by a library of 2-amino-4-(pyrazol-3-yl)­pyridines
with reasonable PK and brain penetration. While compounds without
substituents in the pyrazole C<sup>4</sup>-position (e.g., <bold>18</bold>) were selective against p38 MAP kinase, a 4-fluorophenyl moiety
(<bold>19</bold>) significantly enhanced JNK inhibition while also
reducing p38 MAP kinase selectivity (Figure <xref rid="fig11"/>).<xref rid="ref101" ref-type="bibr"/></p>
            <fig id="fig11" position="float" orientation="portrait">
               <label>11</label>
               <caption>
                  <p>Structures, IC<sub>50</sub> values, and
PK data of aminopyridine
JNK inhibitors. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>The p38 isoform was not reported. <sup><italic toggle="yes">b</italic></sup>Brain/plasma ratio in mice. <sup><italic toggle="yes">c</italic></sup>PK in rats.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0011.tif"
                        id="gr11"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Owing to the structural similarity
between <bold>19</bold> and
pyridinylimidazole-derived p38α MAP kinase inhibitors, a similar
binding mode accounting for the decrease in selectivity seems probable.<xref rid="ref102" ref-type="bibr"/> The brain/plasma ratio of <bold>19</bold> compared
unfavorably to <bold>15</bold> and <bold>16</bold>, and the overall
PK profile was inferior as well. On the other hand, <bold>18</bold> offers better brain penetration and an enhanced PK profile, making
this compound class a valid starting point for further optimization.</p>
            <fig id="fig12" position="float" orientation="portrait">
               <label>12</label>
               <caption>
                  <p>Design
of aminoquinazoline JNK inhibitors as hybrid of aminopyrimidines
and aminoisoquinolines. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup><italic toggle="yes">K</italic><sub>i</sub> value. <sup><italic toggle="yes">b</italic></sup>IC<sub>50</sub> value. <sup><italic toggle="yes">c</italic></sup>Inhibition of c-Jun phosphorylation in INS-1 cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0012.tif"
                        id="gr12"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Structurally similar inhibitors based on a 2-aminoquinazoline
scaffold
were established by He et al.<xref rid="ref103" ref-type="bibr"/> These
compounds were designed as hybrids combining the previously mentioned
2-aminopyrimidines<xref rid="ref87" ref-type="bibr"/> and a class of 3-aminoisoquinolines
(e.g., <bold>20</bold>) from patent literature (Figure <xref rid="fig12"/>).<xref rid="ref104" ref-type="bibr"/> The initial lead compound <bold>21</bold> is a potent inhibitor of JNK1/3 in vitro, which moderately
inhibited c-Jun phosphorylation in INS-1 cells and showed a reasonable
brain/plasma ratio of 40%.<xref rid="ref103" ref-type="bibr"/> Unfortunately,
selectivity against p38 MAP kinase was not evaluated except for the
key compound. Studying the SAR of this compound class revealed that
introduction of a substituent to the quinazoline core in the position
ortho to the pyrazole moiety increased potency and certain compounds
possessed an increased brain/plasma ratio as well. The authors did
not provide a structural rationale for the observed SAR, but it can
be speculated that a torsional bias of the pyrazole ring caused by
the ortho substituent, in combination with increased lipophilicity,
might account for the SAR observed.</p>
            <p>Among the molecules presented
in this study, compounds <bold>22</bold> and <bold>23</bold> proved
to be the most potent ones (Figure <xref rid="fig13"/>).<xref rid="ref103" ref-type="bibr"/> Because of its
superior enrichment in the CNS, less active compound <bold>24</bold> was further profiled.<xref rid="ref103" ref-type="bibr"/> It exhibited
an adequate PK profile with a half-life of 3 h and an oral bioavailability
of 19% in rats.</p>
            <fig id="fig13" position="float" orientation="portrait">
               <label>13</label>
               <caption>
                  <p>Structures, IC<sub>50</sub> values, and PK data of aminoquinazoline
JNK inhibitors. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>Inhibition of c-Jun phosphorylation in INS-1 cells. <sup><italic toggle="yes">b</italic></sup>Brain/plasma ratio in mice.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0013.tif"
                        id="gr13"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Inspired by an earlier report on 2-phenoxy substituted 4-anilinopyrimidines,<xref rid="ref40" ref-type="bibr"/> a structurally related class of pyridines and
pyrimidines was established by Song et al.<xref rid="ref105" ref-type="bibr"/> Starting from compound <bold>25</bold>, initial modifications were
focused on substituents in the pyridine C<sup>5</sup>-position and
at the phenoxy moiety (Figure <xref rid="fig14"/>). While a
chlorine atom (<bold>26</bold>) or a trifluoromethyl group (<bold>27</bold>) proved to be the most favorable pyridine C<sup>5</sup> substituents, alkoxy residues in the para-position were the most
suited decoration for the phenoxy moiety.<xref rid="ref105" ref-type="bibr"/> Insertion of a nitrogen atom in <bold>26</bold> gave pyrimidine <bold>28</bold>,<xref rid="ref105" ref-type="bibr"/> the most potent analog within
this compound set.</p>
            <fig id="fig14" position="float" orientation="portrait">
               <label>14</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of phenoxyanilinopyridine
and phenoxyanilinopyrimidine JNK inhibitors. The dashed line indicates
an intermolecular hydrogen bond.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0014.tif"
                        id="gr14"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>These inhibitors are speculated to bind JNK3 in similar fashion
as the 4-anilinopyrimidines from Liu et al. (PDB code <ext-link ext-link-type="pdb" xlink:href="2NO3"/>),<xref rid="ref40" ref-type="bibr"/> but neither crystallographic data nor molecular modeling
confirming this hypothesis was provided. However, it is likely that
the carboxamide group and the adjacent diarylamine adopt a periplanar
conformation, which is stabilized by an intramolecular hydrogen bond. <bold>26</bold> and <bold>27</bold> showed good oral bioavailability and
a reasonable brain/plasma ratio (75% and 52% for <bold>26</bold> and <bold>27</bold>). The compound with the most favorable overall PK profile
was <bold>27</bold> (<italic toggle="yes">t</italic><sub>1/2</sub> = 1 h and <italic toggle="yes">F</italic> = 79% in rat), while <bold>28</bold> suffered from poor
in vivo PK. Unfortunately, no cellular potency data were reported.</p>
            <p>In a follow-up study aiming toward JNK2 inhibitors for the treatment
of glioblastoma multiforme (GBM), an extremely potent class of 2,4-dianilinopyrimidines
was established by Song et al.<xref rid="ref106" ref-type="bibr"/> The initial
pyridine-derived lead compound <bold>29</bold> was extensively modified
to obtain highly potent pyrimidine analogs <bold>30</bold> and <bold>31</bold> strongly resembling compound classes from Abbott<xref rid="ref40" ref-type="bibr"/> and Novartis (Figure <xref rid="fig15"/>).<named-content content-type="bibref-group"><xref rid="ref107" ref-type="bibr"/>,<xref rid="ref108" ref-type="bibr"/></named-content> In vitro potency in the biochemical assay
could be further enhanced by replacing the morpholino side chain by
a pyrrolidonyl residue giving <bold>32</bold>, one of the most active
JNK inhibitors reported to date.<xref rid="ref106" ref-type="bibr"/> Unfortunately, <bold>32</bold> possessed a poor PK profile and neither cellular nor JNK1
inhibition data were reported. The best brain penetration was observed
for <bold>30</bold> (brain/plasma ratio of 100%), while <bold>31</bold> was very potent in cells and had the most favorable overall PK profile
(<italic toggle="yes">t</italic><sub>1/2</sub> = 1 h and <italic toggle="yes">F</italic> = 30%
in rat, <italic toggle="yes">B</italic>/<italic toggle="yes">P</italic> = 17% in mouse).</p>
            <fig id="fig15" position="float" orientation="portrait">
               <label>15</label>
               <caption>
                  <p>Structures
and IC<sub>50</sub> values of dianilinopyridine and
dianilinopyrimidine JNK inhibitors. Footnote is the following: <sup><italic toggle="yes">a</italic></sup>Inhibition of c-Jun phosphorylation in INS-1
cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0015.tif"
                        id="gr15"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Another series of aminopyrimidines
was recently reported from researchers
at Roche (Figure <xref rid="fig16"/>).<xref rid="ref109" ref-type="bibr"/> Since both JNK1 and JNK2 might be important for immune-modulatory
function,<xref rid="ref19" ref-type="bibr"/> the investigators aimed to
design dual JNK1/JNK2 inhibitors for potential treatment of RA. Initial
hit <bold>33</bold> was originated from another kinase program.<xref rid="ref110" ref-type="bibr"/> Compound <bold>33</bold> shows some selectivity
for JNKs versus CDKs and no inhibition of p38α MAP kinase. The
phosphorylation of c-Jun in SW1353 cells was inhibited by <bold>33</bold> in the low micromolar range.<xref rid="ref109" ref-type="bibr"/> Some
benzotriazolyl aminopyrimidines showed high affinity for cytochrome
P450 enzymes. Replacement of 1,2,3-benzotriazole group by an indazole
or indole ring resulted in compounds with improved selectivity profiles
and no CYP liabilities. Within the indazole series, potency was increased
by introduction of substituents in the 4-position, e.g., compound <bold>34</bold>.<xref rid="ref109" ref-type="bibr"/> Crystallographic data of <bold>34</bold> complexed with JNK1 revealed that the methylsulfonylpropoxy
moiety properly fills the space underneath the glycine-rich loop (PDB
code <ext-link ext-link-type="pdb" xlink:href="4HYU"/>).
Each oxygen atom of the sulfone group is involved in hydrogen bonding
to Lys55 and Gln37. Similar to the structure from Alam et al. (Figure <xref rid="fig9"/>), the aminopyrimidine part forms a bidentate hydrogen
bond to the hinge region.</p>
            <fig id="fig16" position="float" orientation="portrait">
               <label>16</label>
               <caption>
                  <p>Structures and biological activity data of
aminopyrimidines from
Roche. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>IC<sub>50</sub> values. <italic toggle="yes"><sup>b</sup></italic>p38 isoform not reported. <sup><italic toggle="yes">c</italic></sup><italic toggle="yes">K</italic><sub>d</sub> values.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0016.tif"
                        id="gr16"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Within the series of indole substituted
aminopyrimidines, amide
moieties were introduced at the C<sup>4</sup>-position of the cyclohexane
ring. Compounds bearing alcohol substituted amide moieties, e.g., <bold>35</bold>,<xref rid="ref109" ref-type="bibr"/> showed good cellular potency
and metabolically stability. A profile of compound <bold>35</bold> against a panel of 317 kinases revealed moderate selectivity (43 <italic toggle="yes">K</italic><sub>d</sub> values of &lt;10 μM). However, selectivity
versus p38α and p38β MAP kinases was excellent. Compound <bold>35</bold> showed a low in vivo clearance and reasonable intrinsic
permeability but a high transporter efflux ratio.</p>
         </sec>
         <sec id="sec3.6">
            <title>Pyridinylisoxazoles</title>
            <p>In a very recent report, He et
al. prepared a library of 3-pyridin-4-ylisoxazoles as JNK1/3 inhibitors
(JNK2 was not assessed) with good selectivity against p38 MAP kinase
and a moderate PK profile.<xref rid="ref111" ref-type="bibr"/> Initially,
a series of 4-pyrimidinylpyrazoles from Humphries et al. (i.e., <bold>36</bold>)<xref rid="ref38" ref-type="bibr"/> was used as template to design
pyridin-4-ylpyrazole <bold>37</bold> (Figure <xref rid="fig17"/>).<xref rid="ref111" ref-type="bibr"/> The pyrazole core was subsequently
replaced by isoxazole, giving a new chemotype exemplified by <bold>38</bold>.<xref rid="ref111" ref-type="bibr"/> The compounds strongly resemble
pyridinylimidazoles like SB-203580,<xref rid="ref112" ref-type="bibr"/> prominently
known inhibitors of p38α MAP kinase.<xref rid="ref113" ref-type="bibr"/> Thus, it is likely that these compounds bind JNK in a teardrop-like
binding mode.<xref rid="ref114" ref-type="bibr"/></p>
            <fig id="fig17" position="float" orientation="portrait">
               <label>17</label>
               <caption>
                  <p>Design of pyridinylisoxazole
JNK inhibitors from pyrimidinylpyrazoles.
Biological inhibition data represent IC<sub>50</sub> values. Footnotes
are the following: <sup><italic toggle="yes">a</italic></sup>n.t., not tested. <sup><italic toggle="yes">b</italic></sup>The p38 isoform was not reported.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0017.tif"
                        id="gr17"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Within the current set, compound <bold>39</bold> bearing a hydroxyl-substituent
in the C<sup>5</sup>-position of the isoxazole ring was most potent
for JNK3 with moderate selectivity against JNK1 and p38 MAP kinase
(Figure <xref rid="fig18"/>).<xref rid="ref111" ref-type="bibr"/> Since
this compound class is known to coexist in several tautomeric forms,<xref rid="ref115" ref-type="bibr"/> it remains largely speculative which factors
cause the ≥26-fold increase in potency relative to <bold>38</bold> and other molecules bearing alternative substituents in the isoxazole
C<sup>5</sup>-position. Unfortunately, the compound was poorly stable
in human liver microsomes. Alternative substitution patterns on the
isoxazole and pyridine ring resulted in JNK1/3 inhibitors with potencies
in the double-digit nanomolar range with a more pronounced selectivity
against p38 MAP kinase as shown by compounds <bold>40</bold> and <bold>41</bold>.<xref rid="ref111" ref-type="bibr"/> While <bold>41</bold> was
more potent in vitro, <bold>40</bold> had a more favorable PK profile
(<italic toggle="yes">t</italic><sub>1/2</sub> = 1.5 h; <italic toggle="yes">F</italic> = 37%)
but suffered from a poor brain/plasma ratio of 4.5%.</p>
            <fig id="fig18" position="float" orientation="portrait">
               <label>18</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of pyridinylisoxazole and
-isoxazolone JNK inhibitors Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>The p38 isoform was not reported. <sup><italic toggle="yes">b</italic></sup>n.t., not tested.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0018.tif"
                        id="gr18"
                        position="float"
                        orientation="portrait"/>
            </fig>
         </sec>
         <sec id="sec3.7">
            <title>Triazolones</title>
            <p>Researchers from Elan Pharmaceuticals reported
on 1,2,4-triazolone derivatives as JNK2 and JNK3 inhibitors.<named-content content-type="bibref-group"><xref rid="ref116" ref-type="bibr"/>,<xref rid="ref117" ref-type="bibr"/></named-content> Triazolethione <bold>42</bold> was discovered in an HTS screening
campaign and used as the starting point for optimization studies (Figure <xref rid="fig19"/>).<xref rid="ref116" ref-type="bibr"/> Compound <bold>42</bold> possesses weak inhibitory activity versus all JNKs. Modifications
of the triazolethione core and the naphthyl moiety as well as introduction
of amino moieties at the pyridine C<sup>2</sup>-position gave triazolone
derivative <bold>43</bold>.<xref rid="ref116" ref-type="bibr"/> Compound <bold>43</bold> inhibits JNK2 and JNK3 in the double-digit nanomolar range
and shows moderate selectivity over JNK1. Both of the other MAP kinases,
the ERK2 and the p38α MAP kinase, were not inhibited by <bold>43</bold>, and a panel of 38 additional protein kinases was also
unaffected. <italic toggle="yes">N</italic>-substitution of the triazolone core
was well tolerated and did not affect the selectivity profile. Moreover, <italic toggle="yes">N</italic>-substitution improved permeability as well as cellular
activity. Compound <bold>44a</bold> has an EC<sub>50</sub> value of
12 μM in a human cortical neuronal amyloid-β neurotoxicity
assay,<named-content content-type="bibref-group"><xref rid="ref118" ref-type="bibr"/>,<xref rid="ref119" ref-type="bibr"/></named-content> whereas compound <bold>43</bold> showed
no activity in the same assay (EC<sub>50</sub> &gt; 50 μM).<xref rid="ref116" ref-type="bibr"/></p>
            <fig id="fig19" position="float" orientation="portrait">
               <label>19</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of triazolone
JNK inhibitors
and the parent compound <bold>42</bold>.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0019.tif"
                        id="gr19"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>The crystal structure of <bold>44b</bold> bound to JNK3 reveals
a binding mode typical for teardrop binders (PDB code <ext-link ext-link-type="pdb" xlink:href="3OY1"/>).<xref rid="ref116" ref-type="bibr"/> The pyridine nitrogen atom and the pyridine C<sup>2</sup>-amino function are involved in hydrogen bonding to Met149. The naphthalene
tightly fits into the hydrophobic region I and interacts via a sulfur−π
interaction with the Met146 side chain. Because of the bulky naphthyl
moiety, kinases with a smaller selectivity pocket including other
members of MAP kinase family were not addressed by these inhibitors,
resulting in an excellent selectivity profile. JNK2 and JNK3 possess
a Leu144 in the hydrophobic region I compared to a more bulky Ile106
in JNK1 (Figure <xref rid="fig1"/>) and better tolerate inhibitors <bold>42</bold>–<bold>44</bold>, thus resulting in a moderate selectivity
versus JNK1. This approach to gain isoform selectivity was also pursued
with other templates.<named-content content-type="bibref-group"><xref rid="ref95" ref-type="bibr"/>,<xref rid="ref96" ref-type="bibr"/>,<xref rid="ref120" ref-type="bibr"/>,<xref rid="ref121" ref-type="bibr"/></named-content></p>
         </sec>
         <sec id="sec3.8">
            <title>Benzimidazoles</title>
            <p>A series of 1-heteroaryl-2-aryl-1<italic toggle="yes">H</italic>-benzimidazole-derived
JNK3 inhibitors that also feature
a teardrop-binding mode was reported by Kim et  al.<xref rid="ref122" ref-type="bibr"/> Compound <bold>45</bold>, a moderate dual JNK2 and JNK3
inhibitor (JNK1 inhibition data not shown) identified by HTS, was
the starting point for this work (Figure <xref rid="fig20"/>). Inhibitor <bold>45</bold> exhibits good selectivity against 50
kinases (panel not shown). Docking studies of <bold>45</bold> suggests
a binding mode wherein the 3-hydroxyphenyl moiety is located in the
hydrophobic region I. The pyridine nitrogen atom and the pyridine
C<sup>2</sup>-amino function interact via a bidentate hydrogen bond
with the backbone of Met149 in the hinge region. The piperidine ring
binds to the hydrophobic region II. Modifications of <bold>45</bold> such as replacement of the phenol moiety by a bulkier 2-naphthyl
substituent, introduction of a hydroxyl group at the benzimidazole
C<sup>6</sup>-amino function, acylation of the piperidine ring, and
replacement of the pyridine by a pyrimidine ring resulted in the potent
JNK3 inhibitor <bold>46</bold> having a <italic toggle="yes">K</italic><sub>d</sub> value in the double-digit nanomlor range.<xref rid="ref122" ref-type="bibr"/> Inhibitor <bold>46</bold> almost completely blocks the phosphorylation
of c-Jun in human neuroblastoma SH-SY5Y cells at a concentration of
10 μM and inhibits TNF-α mRNA expression in these cells
with an IC<sub>50</sub> value of 1.09 μM.</p>
            <fig id="fig20" position="float" orientation="portrait">
               <label>20</label>
               <caption>
                  <p>Structures and <italic toggle="yes">K</italic><sub>d</sub> values of benzimidazole
JNK inhibitors.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0020.tif"
                        id="gr20"
                        position="float"
                        orientation="portrait"/>
            </fig>
         </sec>
         <sec id="sec3.9">
            <title>Piperazineamides</title>
            <p>Shin et al. reported a series of piperazineamides
as inhibitors of JNK1 and JNK3 (JNK2 inhibition was not assessed).<xref rid="ref123" ref-type="bibr"/> The starting point was compound <bold>47</bold>, which was identified by HTS (Figure <xref rid="fig21"/>).<xref rid="ref123" ref-type="bibr"/> Compound <bold>47</bold> is a moderate ATP
competitive JNK inhibitor with good selectivity versus p38α
MAP kinase. The chloro substituent, the five-membered heterocyclic
ring, and the piperazine moiety were optimized. Small unsaturated
alkyl side chains at the piperazine N<sup>4</sup>-position, e.g.,
allyl (compound <bold>48</bold>) or propargyl (compound <bold>49</bold>), improved the inhibitory activity down to the double-digit nanomolar
range.<xref rid="ref123" ref-type="bibr"/> An X-ray crystal structure of
inhibitor <bold>49</bold> bound into the ATP-binding site of JNK3
revealed that the inhibitor binds with both aryl rings and the amide
bond arranged in a coplanar fashion (PDB code <ext-link ext-link-type="pdb" xlink:href="3FV8"/>). The planar orientation
might be stabilized by an intramolecular hydrogen bond formed between
the amide NH and the oxygen atom of the furan ring. The 5-bromofuran-2-yl
moiety is located at the adenine-binding region. The piperazine ring
is arranged perpendicular to the rest of the molecule and forms van
der Waals contacts with Ile70 and Val78 as well as with Val196 and
Leu206, which are stabilizing the p-loop. The furan ring interacts
via van der Waals contacts with the side chain of the gatekeeper amino
acid Met146. The amide oxygen atom is hydrogen bonded to the backbone
NH of Met149 located in the hinge region.</p>
            <fig id="fig21" position="float" orientation="portrait">
               <label>21</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of piperazine amide JNK inhibitors.
The dashed line indicates an intramolecular hydrogen bond. Footnote
is the following: <italic toggle="yes"><sup>a</sup></italic>n.i., no inhibition.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0021.tif"
                        id="gr21"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Further modifications revealed
that small moieties at the phenyl
C<sup>3</sup>-position like Cl, CH<sub>3</sub>, and F were better
tolerated by both enzymes than larger ones. Replacement of the electron
rich furan moiety by different five- and six-membered heterocyclic
aromatic rings resulted in a substantial decrease in activity supporting
the impact of intramolecular hydrogen bonding. The most potent inhibitors
of this series, compounds <bold>50</bold> and <bold>51</bold>,<xref rid="ref123" ref-type="bibr"/> contain a spiroketal-piperidine moiety instead
of the piperazine ring at the phenyl C<sup>2</sup>-position. Some
molecules from this series were screened for their ability to inhibit
the phosphorylation of c-Jun in a cell based ELISA-assay. However,
these compounds showed a considerable drop in activity (up to 40-fold)
in a cellular setting.</p>
         </sec>
         <sec id="sec3.10">
            <title>Thiophene Based Inhibitors</title>
            <p>Researchers
from Elan Pharmaceuticals
reported on the design of thiophene based JNK inhibitors (Figure <xref rid="fig22"/>).<named-content content-type="bibref-group"><xref rid="ref124" ref-type="bibr"/>−<xref rid="ref125" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref126" ref-type="bibr"/></named-content> Starting point for this series was inhibitor <bold>52</bold>,<xref rid="ref126" ref-type="bibr"/> which was identified by
HTS.</p>
            <fig id="fig22" position="float" orientation="portrait">
               <label>22</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of thiophene-based JNK inhibitors
developed from Elan Pharmaceuticals. The dashed line indicates an
intramolecular hydrogen bond.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0022.tif"
                        id="gr22"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>The crystal structure of <bold>52</bold> complexed with JNK3
(PDB
code <ext-link ext-link-type="pdb" xlink:href="3OXI"/>) revealed
that carbonyl oxygen of the amide group interacts with the NH of Met149
via hydrogen bonding. An intramolecular hydrogen bond between of the
carbonyl oxygen of ester group and the adjacent amide NH results in
a planar orientation of the central part of the molecule. The thiophene
ring of the 2-thienylacetyl moiety is oriented almost perpendicular
to the rest of the molecule. Optimization of both thiophene moieties
and bioisosteric replacement of the ester function resulted in very
potent pan-JNK inhibitors with IC<sub>50</sub> values down to single-digit
nanomolar range, e.g., inhibitor <bold>53</bold>.<xref rid="ref125" ref-type="bibr"/></p>
            <p>General SAR indicated that larger bicyclic ring systems
were tolerated
at the 2-acetyl position. Replacement of the ester function by other
groups of similar size unable to form an intramolecular hydrogen bond
with the amide NH resulted in loss of activity, highlighting the importance
of the planar arrangement for JNK binding. Replacement of the ester
function by five-membered heterocyclic rings, which were able to act
as a hydrogen bond acceptor for the NH of the secondary amide, like
a triazole, was tolerated. Replacement of the <italic toggle="yes">N</italic>-thienyl
ring by other five- and six-membered (hetero)­aromatic rings resulted
in a clear drop of potency except in case of an isosteric phenyl ring.
The position of the sulfur atom in this thiophene ring has only a
minor influence on inhibitory activity. Therefore, a trisubstituted
thiophene ring with the sulfur atom shifted to the ortho-position
of the amide function was introduced and potential hydrophobic contacts
of the third substituent with Met146 were explored. Small substituents,
like methyl or cyano, e.g., in compound <bold>53</bold>, were well
tolerated, whereas larger moieties resulted in a dramatic decrease
in activity.</p>
            <p>Crystal structures of <bold>53</bold> complexed
with JNK3 (PDB
codes <ext-link ext-link-type="pdb" xlink:href="3PTG"/> and <ext-link ext-link-type="pdb" xlink:href="3RTP"/>) revealed the same
key interactions as for compound <bold>52</bold>. The carbonyl oxygen
interacts via a hydrogen bond with the NH of Met149 and the amide
NH forms an intramolecular hydrogen bond to the triazole ring, resulting
in a planar orientation of this part of the inhibitor molecule. The
cyano group at position C<sup>4</sup> of the thiophene ring is located
in proximity (3.4 Å) to the gatekeeper side chain and the carbonyl
group of the dihydroquinolone acts as a hydrogen bond acceptor for
the Asn152 side chain. The fused bicyclic ring is arranged in periplanar
fashion and points toward the hydrophobic region II. In a subsequent
optimization step, the dihydroquinolinone ring was exchanged by a
metabolically more stable quinolinone ring, and substituents at the
phenyl part of the quinolinone ring were introduced to interact with
the solvent exposed hydrophobic region II. Position C<sup>6</sup> of
the quinolinone core proved to be an adequate position for enhancing
metabolic stability leading to compounds <bold>54</bold> and <bold>55</bold>.<xref rid="ref124" ref-type="bibr"/></p>
            <p>Selected inhibitors
were evaluated for their PK profile. Compound <bold>54</bold> possessed
a low P-gp efflux ratio of 0.61 at pH 7.4 in
MDR1-MDCK cells and displayed a brain/plasma ratio of 70%. Inhibitor <bold>54</bold> is orally bioavailable in rat (<italic toggle="yes">F</italic> = 34%,
dosed at 2 mg/kg, po) but shows a short half-life of 4.6 min (dosed
at 1 mg/kg, iv). A selectivity screen of inhibitor <bold>54</bold> revealed a clean profile. Out of 36 kinases, only JNK3 was inhibited
at 10 μM (JNK1 and JNK2 were not included in the kinase panel).
Furthermore, it was shown that compound <bold>54</bold> exhibits neuroprotective
properties in a human cortical neuronal amyloid-β neurotoxicity
assay (EC<sub>50</sub> = 2.9 μM).</p>
            <p>Another series of thiophene-based
inhibitors of JNK1 and JNK2 is
reported by De et al.<xref rid="ref127" ref-type="bibr"/> Thiophene-3-carboxamides
possibly target the ATP-binding site as well as the JIP-binding site
of JNK1, albeit with relatively low potency (Figure <xref rid="fig23"/>). The most potent compound of this series, <bold>56</bold>, possesses an IC<sub>50</sub> value of 1.32 μM in the kinase
assay and displaced pepJIP1 with an IC<sub>50</sub> value of 4.62
μM.<xref rid="ref127" ref-type="bibr"/> The TNF-α-stimulated
phosphorylation of c-Jun in HeLa cells is inhibited by <bold>56</bold> with an IC<sub>50</sub> value of 7.5 μM.</p>
            <fig id="fig23" position="float" orientation="portrait">
               <label>23</label>
               <caption>
                  <p>Structure and IC<sub>50</sub> values of thiophene-3-carboxamide
inhibitor <bold>56</bold>. Footnote is the following: <sup><italic toggle="yes">a</italic></sup>Phosphorylation of c-Jun in HeLa cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0023.tif"
                        id="gr23"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Screening of <bold>56</bold> against a panel of
26 kinases revealed
that this compound exclusively inhibits JNKs (79%, 72%, and 18% inhibition
of JNK1, JNK2, and JNK3, respectively, at a test concentration of
25 μM) and is inactive versus other MAP kinases and lipid kinases.
Isothermal titration calorimetry experiments in the presence and absence
of saturating concentrations of either a nonhydrolyzable ATP analog
or pepJIP1 revealed that compound <bold>56</bold> binds to JNK2 with
a <italic toggle="yes">K</italic><sub>d</sub> value of 640 nM, with a 2:1 ligand
to protein stoichiometry. The binding affinity of <bold>56</bold> decreases
significantly in the presence of ATP or pepJIP1. The determined <italic toggle="yes">K</italic><sub>d</sub> values for interactions between compound <bold>56</bold> and JNK1 under these same conditions were 1.1 μM
and 3.1 μM in the presence of ATP and pepJIP1, respectively,
both with a ligand to protein stoichiometry of 1:1.</p>
         </sec>
         <sec id="sec3.11">
            <title>Quinolones
and Azaquinolones</title>
            <p>Researchers from Roche
published a series of 4-quinolones as dual inhibitors of JNK1 and
JNK2 (JNK3 inhibition data not shown).<xref rid="ref128" ref-type="bibr"/> Lead compound <bold>57</bold> was derived from an HTS hit by applying
the combined knowledge from an early SAR study with results from similar
JNK inhibitors reported from Takeda<named-content content-type="bibref-group"><xref rid="ref129" ref-type="bibr"/>,<xref rid="ref130" ref-type="bibr"/></named-content> (Figure <xref rid="fig24"/>).<xref rid="ref128" ref-type="bibr"/> A cocrystal structure
of an inhibitor from this series bound to JNK1 (PDB code <ext-link ext-link-type="pdb" xlink:href="4G1W"/>) revealed that the
carbonyl oxygen of this class of inhibitors forms a hydrogen bond
to Met111 located in the hinge region. The chlorine atom points toward
the hydrophobic region I while the para-position of the benzyl moiety
is oriented toward the solvent exposed front region enabling the introduction
of various groups at this position. Larger moieties were tolerated
by both enzymes resulting in more potent JNK1 and JNK2 inhibitors,
e.g., compound <bold>58</bold>.<xref rid="ref128" ref-type="bibr"/> Displaying
excellent selectivity, inhibitor <bold>58</bold> also features reasonable
pharmacodynamics. Out of 317 protein kinases, <bold>58</bold> only
shows potency for JNK enzymes (not stated if JNK3 was included in
the panel). Compound <bold>58</bold> inhibited neutrophil infiltration
in bronchial alveolar lavage (BAL) by 55% at 4 h after administration
and the total white blood cells infiltration in BAL by 40% when dosed
at 10 mg/kg, sc. However, the inhibitor failed to show the necessary
levels of JNK inhibition when challenged with TNF-α in vivo
(data not shown).<xref rid="ref131" ref-type="bibr"/></p>
            <fig id="fig24" position="float" orientation="portrait">
               <label>24</label>
               <caption>
                  <p>Structures and biological
data of 4-quinolone and azaquinolone
JNK inhibitors. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>IC<sub>50</sub> values. <sup><italic toggle="yes">b</italic></sup>EC<sub>50</sub> values.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0024.tif"
                        id="gr24"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>The introduction of
a nitrogen atom in the carbocycle of the quinolone
system resulted in a series of 8-azaquinolones. Bulky adamantyl moieties
at the amide group at the para-position of the benzyl ring were well
tolerated as exemplified by the <italic toggle="yes">trans</italic>-hydroxyadamantyl
residue in compound <bold>59</bold>.<xref rid="ref131" ref-type="bibr"/> 8-Azaquinolone <bold>59</bold> shows higher in vitro and cellular
potency compared to 4-quinolone <bold>58</bold>. Inhibitor <bold>59</bold> possesses an excellent selectivity profile. In a screen versus 451
kinases, no protein kinases other than the JNKs were inhibited by
more than 50% at a testing concentration of 10 μM (percent of
competition for JNK1, JNK2, and JNK3 is 96, 98, and 99, respectively).
Beside this outstanding selectivity, inhibitor <bold>59</bold> exhibited
moderate solubility and clearance. Further in vivo profiling in rats
revealed that compound <bold>59</bold> lowered the TNF-α stimulated
phosphorylation of c-Jun after 7 h by 51% when dosed at 75 mg/kg po
as a microprecipitated bulk powder formulation.</p>
         </sec>
         <sec id="sec3.12">
            <title>Indenoquinoxalines</title>
            <p>Schepetkin et al. reported a series
of 11<italic toggle="yes">H</italic>-indeno­[1,2-<italic toggle="yes">b</italic>]­quinoxalin-11-one
oximes as potent JNK inhibitors.<xref rid="ref132" ref-type="bibr"/> Compound <bold>60</bold> was originally identified as a noncytotoxic inhibitor of
NF-κB/AP1 in macrophages (Figure <xref rid="fig25"/>). <italic toggle="yes">O</italic>-Acyloxime <bold>61</bold> was profiled in a diverse panel
of 131 kinases, containing representative members of all known kinase
families. Only the protein kinases JNK1, JNK2, JNK3, and CK1δ
were inhibited &gt;90% at a test concentration of 10 μM. The
p38α
and p38β MAP kinases were not inhibited by <bold>61</bold>.
The <italic toggle="yes">K</italic><sub>d</sub> values of indenoquinoxalines <bold>60</bold>–<bold>62</bold> versus kinases that exhibited the
highest binding activity for <bold>61</bold> in the kinase profile
are listed in Figure <xref rid="fig25"/>.<xref rid="ref132" ref-type="bibr"/> Compounds <bold>61</bold> and <bold>62</bold> were potent
inhibitors of JNK3 with <italic toggle="yes">K</italic><sub>d</sub> values in the
double-digit nanomolar range displaying a marginal selectivity against
JNK1 and JNK2 (&lt;3.6-fold). Use of a 3,4-dimethoxybenzoate as an <italic toggle="yes">O</italic>-acyl moiety results in no loss of JNK inhibitory activity
but causes a substantial gain of selectivity versus CK1, PI3Kγ,
and MKNK2 (inhibitor <bold>61</bold> vs <bold>62</bold>). Lineweaver–Burk
analysis demonstrated that <bold>61</bold> acts as an ATP competitive
inhibitor.</p>
            <fig id="fig25" position="float" orientation="portrait">
               <label>25</label>
               <caption>
                  <p>Structures and <italic toggle="yes">K</italic><sub>d</sub> values of
indenoquinoxaline
JNK inhibitors.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0025.tif"
                        id="gr25"
                        position="float"
                        orientation="portrait"/>
            </fig>
         </sec>
         <sec id="sec3.13">
            <title>Allosteric, Bidentate,
and Peptidic JNK Inhibitors</title>
            <p>Targeting the allosteric binding
sites of JNKs is a distinct approach
to JNK inhibition. Early well-characterized examples of this inhibitor
class are represented by the JIP-peptides (pepJIP) and the cell-permeable
JIP1-derived JNK inhibitory peptides-1 (<sc>l</sc>- and <sc>d</sc>-JNKI-1), which have been the subject of several reviews.<named-content content-type="bibref-group"><xref rid="ref51" ref-type="bibr"/>,<xref rid="ref52" ref-type="bibr"/>,<xref rid="ref133" ref-type="bibr"/></named-content> Those peptides bind the JIP
docking groove of the JNKs and do not directly interact with the ATP
binding site as revealed by kinetic studies and X-ray crystallography
(e.g., PDB code <ext-link ext-link-type="pdb" xlink:href="1UKH"/>).<named-content content-type="bibref-group"><xref rid="ref134" ref-type="bibr"/>,<xref rid="ref135" ref-type="bibr"/></named-content> Especially the <sc>d</sc>-retro-inverso
peptide <sc>d</sc>-JNKI-1 (XG-102, Table <xref rid="tbl1"/><named-content content-type="anchor" rid="tbl1"/>) comprising a TAT-peptide sequence for increasing cell
permeability has been studied in several in vivo models. It proved
to be neuroprotective in animal cerebral ischemia, AD, and stroke
models among others and is currently in clinical trials.<named-content content-type="bibref-group"><xref rid="ref58" ref-type="bibr"/>−<xref rid="ref59" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref60" ref-type="bibr"/>,<xref rid="ref136" ref-type="bibr"/>−<xref rid="ref137" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref138" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref139" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref140" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref141" ref-type="bibr"/></named-content></p>
            <p>More recently, Ngoei et al. identified the peptides <sc>l</sc>-PYC71N and <sc>d</sc>-PYC98 from a yeast two-hybrid screen of a
biodiverse gene fragment library.<named-content content-type="bibref-group"><xref rid="ref142" ref-type="bibr"/>,<xref rid="ref143" ref-type="bibr"/></named-content> Both peptides
are pan-JNK inhibitors, effectively preventing c-Jun phosphorylation
at low micromolar concentrations (no IC<sub>50</sub> values given)
by a non-ATP competitive mechanism. Both peptides also disrupt the
phosphorylation of the ATF-2 transcription factor by p38α MAP
kinase albeit with a weaker potency. While <sc>l</sc>-PYC71N was shown
to bind c-Jun preventing its interaction with the JNKs, <sc>d</sc>-PYC98 was supposed to occupy the JIP docking site. Interestingly,
the <sc>d</sc>-retro-inverso peptide <sc>d</sc>-PYC98 proved to be
5 times more potent than the analogous parent compound <sc>l</sc>-PYC98.
A cell penetrable conjugate of <sc>d</sc>-PYC98 bearing a TAT-sequence
was shown to prevent c-Jun Ser63 phosphorylation in murine embryonic
fibroblasts (MEFs) during hyperosmotic stress at single digit micromolar
inhibitor concentrations. It is worth mentioning that the cellular
inhibition of c-Jun Ser63 phosphorylation occurred without altering
JNK phosphorylation, further supporting the allosteric mechanism.</p>
            <p>Several examples of more potent JIP-based peptide inhibitors were
developed by Kaoud et al.<xref rid="ref144" ref-type="bibr"/> JIP<sup>10</sup>-Δ-TAT consists of the 10-mer JIP peptide and the N-terminus
of an inverted HIV-TAT sequence, both of which are connected through
a flexible 6-aminohexanoyl linker. This peptide inhibits JNK2 in the
double-digit nanomolar range (IC<sub>50</sub> = 0.092 μM) and
displays a more than 10-fold selectivity over JNK1 (IC<sub>50</sub> = 1.2 μM) and JNK3 (IC<sub>50</sub> = 1.16 μM) as well
as a more than 160-fold selectivity over p38α MAP kinase (IC<sub>50</sub> = 13.7 μM). Replacement of the TAT sequence by nine
arginine residues resulted in peptide JIP<sup>10</sup>-Δ-R<sub>9</sub> exhibiting a similar potency and selectivity profile than
JIP<sup>10</sup>-Δ-TAT. Both peptides possess the ability in
HEK293 cells to inhibit the phosphorylation of JNKs and c-Jun.</p>
            <table-wrap id="tbl1" position="float" orientation="portrait">
               <label>1</label>
               <caption>
                  <title>Amino Acid Sequence of Peptidic Inhibitors
of JNKs</title>
               </caption>
               <oasis:table colsep="0" rowsep="0">
                  <oasis:tgroup cols="3">
                     <oasis:colspec align="left" colname="col1"/>
                     <oasis:colspec align="left" colname="col2"/>
                     <oasis:colspec align="left" colname="col3"/>
                     <oasis:thead>
                        <oasis:row>
                           <oasis:entry align="center">identifier</oasis:entry>
                           <oasis:entry align="center">amino acid
sequence</oasis:entry>
                           <oasis:entry align="center">ref</oasis:entry>
                        </oasis:row>
                     </oasis:thead>
                     <oasis:tbody>
                        <oasis:row>
                           <oasis:entry>pepJIP1</oasis:entry>
                           <oasis:entry>RPKRPTTLNLF</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref134" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry><sc>d</sc>-JNKI-1 (XG-102)</oasis:entry>
                           <oasis:entry>dqsrpvqpflnlttprkprpprrrqrrkkrG</oasis:entry>
                           <oasis:entry><named-content content-type="bibref-group"><xref rid="ref136" ref-type="bibr"/>, <xref rid="ref145" ref-type="bibr"/></named-content></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry><sc>l</sc>-PYC71N</oasis:entry>
                           <oasis:entry>FFWRLNKIFYFID</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref142" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry><sc>l</sc>-PYC98</oasis:entry>
                           <oasis:entry>LAYRVIIPCFRKRYFCFL</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref143" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry><sc>d</sc>-PYC98-TAT</oasis:entry>
                           <oasis:entry>lfcfyrkrfcpiivryalGrrrqrrkkrG</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref143" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry>JIP<sup>10</sup>-Δ-TAT</oasis:entry>
                           <oasis:entry>PKRPTTLNLF-aminohexanoyl-RRRQRRKKRG</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref144" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                        <oasis:row>
                           <oasis:entry>JIP<sup>10</sup>-Δ-R<sub>9</sub></oasis:entry>
                           <oasis:entry>PKRPTTLNLF-aminohexanoyl-RRRRRRRRR</oasis:entry>
                           <oasis:entry><xref specific-use="ref-style=base-text" rid="ref144" ref-type="bibr"/></oasis:entry>
                        </oasis:row>
                     </oasis:tbody>
                  </oasis:tgroup>
               </oasis:table>
            </table-wrap>
            <p>Another non-ATP
competitive JNK inhibitor was identified by Kaoud
et al. based on a virtual screening study.<xref rid="ref146" ref-type="bibr"/> The natural product (−)-zuonin A (<bold>63</bold>) is an
inhibitor of JNK-JIP binding (Figure <xref rid="fig26"/>) displaying
selectivity for the JNKs over other MAP kinase family members. Further
studies showed that <bold>63</bold> inhibits also the activation of
JNK1 by their upstream kinases MKK4 and MKK7.<xref rid="ref147" ref-type="bibr"/></p>
            <fig id="fig26" position="float" orientation="portrait">
               <label>26</label>
               <caption>
                  <p>Structure and IC<sub>50</sub> values of the JNK-JIP binding
inhibitor
(−)-zuonin A. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>Inhibition of c-Jun phosphorylation. <sup><italic toggle="yes">b</italic></sup>Inhibition of phosphorylation of JNK1.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0026.tif"
                        id="gr26"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Stebbins et al. generated bidentate ligands to interact with
both
the ATP pocket and the binding site of the JIP scaffolding protein.<xref rid="ref148" ref-type="bibr"/> The authors combined a weak ATP-competitive
inhibitor from an earlier study<xref rid="ref149" ref-type="bibr"/> with
a peptide targeting the JIP docking site. While the isolated fragments <bold>64</bold> and <bold>65</bold> displayed very weak activity, linking
led to inhibitor <bold>66</bold>, which inhibited both the JNK1 kinase
activity and the JNK1-pepJIP interaction with subnanomolar IC<sub>50</sub> values (Figure <xref rid="fig27"/>).<xref rid="ref148" ref-type="bibr"/></p>
            <fig id="fig27" position="float" orientation="portrait">
               <label>27</label>
               <caption>
                  <p>Design of bidentate ligands targeting the ATP pocket and
the JIP
binding site of JNK1. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>JIP peptide displacement, IC<sub>50</sub> value. <sup><italic toggle="yes">b</italic></sup>Inhibition of ATF-2 substrate phosphorylation, IC<sub>50</sub> value.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0027.tif"
                        id="gr27"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>To enhance in vivo stability,
the peptide was replaced by the corresponding <sc>d</sc>-retro-inverso
sequence and a <sc>d</sc>-retro-inverso HIV-TAT
peptide was attached for increasing cell permeability. The obtained
inhibitor <bold>67</bold> was about one order of magnitude less potent
in vitro but active in cells and completely inactive against p38α
MAP kinase (Figure <xref rid="fig28"/>).<xref rid="ref148" ref-type="bibr"/> Since the authors did not supply any data for JNK2/3, no
conclusion can be drawn on intra-JNK selectivity. However, compound <bold>67</bold> was effective in restoring normoglycemia without causing
hypoglycemia dosed 4 days at 25 mg kg<sup>–1</sup> day<sup>–1</sup> in a NONcNZO10/LtJ diabetes mellitus type 2 mouse
model.</p>
            <fig id="fig28" position="float" orientation="portrait">
               <label>28</label>
               <caption>
                  <p>Design of cell permeable bidentate ligand <bold>67</bold>. Footnotes
are the following: <sup><italic toggle="yes">a</italic></sup>JIP peptide displacement. <sup><italic toggle="yes">b</italic></sup>Inhibition of ATF-2 substrate phosphorylation. <sup><italic toggle="yes">c</italic></sup>IC<sub>50</sub> value. <sup><italic toggle="yes">d</italic></sup><italic toggle="yes">K</italic><sub>d</sub> value. <sup><italic toggle="yes">e</italic></sup>Inhibition c-Jun phosphorylation in TNF-α stimulated
B16-F10 melanoma cells/anisomycin stimulated HEK293T cells.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0028.tif"
                        id="gr28"
                        position="float"
                        orientation="portrait"/>
            </fig>
         </sec>
         <sec id="sec3.14">
            <title>Nonpeptidic Bidentate Dual
JNK/LRRK2 Inhibitor</title>
            <p>Diseases
like cancer and neurodegenerative diseases are multifaceted, and for
the treatment of each of these diseases, a plethora of molecular targets
have been identified. Multitarget drugs, compounds that address different
targets involved in the same disease, are expected to be superior
to single-target drugs for the therapy of these complex diseases.
They can be expected to have higher efficacy often paired with a more
favorable side effect profile and a reduced susceptibility to resistance
development. Further advantages of multitarget drugs compared to drug
combinations (several drugs for the same indication) include a lower
risk of drug–drug interactions, a better patient compliance,
and an easier prediction of pharmacodynamics and PK.<xref rid="ref150" ref-type="bibr"/></p>
            <p>Nonpeptidic bidentate ligands binding to the ATP
binding site as well as to a surface binding pocket of JNK3 were reported
by Feng et al.<xref rid="ref68" ref-type="bibr"/> The compounds, e.g., <bold>68</bold>,<xref rid="ref68" ref-type="bibr"/> share the same hinge-binding
motif like bidentate peptides <bold>64</bold>, <bold>66</bold>, and <bold>67</bold> (Figure <xref rid="fig29"/>). In contrast to compounds <bold>66</bold> and <bold>67</bold>, the linker (propyl-1,3-diamine coupled
with a di-Gly) was replaced by a shorter hexamethylenediamino moiety.
The peptidic motif present in <bold>66</bold> and <bold>67</bold> was
optimized to further reduce the peptidic nature of these inhibitors,
leading to potent JNK3 inhibitor <bold>68</bold> having an IC<sub>50</sub> value in the low nanomolar range. Compound <bold>68</bold> displays 10-fold selectivity versus JNK1 and possesses the ability
to displace the JIP-peptide with an IC<sub>50</sub> value of 336 nM.</p>
            <fig id="fig29" position="float" orientation="portrait">
               <label>29</label>
               <caption>
                  <p>Structure
and IC<sub>50</sub> values of nonpeptidic bidentate binder <bold>68</bold>.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0029.tif"
                        id="gr29"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>An initial kinase screen versus
21 kinases revealed that only JNKs
(∼100% inhibition) and leucine rich repeat kinase 2 (LRRK2)
(94% inhibition) were significantly inhibited by compound <bold>68</bold> at a test concentration of 10 μM. Since both JNK3 and LRRK2
were associated with the progression of PD, <bold>68</bold> was further
evaluated for its ability to inhibit the LRRK2-G1019S mutant, since
this mutation is common cause for familial PD in Caucasians.<xref rid="ref151" ref-type="bibr"/> The IC<sub>50</sub> value of compound <bold>68</bold> in the LRRK2-G2019S assay was 99 nM. Dual inhibitor <bold>68</bold> can therefore be considered as a multitarget drug addressing
two different targets involved in the same disease. Compounds inhibiting
several different targets involved in neurodegeneration may exhibit
additive or even synergistic effects.<named-content content-type="bibref-group"><xref rid="ref152" ref-type="bibr"/>−<xref rid="ref153" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref154" ref-type="bibr"/></named-content> Inhibitor <bold>68</bold> is thus a valuable in vitro probe to further investigate the role
of dual inhibition of JNK3 and LRRK2 for the treatment of PD.</p>
         </sec>
         <sec id="sec3.15">
            <title>Covalent
Inhibitors</title>
            <p>A recent report on highly selective
JNK inhibitors containing a covalent tag was published by researchers
from Harvard Medical School.<xref rid="ref69" ref-type="bibr"/> During the
past decades, molecules bearing electrophilic “warheads”
have been claimed as not druglike because of potential off-target
effects, haptenization, and irreversible blockage of protein targets.
Recently, the covalent inhibition of enzymes including kinases has
experienced a resurgence.<xref rid="ref155" ref-type="bibr"/> Against the
prevalent opinion, carefully designed irreversible inhibitors have
been demonstrated to be even more selective than their reversibly
binding counterparts and this mode of action has a lower susceptibility
toward resistance development.<named-content content-type="bibref-group"><xref rid="ref156" ref-type="bibr"/>,<xref rid="ref157" ref-type="bibr"/></named-content> With the recent approval
of afatinib, a covalent EGFR inhibitor,<xref rid="ref158" ref-type="bibr"/> this concept finally gained the attention of the kinase research
community. Searching for a covalent type II inhibitor<xref rid="ref159" ref-type="bibr"/> of the c-Kit, PDGFR, and Abl kinases, Zhang
et al. serendipitously discovered imatinib derived pan-JNK inhibitor <bold>69</bold> (JNK-IN-1, Figure <xref rid="fig30"/>).<xref rid="ref69" ref-type="bibr"/> In a screening against a panel of 400 kinases,
the lead compound possessed a high degree of selectivity for the JNK
family and inhibited only a few other kinases. Modified compound <bold>70</bold> (JNK-IN-2)<xref rid="ref69" ref-type="bibr"/> lacking the imatinib
“flag methyl” group responsible for kinome selectivity<xref rid="ref160" ref-type="bibr"/> had a roughly 5- to 10-fold increased affinity
toward the JNKs, and the covalent binding mode was confirmed by mass
spectrometry.</p>
            <fig id="fig30" position="float" orientation="portrait">
               <label>30</label>
               <caption>
                  <p>Structures and IC<sub>50</sub> values of irreversible
JNK inhibitors
based on the imatinib scaffold. Footnotes are the following: <sup><italic toggle="yes">a</italic></sup>1 h of incubation. <sup><italic toggle="yes">b</italic></sup>Inhibition of c-Jun phosphorylation in HeLa/A375 cells, EC<sub>50</sub> value.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0030.tif"
                        id="gr30"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Crystallization of <bold>70</bold> in complex with JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="3V6R"/>) unambiguously showed
the covalent link between the Michael acceptor system and Cys154 (Figure <xref rid="fig31"/>). By use of structure-based design, a series of
analogs was established. A 500-fold increase in activity was observed
for compound <bold>71</bold> (JNK-IN-7),<xref rid="ref69" ref-type="bibr"/> which showed IC<sub>50</sub> values in the single digit nanomolar
range (1 h incubation) and potently inhibited c-Jun phosphorylation
in HeLa and A375 cells.</p>
            <fig id="fig31" position="float" orientation="portrait">
               <label>31</label>
               <caption>
                  <p>Superimposition of <bold>70</bold> bound to
JNK3 (PDB code <ext-link ext-link-type="pdb" xlink:href="3V6R"/>, cyan) and imatinib
(salmon) bound to p38α MAP kinase (PDB code <ext-link ext-link-type="pdb" xlink:href="3HEC"/>, gray). <bold>70</bold> is bound to JNK3 in a covalent type I binding mode with the kinase
in the active DFG-in conformation. Imatinib binds the inactive DFG-out
conformation of p38α MAP kinase as shown by the steric clash
with the DFG motif (depicted as red spheres) of the active conformation
of JNK3.</p>
               </caption>
               <graphic xlink:href="jm-2014-01212r_0031.tif"
                        id="gr31"
                        position="float"
                        orientation="portrait"/>
            </fig>
            <p>Despite the expected type II binding
mode, the crystal structure
of JNK3 in complex with <bold>71</bold> (PDB code <ext-link ext-link-type="pdb" xlink:href="3V6S"/>) reveals an interaction
geometry similar to 2-aminopyrimidine derived type I inhibitor <bold>15</bold> (average rmsd of 2.40 Å) from Kamenecka et al.<xref rid="ref87" ref-type="bibr"/> The X-ray crystal structure showed that the
3-pyridinyl moiety of <bold>71</bold> did not optimally fill the hydrophobic
region II of the kinase. Replacing this residue by a bulkier 3-(2-phenylpyrazolo­[1,5-<italic toggle="yes">a</italic>]­pyridinyl) substituent furnished compound <bold>73</bold> (JNK-IN-11)<xref rid="ref69" ref-type="bibr"/> with significantly enhanced
potency down to subnanomolar range. Further modifications in this
position might lead to extremely potent inhibitors with a clean selectivity
profile. Compounds <bold>70</bold> and <bold>73</bold> exhibited reasonable
selectivity for the JNK kinase family, but both compounds hit several
off-targets. In a cellular kinase profiling against more than 200
kinases using the KiNativ technology<xref rid="ref161" ref-type="bibr"/> those compounds shared the JNKs as principal targets. However, <bold>70</bold> also bound to IRAK1, PFTAIRE1, OIK3C3, PIP5K3, and PIP4K2C
while <bold>73</bold> strongly bound p38α MAP kinase along with
PIP5K3, ZAK, TC2, and CK1. An in vitro kinase screening against a
panel of 442 kinases using the KINOMEscan technology<xref rid="ref2" ref-type="bibr"/> showed that <bold>71</bold> inhibited eight kinases with
a <italic toggle="yes">K</italic><sub>D</sub> of &lt;100 nM while <bold>73</bold> hit six kinase targets. The selectivity within the kinome could
be further increased by reintroducing the “flag methyl”
group on <bold>71</bold>, giving <bold>72</bold> (JNK-IN-8). Although
being slightly less potent, this compound also possessed a certain
degree of selectivity for JNK3 versus JNK1 (∼5-fold) and JNK2
(∼20-fold).<xref rid="ref69" ref-type="bibr"/> In cells, <bold>72</bold> exclusively inhibited JNKs, and in vitro, only two mutants of the
KIT kinase were inhibited with a <italic toggle="yes">K</italic><sub>D</sub> of
&lt;100 nM. Because of this excellent selectivity profile, the compound
was recently selected by Knapp et al. as high-quality kinase probe
for JNK inhibition.<xref rid="ref162" ref-type="bibr"/> Unlike <bold>73</bold>, compounds <bold>71</bold> and <bold>72</bold> showed only on-pathway
activity assessed in a microscopy based cellular pathway profiling.
By use of a protein engineering approach, Cys116 was mutated to serine
to determine functional selectivity. The mutant displayed similar
in vitro substrate phosphorylation kinetics as the wild-type kinase,
and a &gt;100-fold decrease in potency was observed for <bold>71</bold>/<bold>72</bold> while <bold>73</bold> was only 10 times less potent
against JNK2C116S. Unfortunately, this study did not assess blood–brain
barrier penetration. Since no in vivo experiments were conducted,
it remains to be seen if covalent JNK inhibition will be useful in
a clinical setting. Remarkably, the compound class presented relies
on a well characterized scaffold derived from the well-validated kinase
inhibitor imatinib, making it a promising starting point for further
optimization or even a candidate for preclinical characterization.</p>
         </sec>
      </sec>
      <sec id="sec4">
         <title>Conclusion and Perspective</title>
         <p>The design of numerous JNK inhibitors
displaying selectivity versus
other members of the MAP kinase family, like p38α MAP kinase,
was achieved during the past 4 years by either not addressing the
hydrophobic region I or targeting this region with a bulky naphthyl
moiety exploiting the flexibility of the methionine gatekeeper residue
as well as sulfur−π interactions.</p>
         <p>In 2013, the
first example of a JNK-selective inhibitor has been
reported. Azaquinolone <bold>59</bold> displayed in a panel of 451
kinases an exceptional selectivity for all three JNKs. Moreover, the
covalent inhibitor <bold>72</bold> (JNK-IN-8) reached, because of
its excellent selectivity, the status of a high-quality kinase probe
for JNKs.</p>
         <p>However, no JNK-isoform selective inhibitor is published
up to
now. Although it is controversially discussed if there is a need for
isoform selectivity, e.g., for the treatment of neurodegenerative
diseases, a final answer to this question can only be given if such
compounds are available as biological tools.</p>
         <p>Unfortunately,
the development of isoform selective inhibitors
targeting the active conformation of the kinase is not a trivial task
from the design perspective. Within the ATP binding pocket, differences
between the JNKs are very subtle and limited to two positions in the
hydrophobic region I. In this region, JNK1 and JNK2 differ by only
two amino acids (see Figure <xref rid="fig1"/>;  Met77 vs Leu77
and Ile106 vs Leu106) and JNK1/3 and JNK2/3 differ by only one amino
acid each (Ile106 vs Leu144 or Leu77 vs Met115). Therefore, one possibility
to obtain JNK1/3 selective inhibitors might be to target the methionine
side chain located deep in the hydrophobic region I. A promising strategy
could exploit the methionine sulfur atom for attractive halogen bonding
interactions<xref rid="ref163" ref-type="bibr"/> or utilize the flexibility
of this side chain compared to Leu77. The marginal difference between
Ile106 in JNK1 and the leucine in JNK2 and JNK3 might be even more
difficult to address. The amino acids in position “N2”
(Figure <xref rid="fig1"/>, Ile54/Val54/Ile92), which also differ
among the JNKs, flank the binding cleft only via backbone atoms and
might not be a major selectivity determinant.</p>
         <p>Although difficult
to predict, making use of subtle differences
in the arrangement of secondary structure elements or addressing the
inactive DFG-out conformation by type II inhibitors, which are largely
underrepresented in the current JNK inhibitor portfolio, could also
offer a way to achieve intra-JNK selectivity.</p>
         <p>Apart from the
use of non-ATP-competitive JNK inhibitors, a further
approach to design more effective inhibitors of the JNK pathway might
be the targeting of upstream kinases that regulate the JNKs. One possible
target represents the dual leucine zipper kinase (DLK, MAP3K12), which
is expressed predominately in neuronal cells. DLK activates JNKs via
phosphorylation of MKK4 and MKK7.<named-content content-type="bibref-group"><xref rid="ref164" ref-type="bibr"/>,<xref rid="ref165" ref-type="bibr"/></named-content> Recent studies
suggest that DLK plays a central role as a regulator of neuronal degeneration.<named-content content-type="bibref-group"><xref rid="ref166" ref-type="bibr"/>−<xref rid="ref167" specific-use="suppress-in-print" ref-type="bibr"/><xref rid="ref168" ref-type="bibr"/></named-content> Therefore, this kinase may be an attractive target for the treatment
of neurodegenerative diseases.<xref rid="ref169" ref-type="bibr"/></p>
         <p>Another future direction for targeting the JNK pathway might be
the selective inhibition of splice variants, which have different
substrate affinities and enzyme kinetics and are consequently assumed
to vary in biological function. Since those splice isoforms do not
differ in the ATP binding pockets, classical ATP-competitive inhibitors
are unlikely to be successful in this approach. Here, small molecules
addressing allosteric binding sites and dual inhibitors targeting
substrate binding sites plus the ATP pocket could come into play.
An alternative approach is the selective targeting of interactions
between the JNKs and individual substrates by specifically disrupting
protein–protein interactions. Since the compounds needed for
those purposes require distinct scaffolds unrelated to the well-known
ATP-mimetics, an increase in structural diversity widening the chemical
space of JNK inhibitors is required. A further step forward would
be compartment specific JNK targeting, since it becomes more and more
clear that the physiological roles of JNKs are largely dependent on
their cellular localization.</p>
         <p>However, all of these approaches
require innovative strategies
in inhibitor design combining expertise in classical medicinal and
organic chemistry with competences in chemical biology and biotechnology.
Moreover, novel cellular and in vitro assays will have to be established
to enable the development of such inhibitors and to assess their clinical
potential.</p>
      </sec>
   </body>
   <back>
      <notes id="notes-1" notes-type="author-contributions">
         <p><sup>†</sup> P.K. and
M.G. contributed equally.</p>
      </notes>
      <notes id="notes-2" notes-type="conflict-of-interest">
         <p>The authors
declare no competing financial interest.</p>
      </notes>
      <bio id="BIO-d2969e2951-autogenerated" rid="ath1">
         <p><bold>Pierre Koch</bold> graduated in Chemistry in 2005 at the
Eberhard Karls Universität Tübingen, Germany, and received
his Ph.D. in Pharmaceutical Chemistry in 2009 from the same institution.
In 2010–2011, he worked as a Postdoctoral Fellow at the University
of CaliforniaLos Angeles (UCLA) under the supervision of Prof.
Michael E. Jung. In 2012, he joined the group of Prof. Christa E.
Müller at the University of Bonn, Germany, for a second postdoctoral
stay. Since 2013, he has been Assistant Professor for Medicinal Chemistry
at the Eberhard Karls Universität Tübingen. His research
interest includes novel inhibitors of protein kinases involved in
CNS diseases as well as the (total) synthesis of biologically active
natural products.</p>
      </bio>
      <bio id="BIO-d2969e2956-autogenerated" rid="ath2">
         <p><bold>Matthias Gehringer</bold> studied chemistry at the KIT Karlsruhe,
the University of Heidelberg (Germany), and the ENSC Montpellier (France).
He completed his undergraduate studies in medicinal chemistry under
guidance of Prof. Christian Klein at the University of Heidelberg.
Then he moved to the Eberhard Karls University Tübingen, Germany,
where he recently completed his Ph.D. studies in the group of Prof.
Stefan A. Laufer. His current research focuses on the design, synthesis,
and biological evaluation of novel kinase inhibitors.</p>
      </bio>
      <bio id="BIO-d2969e2961-autogenerated" rid="ath3">
         <p><bold>Stefan A. Laufer</bold> studied pharmacy and completed
his
Ph.D. from Regensburg University, Germany (supervisor, Prof. G. Dannhardt).
After postdoctoral research in Frankfurt, he took a position in the
pharmaceutical industry but maintained lectureships at Frankfurt and
later Mainz University, Germany, where he finished his habilitation
in 1997. Since 1999, he has been Full Professor (Chair) of Pharmaceutical
and Medicinal Chemistry at the Eberhard Karls Universität Tübingen,
Germany. He is cofounder/spokesman of CAIR Biosciences and ICEPHA
(Interfaculty Center for Pharmacogenomics and Pharma Research). Since
2006, he has been Vice President of the Board of Trustees of Eberhard
Karls Universität Tübingen, and since 2012 Vice President
of the DPhG. Recently, he was accepted as a corresponding member of
the Brazilian Academy of Sciences (ABC). His research interests are
in protein kinase inhibitors and eicosanoid modulators.</p>
      </bio>
      <ack>
         <title>Acknowledgments</title>
         <p>Peter Keck is gratefully acknowledged for contributing
the
table of contents graphic. The authors thank Dr. Brian T. Chamberlain
(University of CaliforniaLos Angeles) for useful suggestions
in further refining of the manuscript. M.G. gratefully acknowledges
support by the Institutional Strategy of the University of Tübingen
(Deutsche Forschungsgemeinschaft, ZUK 63). The authors are grateful
to Inte:Ligand Software-Entwicklungs und Consulting GmbH (Maria Enzersdorf,
Austria) for providing the LigandScout software.</p>
      </ack>
      <glossary>
         <def-list id="dl1" specific-use="delimiter-char:, ">
            <title>Abbreviations Used</title>
            <def-item>
               <term>6-OHDA</term>
               <def>
                  <p>6-hydroxydopamine</p>
               </def>
            </def-item>
            <def-item>
               <term>TPA</term>
               <def>
                  <p>12-<italic toggle="yes">O</italic>-tetradecanoylphorbol 13-acetate</p>
               </def>
            </def-item>
            <def-item>
               <term>AD</term>
               <def>
                  <p>Alzheimer’s disease</p>
               </def>
            </def-item>
            <def-item>
               <term>Aβ42</term>
               <def>
                  <p>amyloid-β 42</p>
               </def>
            </def-item>
            <def-item>
               <term>BAL</term>
               <def>
                  <p>bronchial alveolar lavage</p>
               </def>
            </def-item>
            <def-item>
               <term>CNS</term>
               <def>
                  <p>central nervous
system</p>
               </def>
            </def-item>
            <def-item>
               <term>ERK</term>
               <def>
                  <p>extracellular-regulated
kinase</p>
               </def>
            </def-item>
            <def-item>
               <term>HD</term>
               <def>
                  <p>Huntington’s
disease</p>
               </def>
            </def-item>
            <def-item>
               <term>HK-2</term>
               <def>
                  <p>human
kidney cell</p>
               </def>
            </def-item>
            <def-item>
               <term>HTS</term>
               <def>
                  <p>high throughput screening</p>
               </def>
            </def-item>
            <def-item>
               <term>IBD</term>
               <def>
                  <p>inflammatory bowel disease</p>
               </def>
            </def-item>
            <def-item>
               <term>IL-1β</term>
               <def>
                  <p>interleukin 1β</p>
               </def>
            </def-item>
            <def-item>
               <term>IPF</term>
               <def>
                  <p>idiopathic pulmonary fibrosis</p>
               </def>
            </def-item>
            <def-item>
               <term>JIP-1</term>
               <def>
                  <p>JNK-interacting
protein 1</p>
               </def>
            </def-item>
            <def-item>
               <term>JNK</term>
               <def>
                  <p>c-Jun
N-terminal kinase</p>
               </def>
            </def-item>
            <def-item>
               <term>MAP</term>
               <def>
                  <p>mitogen-activated protein</p>
               </def>
            </def-item>
            <def-item>
               <term>LRRK2</term>
               <def>
                  <p>leucine rich repeat kinase 2</p>
               </def>
            </def-item>
            <def-item>
               <term>MEF</term>
               <def>
                  <p>murine embryonic fibroblast mitogen-activated
protein</p>
               </def>
            </def-item>
            <def-item>
               <term>MEF</term>
               <def>
                  <p>murine
embryonic fibroblast</p>
               </def>
            </def-item>
            <def-item>
               <term>MKK</term>
               <def>
                  <p>mitogen-activated protein kinase kinase</p>
               </def>
            </def-item>
            <def-item>
               <term>MS</term>
               <def>
                  <p>multiple sclerosis</p>
               </def>
            </def-item>
            <def-item>
               <term>PD</term>
               <def>
                  <p>Parkinson’s disease</p>
               </def>
            </def-item>
            <def-item>
               <term>pepJIP</term>
               <def>
                  <p>JNK-interacting protein
peptide</p>
               </def>
            </def-item>
            <def-item>
               <term>PK</term>
               <def>
                  <p>pharmacokinetics</p>
               </def>
            </def-item>
            <def-item>
               <term>RA</term>
               <def>
                  <p>rheumatoid arthritis</p>
               </def>
            </def-item>
            <def-item>
               <term>ROS</term>
               <def>
                  <p>reactive oxygen
species</p>
               </def>
            </def-item>
            <def-item>
               <term>TNF-α</term>
               <def>
                  <p>tumor necrosis factor α</p>
               </def>
            </def-item>
         </def-list>
      </glossary>
      <ref-list>
         <title>References</title>
         <ref id="ref1">
            <element-citation publication-type="journal" id="cit1">
               <name name-style="western">
                  <surname>Seki</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brenner</surname>
                  <given-names>D. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>A liver full of JNK: signaling in
regulation of cell function and disease pathogenesis, and clinical
approaches</article-title>
               <source>Gastroenterology</source>
               <year>2012</year>
               <volume>143</volume>
               <fpage>307</fpage>
               <lpage>320</lpage>
            </element-citation>
         </ref>
         <ref id="ref2">
            <element-citation publication-type="journal" id="cit2">
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>M. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hunt</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herrgard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciceri</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wodicka</surname>
                  <given-names>L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pallares</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hocker</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Treiber</surname>
                  <given-names>D. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zarrinkar</surname>
                  <given-names>P. P.</given-names>
               </name>
               <article-title>Comprehensive
analysis of kinase inhibitor selectivity</article-title>
               <source>Nat.
Biotechnol.</source>
               <year>2011</year>
               <volume>29</volume>
               <fpage>1046</fpage>
               <lpage>1051</lpage>
            </element-citation>
         </ref>
         <ref id="ref3">
            <element-citation publication-type="journal" id="cit3">
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <article-title>Signal
transduction by the JNK group of MAP kinases</article-title>
               <source>Cell (Cambridge, MA, U. S.)</source>
               <year>2000</year>
               <volume>103</volume>
               <fpage>239</fpage>
               <lpage>252</lpage>
            </element-citation>
         </ref>
         <ref id="ref4">
            <element-citation publication-type="journal" id="cit4">
               <name name-style="western">
                  <surname>Hibi</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>A. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smeal</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Minden</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Identification
of an oncoprotein-responsive and UV-responsive protein-kinase that
binds and potentiates the c-Jun activation domain</article-title>
               <source>Genes Dev.</source>
               <year>1993</year>
               <volume>7</volume>
               <fpage>2135</fpage>
               <lpage>2148</lpage>
            </element-citation>
         </ref>
         <ref id="ref5">
            <element-citation publication-type="journal" id="cit5">
               <name name-style="western">
                  <surname>Hanks</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hunter</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Protein kinases 6. The eukaryotic protein-kinase superfamilykinase
(catalytic) domain-structure and classification</article-title>
               <source>FASEB J.</source>
               <year>1995</year>
               <volume>9</volume>
               <fpage>576</fpage>
               <lpage>596</lpage>
            </element-citation>
         </ref>
         <ref id="ref6">
            <element-citation publication-type="journal" id="cit6">
               <name name-style="western">
                  <surname>Dérijard</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hibi</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>I.-H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barrett</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Su</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Deng</surname>
                  <given-names>T. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <article-title>JNK1a protein-kinase
stimulated by UV-light and Ha-Ras that binds and phosphorylates the
C-Jun activation domain</article-title>
               <source>Cell (Cambridge, MA,
U. S.)</source>
               <year>1994</year>
               <volume>76</volume>
               <fpage>1025</fpage>
               <lpage>1037</lpage>
            </element-citation>
         </ref>
         <ref id="ref7">
            <element-citation publication-type="journal" id="cit7">
               <name name-style="western">
                  <surname>Gupta</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barrett</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Whitmarsh</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cavanagh</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sluss</surname>
                  <given-names>H. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Derijard</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <article-title>Selective
interaction of JNK protein
kinase isoforms with transcription factors</article-title>
               <source>EMBO J.</source>
               <year>1996</year>
               <volume>15</volume>
               <fpage>2760</fpage>
               <lpage>2770</lpage>
            </element-citation>
         </ref>
         <ref id="ref8">
            <element-citation publication-type="journal" id="cit8">
               <name name-style="western">
                  <surname>Bogoyevitch</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kobe</surname>
                  <given-names>B.</given-names>
               </name>
               <article-title>Uses for JNK:
the many and varied substrates of the c-Jun N-terminal
kinases</article-title>
               <source>Microbiol. Mol. Biol. Rev.</source>
               <year>2006</year>
               <volume>70</volume>
               <fpage>1061</fpage>
               <lpage>1095</lpage>
            </element-citation>
         </ref>
         <ref id="ref9">
            <mixed-citation publication-type="computer-program" id="cit9"><source>The PyMOL Molecular
Graphics System</source>, version <edition>1.41</edition>; <publisher-name>Schrodinger, LLC</publisher-name>: <publisher-loc>New York</publisher-loc>, <year>2010</year>.</mixed-citation>
         </ref>
         <ref id="ref10">
            <element-citation publication-type="journal" id="cit10">
               <name name-style="western">
                  <surname>Graczyk</surname>
                  <given-names>P.
P.</given-names>
               </name>
               <article-title>JNK inhibitors
as anti-inflammatory and neuroprotective agents</article-title>
               <source>Future Med. Chem.</source>
               <year>2013</year>
               <volume>5</volume>
               <fpage>539</fpage>
               <lpage>551</lpage>
            </element-citation>
         </ref>
         <ref id="ref11">
            <element-citation publication-type="journal" id="cit11">
               <name name-style="western">
                  <surname>Ferrer</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blanco</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carmona</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Puig</surname>
                  <given-names>B.</given-names>
               </name>
               <article-title>Phosphorylated mitogen-activated
protein kinase (MAPK/ERK-P), protein kinase of 38kDa (p38-P), stress-activated
protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase
II (CaM kinase II) are differentially expressed in tau deposits in
neurons and glial cells in tauopathies</article-title>
               <source>J. Neural
Transm.</source>
               <year>2001</year>
               <volume>108</volume>
               <fpage>1397</fpage>
               <lpage>1415</lpage>
            </element-citation>
         </ref>
         <ref id="ref12">
            <element-citation publication-type="journal" id="cit12">
               <name name-style="western">
                  <surname>Ferrer</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blanco</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carmona</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Puig</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Domínguez</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Viñals</surname>
                  <given-names>F.</given-names>
               </name>
               <article-title>Active, phosphorylation-dependent
MAP kinases, MAPK/ERK,
SAPK/JNK and p38, and specific transcription factor substrates are
differentially expressed following systemic administration of kainic
acid to the adult rat</article-title>
               <source>Acta Neuropathol.</source>
               <year>2002</year>
               <volume>103</volume>
               <fpage>391</fpage>
               <lpage>407</lpage>
            </element-citation>
         </ref>
         <ref id="ref13">
            <element-citation publication-type="journal" id="cit13">
               <name name-style="western">
                  <surname>Yoon</surname>
                  <given-names>S. O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ryu</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ozer</surname>
                  <given-names>H. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tep</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lim</surname>
                  <given-names>T. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pastorino</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kunwar</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Walton</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nagahara</surname>
                  <given-names>A. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lu</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nelson</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tuszynski</surname>
                  <given-names>M. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>K.</given-names>
               </name>
               <article-title>JNK3 perpetuates metabolic
stress induced by Aβ peptides</article-title>
               <source>Neuron</source>
               <year>2012</year>
               <volume>75</volume>
               <fpage>824</fpage>
               <lpage>837</lpage>
            </element-citation>
         </ref>
         <ref id="ref14">
            <element-citation publication-type="journal" id="cit14">
               <name name-style="western">
                  <surname>Hunot</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vila</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Teismann</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hirsch</surname>
                  <given-names>E. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Przedborski</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rakic</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <article-title>JNK-mediated induction
of cyclooxygenase 2 is required for neurodegeneration in a mouse model
of Parkinson’s disease</article-title>
               <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
               <year>2004</year>
               <volume>101</volume>
               <fpage>665</fpage>
               <lpage>670</lpage>
            </element-citation>
         </ref>
         <ref id="ref15">
            <element-citation publication-type="journal" id="cit15">
               <name name-style="western">
                  <surname>Ungerstedt</surname>
                  <given-names>U.</given-names>
               </name>
               <article-title>6-Hydroxy-dopamine
induced degeneration of central monoamine neurons</article-title>
               <source>Eur. J. Pharmacol.</source>
               <year>1968</year>
               <volume>5</volume>
               <fpage>107</fpage>
               <lpage>110</lpage>
            </element-citation>
         </ref>
         <ref id="ref16">
            <element-citation publication-type="journal" id="cit16">
               <name name-style="western">
                  <surname>Ungerstedt</surname>
                  <given-names>U.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arbuthnott</surname>
                  <given-names>G. W.</given-names>
               </name>
               <article-title>Quantitative recording of rotational behavior in rats
after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</article-title>
               <source>Brain Res.</source>
               <year>1970</year>
               <volume>24</volume>
               <fpage>485</fpage>
               <lpage>493</lpage>
            </element-citation>
         </ref>
         <ref id="ref17">
            <element-citation publication-type="journal" id="cit17">
               <name name-style="western">
                  <surname>Brecht</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirchhof</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chromik</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Willesen</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicolaus</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Raivich</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wessig</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Waetzig</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goetz</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Claussen</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pearse</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuan</surname>
                  <given-names>C. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vaudano</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Behrens</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herdegen</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>Specific pathophysiological functions of JNK isoforms
in the brain</article-title>
               <source>Eur. J. Neurosci.</source>
               <year>2005</year>
               <volume>21</volume>
               <fpage>363</fpage>
               <lpage>377</lpage>
            </element-citation>
         </ref>
         <ref id="ref18">
            <element-citation publication-type="journal" id="cit18">
               <name name-style="western">
                  <surname>Swantek</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cobb</surname>
                  <given-names>M. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Geppert</surname>
                  <given-names>T. D.</given-names>
               </name>
               <article-title>Jun N-terminal
kinase stress-activated
protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation
of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids
inhibit TNF-alpha translation by blocking JNK/SAPK</article-title>
               <source>Mol. Cell. Biol.</source>
               <year>1997</year>
               <volume>17</volume>
               <fpage>6274</fpage>
               <lpage>6282</lpage>
            </element-citation>
         </ref>
         <ref id="ref19">
            <element-citation publication-type="journal" id="cit19">
               <name name-style="western">
                  <surname>Han</surname>
                  <given-names>Z. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>L. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yamanishi</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Firestein</surname>
                  <given-names>G. S.</given-names>
               </name>
               <article-title>Joint damage
and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive
murine collagen-induced arthritis</article-title>
               <source>Arthritis
Rheum.</source>
               <year>2002</year>
               <volume>46</volume>
               <fpage>818</fpage>
               <lpage>823</lpage>
            </element-citation>
         </ref>
         <ref id="ref20">
            <element-citation publication-type="journal" id="cit20">
               <name name-style="western">
                  <surname>Guma</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ronacher</surname>
                  <given-names>L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Firestein</surname>
                  <given-names>G. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Corr</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>JNK-1 deficiency
limits macrophage-mediated antigen-induced arthritis</article-title>
               <source>Arthritis Rheum.</source>
               <year>2011</year>
               <volume>63</volume>
               <fpage>1603</fpage>
               <lpage>1612</lpage>
            </element-citation>
         </ref>
         <ref id="ref21">
            <element-citation publication-type="journal" id="cit21">
               <name name-style="western">
                  <surname>Bubici</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Papa</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>JNK signalling in cancer: in need of new, smarter therapeutic targets</article-title>
               <source>Br. J. Pharmacol.</source>
               <year>2014</year>
               <volume>171</volume>
               <fpage>24</fpage>
               <lpage>37</lpage>
            </element-citation>
         </ref>
         <ref id="ref22">
            <element-citation publication-type="journal" id="cit22">
               <name name-style="western">
                  <surname>Tournier</surname>
                  <given-names>C.</given-names>
               </name>
               <article-title>The 2 faces
of JNK signaling in cancer</article-title>
               <source>Genes Cancer</source>
               <year>2013</year>
               <volume>4</volume>
               <fpage>397</fpage>
               <lpage>400</lpage>
            </element-citation>
         </ref>
         <ref id="ref23">
            <element-citation publication-type="journal" id="cit23">
               <name name-style="western">
                  <surname>Cellurale</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Girnius</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cavanagh-Kyros</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lu</surname>
                  <given-names>S. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Garlick</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mercurio</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <article-title>Role of
JNK in mammary gland development and breast cancer</article-title>
               <source>Cancer Res.</source>
               <year>2012</year>
               <volume>72</volume>
               <fpage>472</fpage>
               <lpage>481</lpage>
            </element-citation>
         </ref>
         <ref id="ref24">
            <element-citation publication-type="journal" id="cit24">
               <name name-style="western">
                  <surname>She</surname>
                  <given-names>Q.-B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>N. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bode</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dong</surname>
                  <given-names>Z. G.</given-names>
               </name>
               <article-title>Deficiency
of c-Jun-NH<sub>2</sub>-terminal kinase-1 in mice enhances skin tumor
development by 12-<italic toggle="yes">O</italic>-tetradecanoylphorbol-13-acetate</article-title>
               <source>Cancer Res.</source>
               <year>2002</year>
               <volume>62</volume>
               <fpage>1343</fpage>
               <lpage>1348</lpage>
            </element-citation>
         </ref>
         <ref id="ref25">
            <element-citation publication-type="journal" id="cit25">
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>N. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nomura</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>She</surname>
                  <given-names>Q. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ma</surname>
                  <given-names>W. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bode</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>L. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dong</surname>
                  <given-names>Z. G.</given-names>
               </name>
               <article-title>Suppression of skin
tumorigenesis in c-Jun NH2-terminal kinase-2-deficient mice</article-title>
               <source>Cancer Res.</source>
               <year>2001</year>
               <volume>61</volume>
               <fpage>3908</fpage>
               <lpage>3912</lpage>
            </element-citation>
         </ref>
         <ref id="ref26">
            <element-citation publication-type="journal" id="cit26">
               <name name-style="western">
                  <surname>Hui</surname>
                  <given-names>L. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zatloukal</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Scheuch</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stepniak</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>E. F.</given-names>
               </name>
               <article-title>Proliferation
of human HCC cells and chemically induced mouse liver cancers requires
JNK1-dependent p21 downregulation</article-title>
               <source>J. Clin.
Invest.</source>
               <year>2008</year>
               <volume>118</volume>
               <fpage>3943</fpage>
               <lpage>3953</lpage>
            </element-citation>
         </ref>
         <ref id="ref27">
            <element-citation publication-type="journal" id="cit27">
               <name name-style="western">
                  <surname>Belgardt</surname>
                  <given-names>B.
F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mauer</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brüning</surname>
                  <given-names>J. C.</given-names>
               </name>
               <article-title>Novel roles for JNK1 in metabolism</article-title>
               <source>Aging (Albany, NY, U. S.)</source>
               <year>2010</year>
               <volume>2</volume>
               <fpage>621</fpage>
               <lpage>626</lpage>
            </element-citation>
         </ref>
         <ref id="ref28">
            <element-citation publication-type="journal" id="cit28">
               <name name-style="western">
                  <surname>Kaneto</surname>
                  <given-names>H.</given-names>
               </name>
               <article-title>The JNK pathway
as a therapeutic target for diabetes</article-title>
               <source>Expert.
Opin. Ther. Targets</source>
               <year>2005</year>
               <volume>9</volume>
               <fpage>581</fpage>
               <lpage>592</lpage>
            </element-citation>
         </ref>
         <ref id="ref29">
            <element-citation publication-type="journal" id="cit29">
               <name name-style="western">
                  <surname>Kuan</surname>
                  <given-names>C. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burke</surname>
                  <given-names>R. E.</given-names>
               </name>
               <article-title>Targeting the JNK signaling pathway for stroke and
Parkinson’s diseases therapy</article-title>
               <source>Curr. Drug
Targets: CNS Neurol. Disord.</source>
               <year>2005</year>
               <volume>4</volume>
               <fpage>63</fpage>
               <lpage>67</lpage>
            </element-citation>
         </ref>
         <ref id="ref30">
            <element-citation publication-type="journal" id="cit30">
               <name name-style="western">
                  <surname>Kuan</surname>
                  <given-names>C. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Whitmarsh</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>D. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liao</surname>
                  <given-names>G. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schloemer</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dong</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bao</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Banasiak</surname>
                  <given-names>K. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haddad</surname>
                  <given-names>G. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rakic</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>A critical role of
neural-specific JNK3 for ischemic apoptosis</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2003</year>
               <volume>100</volume>
               <fpage>15184</fpage>
               <lpage>15189</lpage>
            </element-citation>
         </ref>
         <ref id="ref31">
            <element-citation publication-type="journal" id="cit31">
               <name name-style="western">
                  <surname>Kaiser</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liang</surname>
                  <given-names>Q. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bueno</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lackey</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Klevitsky</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hewett</surname>
                  <given-names>T. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Molkentin</surname>
                  <given-names>J. D.</given-names>
               </name>
               <article-title>Genetic
inhibition or activation of JNK1/2 protects the myocardium from ischemia–reperfusion-induced
cell death in vivo</article-title>
               <source>J. Biol. Chem.</source>
               <year>2005</year>
               <volume>280</volume>
               <fpage>32602</fpage>
               <lpage>32608</lpage>
            </element-citation>
         </ref>
         <ref id="ref32">
            <element-citation publication-type="journal" id="cit32">
               <name name-style="western">
                  <surname>Wei</surname>
                  <given-names>J. Q.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>W. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chopra</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>H. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dougherty</surname>
                  <given-names>C. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Adi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Adi</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Webster</surname>
                  <given-names>K. A.</given-names>
               </name>
               <article-title>c-Jun N-terminal
kinase (JNK-1) confers protection against brief but not extended ischemia
during acute myocardial infarction</article-title>
               <source>J. Biol.
Chem.</source>
               <year>2011</year>
               <volume>286</volume>
               <fpage>13995</fpage>
               <lpage>14006</lpage>
            </element-citation>
         </ref>
         <ref id="ref33">
            <element-citation publication-type="journal" id="cit33">
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J.
W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pachori</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Howard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Iqbal</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>Inhibition
of JNK mitochondrial localization and signaling is protective against
ischemia/reperfusion injury in rats</article-title>
               <source>J. Biol.
Chem.</source>
               <year>2013</year>
               <volume>288</volume>
               <fpage>4000</fpage>
               <lpage>4011</lpage>
            </element-citation>
         </ref>
         <ref id="ref34">
            <element-citation publication-type="journal" id="cit34">
               <name name-style="western">
                  <surname>Bennett</surname>
                  <given-names>B.
L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Satoh</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewis</surname>
                  <given-names>A. J.</given-names>
               </name>
               <article-title>JNK: a new therapeutic target for
diabetes</article-title>
               <source>Curr. Opin. Pharmacol.</source>
               <year>2003</year>
               <volume>3</volume>
               <fpage>420</fpage>
               <lpage>425</lpage>
            </element-citation>
         </ref>
         <ref id="ref35">
            <element-citation publication-type="journal" id="cit35">
               <name name-style="western">
                  <surname>Wellen</surname>
                  <given-names>K. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hotamisligil</surname>
                  <given-names>G. S.</given-names>
               </name>
               <article-title>Inflammation,
stress, and diabetes</article-title>
               <source>J. Clin. Invest.</source>
               <year>2005</year>
               <volume>115</volume>
               <fpage>1111</fpage>
               <lpage>1119</lpage>
            </element-citation>
         </ref>
         <ref id="ref36">
            <element-citation publication-type="journal" id="cit36">
               <name name-style="western">
                  <surname>Hirosumi</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tuncman</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>L. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gorgun</surname>
                  <given-names>C. Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uysal</surname>
                  <given-names>K. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Maeda</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hotamisligil</surname>
                  <given-names>G. S.</given-names>
               </name>
               <article-title>A central
role for JNK in obesity and insulin resistance</article-title>
               <source>Nature (London, U. K.)</source>
               <year>2002</year>
               <volume>420</volume>
               <fpage>333</fpage>
               <lpage>336</lpage>
            </element-citation>
         </ref>
         <ref id="ref37">
            <element-citation publication-type="journal" id="cit37">
               <name name-style="western">
                  <surname>Jaeschke</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rincón</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Doran</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reilly</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neuberg</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Greiner</surname>
                  <given-names>D. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shultz</surname>
                  <given-names>L. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rossini</surname>
                  <given-names>A. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Flavell</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>R. J.</given-names>
               </name>
               <article-title>Disruption of the Jnk2 (Mapk9) gene reduces destructive
insulitis and diabetes in a mouse model of type 1 diabetes</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2005</year>
               <volume>102</volume>
               <fpage>6931</fpage>
               <lpage>6935</lpage>
            </element-citation>
         </ref>
         <ref id="ref38">
            <element-citation publication-type="journal" id="cit38">
               <name name-style="western">
                  <surname>Humphries</surname>
                  <given-names>P. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lafontaine</surname>
                  <given-names>J. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Agree</surname>
                  <given-names>C. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Alexander</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Do</surname>
                  <given-names>Q. Q. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>L. L. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lunney</surname>
                  <given-names>E. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rajapakse</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Siegel</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Timofeevski</surname>
                  <given-names>S. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>T. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilhite</surname>
                  <given-names>D. M.</given-names>
               </name>
               <article-title>Synthesis and SAR of 4-substituted-2-aminopyrimidines
as novel c-Jun N-terminal kinase (JNK) inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2009</year>
               <volume>19</volume>
               <fpage>2099</fpage>
               <lpage>2102</lpage>
            </element-citation>
         </ref>
         <ref id="ref39">
            <element-citation publication-type="journal" id="cit39">
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>H. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xin</surname>
                  <given-names>Z. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kosogof</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Szczepankiewicz</surname>
                  <given-names>B. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clampit</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gum</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haasch</surname>
                  <given-names>D. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trevillyan</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <article-title>Aminopyridine carboxamides as c-Jun N-terminal kinase
inhibitors: targeting the gatekeeper residue and beyond</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2006</year>
               <volume>16</volume>
               <fpage>5723</fpage>
               <lpage>5730</lpage>
            </element-citation>
         </ref>
         <ref id="ref40">
            <element-citation publication-type="journal" id="cit40">
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clampit</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gum</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haasch</surname>
                  <given-names>D. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rondinone</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trevillyan</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abad-Zapatero</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fry</surname>
                  <given-names>E. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>G.</given-names>
               </name>
               <article-title>Discovery of a new
class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors:
synthesis and SAR studies</article-title>
               <source>Bioorg. Med. Chem.
Lett.</source>
               <year>2007</year>
               <volume>17</volume>
               <fpage>668</fpage>
               <lpage>672</lpage>
            </element-citation>
         </ref>
         <ref id="ref41">
            <element-citation publication-type="journal" id="cit41">
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xin</surname>
                  <given-names>Z. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clampit</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gum</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haasch</surname>
                  <given-names>D. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trevillyan</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abad-Zapatero</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fry</surname>
                  <given-names>E. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>G.</given-names>
               </name>
               <article-title>Synthesis
and SAR of
1,9-dihydro-9-hydroxypyrazolo­[3,4-<italic toggle="yes">b</italic>]­quinolin-4-ones
as novel, selective c-Jun N-terminal kinase inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2006</year>
               <volume>16</volume>
               <fpage>2590</fpage>
               <lpage>2594</lpage>
            </element-citation>
         </ref>
         <ref id="ref42">
            <element-citation publication-type="journal" id="cit42">
               <name name-style="western">
                  <surname>Stebbins</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>De</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Machleidt</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Becattini</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vazquez</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuntzen</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cellitti</surname>
                  <given-names>J. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Riel-Mehan</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Emdadi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Solinas</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pellecchia</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Identification of a new JNK inhibitor targeting the
JNK-JIP interaction site</article-title>
               <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
               <year>2008</year>
               <volume>105</volume>
               <fpage>16809</fpage>
               <lpage>16813</lpage>
            </element-citation>
         </ref>
         <ref id="ref43">
            <element-citation publication-type="journal" id="cit43">
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>L. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamata</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Solinas</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Luo</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Maeda</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Venuprasad</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>Y.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>The E3 ubiquitin ligase
Itch couples JNK activation to TNFα-induced cell death by inducing
c-FLIP<sub>L</sub> turnover</article-title>
               <source>Cell (Cambridge,
MA, U. S.)</source>
               <year>2006</year>
               <volume>124</volume>
               <fpage>601</fpage>
               <lpage>613</lpage>
            </element-citation>
         </ref>
         <ref id="ref44">
            <element-citation publication-type="journal" id="cit44">
               <name name-style="western">
                  <surname>Gunawan</surname>
                  <given-names>B.
K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>Z. X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Han</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hanawa</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gaarde</surname>
                  <given-names>W. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kaplowitz</surname>
                  <given-names>N.</given-names>
               </name>
               <article-title>c-jun N-terminal
kinase plays a major role in murine
acetaminophen hepatotoxicity</article-title>
               <source>Gastroenterology</source>
               <year>2006</year>
               <volume>131</volume>
               <fpage>165</fpage>
               <lpage>178</lpage>
            </element-citation>
         </ref>
         <ref id="ref45">
            <element-citation publication-type="journal" id="cit45">
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Van de Water</surname>
                  <given-names>T. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonny</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>de Ribaupierre</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Puel</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zine</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>A peptide
inhibitor of c-Jun N-terminal
kinase protects against both aminoglycoside and acoustic trauma-induced
auditory hair cell death and hearing loss</article-title>
               <source>J.
Neurosci.</source>
               <year>2003</year>
               <volume>23</volume>
               <fpage>8596</fpage>
               <lpage>8607</lpage>
            </element-citation>
         </ref>
         <ref id="ref46">
            <element-citation publication-type="journal" id="cit46">
               <name name-style="western">
                  <surname>Barkdull</surname>
                  <given-names>G.
C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hondarrague</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Meyer</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Harris</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keithley</surname>
                  <given-names>E. M.</given-names>
               </name>
               <article-title>AM-111
reduces hearing loss in a guinea pig model of acute labyrinthitis</article-title>
               <source>Laryngoscope</source>
               <year>2007</year>
               <volume>117</volume>
               <fpage>2174</fpage>
               <lpage>2182</lpage>
            </element-citation>
         </ref>
         <ref id="ref47">
            <element-citation publication-type="journal" id="cit47">
               <name name-style="western">
                  <surname>Coleman</surname>
                  <given-names>J. K. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Littlesunday</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jackson</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Meyer</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>AM-111 protects against
permanent hearing loss from impulse noise trauma</article-title>
               <source>Hearing Res.</source>
               <year>2007</year>
               <volume>226</volume>
               <fpage>70</fpage>
               <lpage>78</lpage>
            </element-citation>
         </ref>
         <ref id="ref48">
            <element-citation publication-type="journal" id="cit48">
               <name name-style="western">
                  <surname>Alcorn</surname>
                  <given-names>J. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>van der Velden</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>McElhinney</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Irvin</surname>
                  <given-names>C. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Janssen-Heininger</surname>
                  <given-names>Y.
M. W.</given-names>
               </name>
               <article-title>c-Jun N-terminal
kinase 1 is required for the development of pulmonary fibrosis</article-title>
               <source>Am. J. Respir. Cell Mol. Biol.</source>
               <year>2009</year>
               <volume>40</volume>
               <fpage>422</fpage>
               <lpage>432</lpage>
            </element-citation>
         </ref>
         <ref id="ref49">
            <element-citation publication-type="journal" id="cit49">
               <name name-style="western">
                  <surname>Sumara</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Belwal</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ricci</surname>
                  <given-names>R.</given-names>
               </name>
               <article-title>"Jnking" atherosclerosis</article-title>
               <source>Cell. Mol. Life Sci.</source>
               <year>2005</year>
               <volume>62</volume>
               <fpage>2487</fpage>
               <lpage>2494</lpage>
            </element-citation>
         </ref>
         <ref id="ref50">
            <element-citation publication-type="journal" id="cit50">
               <name name-style="western">
                  <surname>Repici</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>X. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Morel</surname>
                  <given-names>M. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Doulazmi</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sclip</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cannaya</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Veglianese</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kraftsik</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mariani</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Borsello</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dusart</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Specific inhibition of the JNK pathway
promotes locomotor recovery and neuroprotection after mouse spinal
cord injury</article-title>
               <source>Neurobiol. Dis.</source>
               <year>2012</year>
               <volume>46</volume>
               <fpage>710</fpage>
               <lpage>721</lpage>
            </element-citation>
         </ref>
         <ref id="ref51">
            <element-citation publication-type="journal" id="cit51">
               <name name-style="western">
                  <surname>Siddiqui</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>P. A.</given-names>
               </name>
               <article-title>Small molecule JNK (c-Jun N-terminal
kinase) inhibitors</article-title>
               <source>J. Med. Chem.</source>
               <year>2010</year>
               <volume>53</volume>
               <fpage>3005</fpage>
               <lpage>3012</lpage>
            </element-citation>
         </ref>
         <ref id="ref52">
            <element-citation publication-type="journal" id="cit52">
               <name name-style="western">
                  <surname>Bogoyevitch</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ngoei</surname>
                  <given-names>K. R. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>T. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yeap</surname>
                  <given-names>Y. Y. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ng</surname>
                  <given-names>D. C. H.</given-names>
               </name>
               <article-title>c-Jun
N-terminal kinase (JNK) signaling: recent advances and challenges</article-title>
               <source>Bichim. Biophys. Acta, Proteins Proteomics</source>
               <year>2010</year>
               <volume>1804</volume>
               <fpage>463</fpage>
               <lpage>475</lpage>
            </element-citation>
         </ref>
         <ref id="ref53">
            <element-citation publication-type="journal" id="cit53">
               <name name-style="western">
                  <surname>Halazy</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Designing
heterocyclic selective kinase inhibitors: from concept to new drug
candidates</article-title>
               <source>ARKIVOC (Gainesville, FL, U. S.)</source>
               <year>2006</year>
               <fpage>496</fpage>
               <lpage>508</lpage>
            </element-citation>
         </ref>
         <ref id="ref54">
            <mixed-citation publication-type="patent" id="cit54"><person-group person-group-type="allauthors"><name name-style="western"><surname>Rommel</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Vitte</surname><given-names>P.-A.</given-names></name></person-group> <article-title>Pharmaceutical composition
comprising a JNK inhibitor and cyclosporin</article-title>. <patent>WO2005097116A1</patent>, <year>2005</year>.</mixed-citation>
         </ref>
         <ref id="ref55">
            <mixed-citation publication-type="weblink" id="cit55">NCT01630252.
JNK ClinicalTrials.gov. <uri>https://clinicaltrials.gov/</uri> (accessed
Jul 29, <year>2014</year>).</mixed-citation>
         </ref>
         <ref id="ref56">
            <element-citation publication-type="journal" id="cit56">
               <name name-style="western">
                  <surname>Krenitsky</surname>
                  <given-names>V. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nadolny</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delgado</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ayala</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clareen</surname>
                  <given-names>S. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hilgraf</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Albers</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hegde</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>D’Sidocky</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sapienza</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>McCarrick</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bahmanyar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chamberlain</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delker</surname>
                  <given-names>S. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muir</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Giegel</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Celeridad</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lachowitzer</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bennett</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Moghaddam</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khatsenko</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Katz</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fan</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bai</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shirley</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Benish</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bodine</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blease</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Raymon</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cathers</surname>
                  <given-names>B. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Satoh</surname>
                  <given-names>Y.</given-names>
               </name>
               <article-title>Discovery
of CC-930, an orally active anti-fibrotic JNK inhibitor</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>22</volume>
               <fpage>1433</fpage>
               <lpage>1438</lpage>
            </element-citation>
         </ref>
         <ref id="ref57">
            <mixed-citation publication-type="weblink" id="cit57">NCT01466725,
NCT01203943. JNK ClinicalTrials.gov. <uri>https://clinicaltrials.gov/</uri> (accessed Jun 29, <year>2014</year>).</mixed-citation>
         </ref>
         <ref id="ref58">
            <mixed-citation publication-type="weblink" id="cit58">NCT01570205,
NCT00802425. JNK ClinicalTrials.gov. <uri>https://clinicaltrials.gov/</uri> (accessed Jul 29, <year>2014</year>).</mixed-citation>
         </ref>
         <ref id="ref59">
            <element-citation publication-type="journal" id="cit59">
               <name name-style="western">
                  <surname>Deloche</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lopez-Lazaro</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mouz</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Perino</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abadie</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Combette</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <article-title>XG-102 administered to healthy male volunteers as a
single intravenous infusion: a randomized, double-blind, placebo-controlled,
dose-escalating study</article-title>
               <source>Pharmacol. Res. Perspect.</source>
               <year>2014</year>
               <volume>2</volume>
               <fpage>e00020</fpage>
            </element-citation>
         </ref>
         <ref id="ref60">
            <element-citation publication-type="journal" id="cit60">
               <name name-style="western">
                  <surname>Suckfuell</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Canis</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Strieth</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Scherer</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haisch</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>Intratympanic
treatment of acute acoustic trauma with a cell-permeable JNK ligand:
a prospective randomized phase I/II study</article-title>
               <source>Acta
Oto-Laryngol.</source>
               <year>2007</year>
               <volume>127</volume>
               <fpage>938</fpage>
               <lpage>942</lpage>
            </element-citation>
         </ref>
         <ref id="ref61">
            <mixed-citation publication-type="weblink" id="cit61">Xigen.
Product Pipeline. <uri>http://www.xigenpharma.com/product_pipeline.htm</uri>.</mixed-citation>
         </ref>
         <ref id="ref62">
            <element-citation publication-type="journal" id="cit62">
               <name name-style="western">
                  <surname>Bennett</surname>
                  <given-names>B. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sasaki</surname>
                  <given-names>D. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Murray</surname>
                  <given-names>B. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>O’Leary</surname>
                  <given-names>E. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sakata</surname>
                  <given-names>S. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Leisten</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Motiwala</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pierce</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Satoh</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bhagwat</surname>
                  <given-names>S. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Manning</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Anderson</surname>
                  <given-names>D. W.</given-names>
               </name>
               <article-title>SP600125, an anthrapyrazolone inhibitor
of Jun N-terminal
kinase</article-title>
               <source>Proc. Natl. Acad. Sci. U.S.A.</source>
               <year>2001</year>
               <volume>98</volume>
               <fpage>13681</fpage>
               <lpage>13686</lpage>
            </element-citation>
         </ref>
         <ref id="ref63">
            <element-citation publication-type="journal" id="cit63">
               <name name-style="western">
                  <surname>Guan</surname>
                  <given-names>Q. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pei</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>X. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>X. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>T. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>G. Y.</given-names>
               </name>
               <article-title>Neuroprotection
against ischemic brain injury by SP600125
via suppressing the extrinsic and intrinsic pathways of apoptosis</article-title>
               <source>Brain Res.</source>
               <year>2006</year>
               <volume>1092</volume>
               <fpage>36</fpage>
               <lpage>46</lpage>
            </element-citation>
         </ref>
         <ref id="ref64">
            <element-citation publication-type="journal" id="cit64">
               <name name-style="western">
                  <surname>Yoshimura</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ueno</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nakamura</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sato</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yoshimura</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kishima</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yoshimine</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yamashita</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>C-Jun N-terminal kinase induces axonal degeneration
and limits motor recovery after spinal cord injury in mice</article-title>
               <source>Neurosci. Res.</source>
               <year>2011</year>
               <volume>71</volume>
               <fpage>266</fpage>
               <lpage>277</lpage>
            </element-citation>
         </ref>
         <ref id="ref65">
            <element-citation publication-type="journal" id="cit65">
               <name name-style="western">
                  <surname>Zheng</surname>
                  <given-names>Y. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>M. Q.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>Y. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cai</surname>
                  <given-names>W. W.</given-names>
               </name>
               <article-title>JNK inhibitor SP600125 protects against lipopolysaccharide-induced
acute lung injury via upregulation of claudin-4</article-title>
               <source>Exp. Ther. Med.</source>
               <year>2014</year>
               <volume>8</volume>
               <fpage>153</fpage>
               <lpage>158</lpage>
            </element-citation>
         </ref>
         <ref id="ref66">
            <element-citation publication-type="journal" id="cit66">
               <name name-style="western">
                  <surname>Fabian</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Biggs</surname>
                  <given-names>W. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Treiber</surname>
                  <given-names>D. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Atteridge</surname>
                  <given-names>C. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Azimioara</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Benedetti</surname>
                  <given-names>M. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carter</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciceri</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Edeen</surname>
                  <given-names>P. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Floyd</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ford</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Galvin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gerlach</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grotzfeld</surname>
                  <given-names>R. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herrgard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Insko</surname>
                  <given-names>D. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Insko</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lai</surname>
                  <given-names>A. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lelias</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mehta</surname>
                  <given-names>S. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Milanov</surname>
                  <given-names>Z. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Velasco</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wodicka</surname>
                  <given-names>L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>H. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zarrinkar</surname>
                  <given-names>P. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lockhart</surname>
                  <given-names>D. J.</given-names>
               </name>
               <article-title>A small molecule-kinase interaction
map for clinical kinase inhibitors</article-title>
               <source>Nat. Biotechnol.</source>
               <year>2005</year>
               <volume>23</volume>
               <fpage>329</fpage>
               <lpage>336</lpage>
            </element-citation>
         </ref>
         <ref id="ref67">
            <element-citation publication-type="journal" id="cit67">
               <name name-style="western">
                  <surname>Goettert</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Luik</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Graeser</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laufer</surname>
                  <given-names>S. A.</given-names>
               </name>
               <article-title>A direct ELISA assay
for quantitative determination of the inhibitory potency of small
molecules inhibitors for JNK3</article-title>
               <source>J. Pharm. Biomed.
Anal.</source>
               <year>2011</year>
               <volume>55</volume>
               <fpage>236</fpage>
               <lpage>240</lpage>
            </element-citation>
         </ref>
         <ref id="ref68">
            <element-citation publication-type="journal" id="cit68">
               <name name-style="western">
                  <surname>Feng</surname>
                  <given-names>Y. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Iqbal</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cherry</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hernandez</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Figuera-Losada</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>A small molecule bidentate-binding
dual inhibitor probe
of the LRRK2 and JNK kinases</article-title>
               <source>ACS Chem. Biol.</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>1747</fpage>
               <lpage>1754</lpage>
            </element-citation>
         </ref>
         <ref id="ref69">
            <element-citation publication-type="journal" id="cit69">
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Inesta-Vaquera</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Niepel</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ficarro</surname>
                  <given-names>S. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Machleidt</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xie</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Marto</surname>
                  <given-names>J. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sim</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laughlin</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patricelli</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nomanbhoy</surname>
                  <given-names>T. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sorger</surname>
                  <given-names>P. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Alessi</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gray</surname>
                  <given-names>N. S.</given-names>
               </name>
               <article-title>Discovery
of potent and selective covalent inhibitors of JNK</article-title>
               <source>Chem. Biol.</source>
               <year>2012</year>
               <volume>19</volume>
               <fpage>140</fpage>
               <lpage>154</lpage>
            </element-citation>
         </ref>
         <ref id="ref70">
            <element-citation publication-type="journal" id="cit70">
               <name name-style="western">
                  <surname>Krenitsky</surname>
                  <given-names>V. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delgado</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nadolny</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sahasrabudhe</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ayala</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clareen</surname>
                  <given-names>S. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hilgraf</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Albers</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kois</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hughes</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nowakowski</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sudbeck</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ghosh</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bahmanyar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chamberlain</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Muir</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cathers</surname>
                  <given-names>B. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Giegel</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Celeridad</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Moghaddam</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khatsenko</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Omholt</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Katz</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pai</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fan</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shirley</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Benish</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blease</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Raymon</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bhagwat</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Henderson</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cole</surname>
                  <given-names>A. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bennett</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Satoh</surname>
                  <given-names>Y.</given-names>
               </name>
               <article-title>Aminopurine based JNK
inhibitors for the prevention of ischemia reperfusion injury</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>22</volume>
               <fpage>1427</fpage>
               <lpage>1432</lpage>
            </element-citation>
         </ref>
         <ref id="ref71">
            <element-citation publication-type="journal" id="cit71">
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>L. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>J. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhong</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zheng</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xu</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ji</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>W. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>X. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>L. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wei</surname>
                  <given-names>Y. Q.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <article-title>Structural optimization
and structure–activity relationships of <italic toggle="yes">N</italic><sup>2</sup>-(4-(4-methylpiperazin-1-yl)­phenyl)-<italic toggle="yes">N</italic><sup>8</sup>-phenyl-9<italic toggle="yes">H</italic>-purine-2,8-diamine derivatives,
a new class of reversible kinase inhibitors targeting both EGFR-activating
and resistance mutations</article-title>
               <source>J. Med. Chem.</source>
               <year>2012</year>
               <volume>55</volume>
               <fpage>10685</fpage>
               <lpage>10699</lpage>
            </element-citation>
         </ref>
         <ref id="ref72">
            <element-citation publication-type="journal" id="cit72">
               <name name-style="western">
                  <surname>Traxler</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Tyrosine kinase
inhibitors in cancer treatment (part II)</article-title>
               <source>Expert
Opin. Ther. Pat.</source>
               <year>1998</year>
               <volume>8</volume>
               <fpage>1599</fpage>
               <lpage>1625</lpage>
            </element-citation>
         </ref>
         <ref id="ref73">
            <element-citation publication-type="journal" id="cit73">
               <name name-style="western">
                  <surname>Graczyk</surname>
                  <given-names>P. P.</given-names>
               </name>
               <article-title>Gini coefficient:
a new way to express selectivity of kinase inhibitors against a family
of kinases</article-title>
               <source>J. Med. Chem.</source>
               <year>2007</year>
               <volume>50</volume>
               <fpage>5773</fpage>
               <lpage>5779</lpage>
            </element-citation>
         </ref>
         <ref id="ref74">
            <element-citation publication-type="journal" id="cit74">
               <name name-style="western">
                  <surname>Lipinski</surname>
                  <given-names>C. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lombardo</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dominy</surname>
                  <given-names>B. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Feeney</surname>
                  <given-names>P. J.</given-names>
               </name>
               <article-title>Experimental
and
computational approaches to estimate solubility and permeability in
drug discovery and development settings</article-title>
               <source>Adv.
Drug Delivery Rev.</source>
               <year>1997</year>
               <volume>23</volume>
               <fpage>3</fpage>
               <lpage>25</lpage>
            </element-citation>
         </ref>
         <ref id="ref75">
            <element-citation publication-type="journal" id="cit75">
               <name name-style="western">
                  <surname>Pajouhesh</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lenz</surname>
                  <given-names>G. R.</given-names>
               </name>
               <article-title>Medicinal chemical properties of successful central
nervous system drugs</article-title>
               <source>NeuroRx</source>
               <year>2005</year>
               <volume>2</volume>
               <fpage>541</fpage>
               <lpage>553</lpage>
            </element-citation>
         </ref>
         <ref id="ref76">
            <mixed-citation publication-type="patent" id="cit76"><person-group person-group-type="allauthors"><name name-style="western"><surname>Graczyk</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bhatia</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Iimura</surname><given-names>Y.</given-names></name></person-group> <article-title>Preparation
of pyrrolo­[2,3-<italic toggle="yes">b</italic>]­pyrimidines as inhibitors of c-Jun
N-terminal kinases
(JNKs) inhibitors for the treatment of neurodegenerative disorders</article-title>. <patent>WO2004078756A2</patent>, <year>2004</year>.</mixed-citation>
         </ref>
         <ref id="ref77">
            <mixed-citation publication-type="patent" id="cit77"><person-group person-group-type="allauthors"><name name-style="western"><surname>Graczyk</surname><given-names>P. P.</given-names></name>; <name name-style="western"><surname>Dimopoulos</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Bhatia</surname><given-names>G. S.</given-names></name>; <name name-style="western"><surname>Farthing</surname><given-names>C. N.</given-names></name></person-group> <article-title>7-Azaindole derivatives and
their use in the inhibition of c-Jun N-terminal kinase and their preparation</article-title>. <patent>WO2008095944A1</patent>, <year>2008</year>.</mixed-citation>
         </ref>
         <ref id="ref78">
            <element-citation publication-type="journal" id="cit78">
               <name name-style="western">
                  <surname>McCarthy</surname>
                  <given-names>D.
P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Richards</surname>
                  <given-names>M. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Miller</surname>
                  <given-names>S. D.</given-names>
               </name>
               <article-title>Mouse models of multiple sclerosis:
experimental autoimmune encephalomyelitis and Theiler’s virus-induced
demyelinating disease</article-title>
               <source>Methods Mol. Biol.</source>
               <year>2012</year>
               <volume>900</volume>
               <fpage>381</fpage>
               <lpage>401</lpage>
            </element-citation>
         </ref>
         <ref id="ref79">
            <element-citation publication-type="journal" id="cit79">
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pachori</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Howard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ganno</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hansen</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cherry</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Small molecule c-jun-N-terminal kinase
inhibitors protect dopaminergic neurons in a model of Parkinson’s
disease</article-title>
               <source>ACS Chem. Neurosci.</source>
               <year>2011</year>
               <volume>2</volume>
               <fpage>198</fpage>
               <lpage>206</lpage>
            </element-citation>
         </ref>
         <ref id="ref80">
            <element-citation publication-type="journal" id="cit80">
               <name name-style="western">
                  <surname>Crocker</surname>
                  <given-names>C. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Robertson</surname>
                  <given-names>H. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Robertson</surname>
                  <given-names>G. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>JNK inhibition protects dopamine
neurons and provides behavioral improvement in a rat 6-hydroxydopamine
model of Parkinson’s disease</article-title>
               <source>ACS Chem.
Neurosci.</source>
               <year>2011</year>
               <volume>2</volume>
               <fpage>207</fpage>
               <lpage>212</lpage>
            </element-citation>
         </ref>
         <ref id="ref81">
            <element-citation publication-type="journal" id="cit81">
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J.
W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Howard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>Blocking c-Jun N-terminal kinase
(JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced
toxicity in vitro and in vivo</article-title>
               <source>J. Biol. Chem.</source>
               <year>2013</year>
               <volume>288</volume>
               <fpage>1079</fpage>
               <lpage>1087</lpage>
            </element-citation>
         </ref>
         <ref id="ref82">
            <element-citation publication-type="journal" id="cit82">
               <name name-style="western">
                  <surname>Rech</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yato</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ember</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bergman</surname>
                  <given-names>R. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ellman</surname>
                  <given-names>J. A.</given-names>
               </name>
               <article-title>Synthesis
of potent bicyclic bisarylimidazole
c-jun N-terminal kinase inhibitors by catalytic C–H bond activation</article-title>
               <source>J. Am. Chem. Soc.</source>
               <year>2007</year>
               <volume>129</volume>
               <fpage>490</fpage>
               <lpage>491</lpage>
            </element-citation>
         </ref>
         <ref id="ref83">
            <element-citation publication-type="journal" id="cit83">
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Habel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>3,5-Disubstituted quinolines as novel
c-Jun N-terminal kinase inhibitors</article-title>
               <source>Bioorg.
Med. Chem. Lett.</source>
               <year>2007</year>
               <volume>17</volume>
               <fpage>6378</fpage>
               <lpage>6382</lpage>
            </element-citation>
         </ref>
         <ref id="ref84">
            <element-citation publication-type="journal" id="cit84">
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Habel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Frackowiak</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Structure–activity relationships and X-ray structures
describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal
kinase 3 (JNK3) over p38</article-title>
               <source>J. Biol. Chem.</source>
               <year>2009</year>
               <volume>284</volume>
               <fpage>12853</fpage>
               <lpage>12861</lpage>
            </element-citation>
         </ref>
         <ref id="ref85">
            <element-citation publication-type="journal" id="cit85">
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Frackowiak</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>Design
and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase
inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2013</year>
               <volume>23</volume>
               <fpage>2683</fpage>
               <lpage>2687</lpage>
            </element-citation>
         </ref>
         <ref id="ref86">
            <element-citation publication-type="journal" id="cit86">
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>P. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gray</surname>
                  <given-names>N. S.</given-names>
               </name>
               <article-title>Targeting
cancer with small molecule
kinase inhibitors</article-title>
               <source>Nat. Rev. Cancer</source>
               <year>2009</year>
               <volume>9</volume>
               <fpage>28</fpage>
               <lpage>39</lpage>
            </element-citation>
         </ref>
         <ref id="ref87">
            <element-citation publication-type="journal" id="cit87">
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Habel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laughlin</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Figuera-Losada</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>Synthesis,
biological evaluation, X-ray structure,
and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK)
inhibitors</article-title>
               <source>J. Med. Chem.</source>
               <year>2010</year>
               <volume>53</volume>
               <fpage>419</fpage>
               <lpage>431</lpage>
            </element-citation>
         </ref>
         <ref id="ref88">
            <element-citation publication-type="journal" id="cit88">
               <name name-style="western">
                  <surname>Druker</surname>
                  <given-names>B. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tamura</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Buchdunger</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohno</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Segal</surname>
                  <given-names>G. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fanning</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zimmermann</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lydon</surname>
                  <given-names>N. B.</given-names>
               </name>
               <article-title>Effects of a selective
inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive
cells</article-title>
               <source>Nat. Med.</source>
               <year>1996</year>
               <volume>2</volume>
               <fpage>561</fpage>
               <lpage>566</lpage>
            </element-citation>
         </ref>
         <ref id="ref89">
            <element-citation publication-type="journal" id="cit89">
               <name name-style="western">
                  <surname>Alam</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Beevers</surname>
                  <given-names>R. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ceska</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davenport</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dickson</surname>
                  <given-names>K. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fortunato</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gowers</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Haughan</surname>
                  <given-names>A. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>James</surname>
                  <given-names>L. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>M. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kinsella</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lowe</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Meissner</surname>
                  <given-names>J. W. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nicolas</surname>
                  <given-names>A. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Perry</surname>
                  <given-names>B. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Phillips</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pitt</surname>
                  <given-names>W. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Platt</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ratcliffe</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sharpe</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tait</surname>
                  <given-names>L. J.</given-names>
               </name>
               <article-title>Synthesis and SAR of aminopyrimidines
as novel c-Jun N-terminal kinase (JNK) inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2007</year>
               <volume>17</volume>
               <fpage>3463</fpage>
               <lpage>3467</lpage>
            </element-citation>
         </ref>
         <ref id="ref90">
            <element-citation publication-type="journal" id="cit90">
               <name name-style="western">
                  <surname>Ember</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Kinetic mechanism and inhibitor characterization
for c-jun-N-terminal kinase 3α1</article-title>
               <source>Biochemistry</source>
               <year>2008</year>
               <volume>47</volume>
               <fpage>3076</fpage>
               <lpage>3084</lpage>
            </element-citation>
         </ref>
         <ref id="ref91">
            <element-citation publication-type="journal" id="cit91">
               <name name-style="western">
                  <surname>Kelder</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grootenhuis</surname>
                  <given-names>P. D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bayada</surname>
                  <given-names>D. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Delbressine</surname>
                  <given-names>L. P. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ploemen</surname>
                  <given-names>J. P.</given-names>
               </name>
               <article-title>Polar molecular
surface as a dominating determinant
for oral absorption and brain penetration of drugs</article-title>
               <source>Pharm. Res.</source>
               <year>1999</year>
               <volume>16</volume>
               <fpage>1514</fpage>
               <lpage>1519</lpage>
            </element-citation>
         </ref>
         <ref id="ref92">
            <element-citation publication-type="journal" id="cit92">
               <name name-style="western">
                  <surname>Di</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rong</surname>
                  <given-names>H. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Feng</surname>
                  <given-names>B.</given-names>
               </name>
               <article-title>Demystifying brain penetration in
central nervous system drug discovery</article-title>
               <source>J. Med.
Chem.</source>
               <year>2013</year>
               <volume>56</volume>
               <fpage>2</fpage>
               <lpage>12</lpage>
            </element-citation>
         </ref>
         <ref id="ref93">
            <element-citation publication-type="journal" id="cit93">
               <name name-style="western">
                  <surname>Wolber</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Langer</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>LigandScout: 3-D pharmacophores
derived from protein-bound
ligands and their use as virtual screening filters</article-title>
               <source>J. Chem. Inf. Model.</source>
               <year>2005</year>
               <volume>45</volume>
               <fpage>160</fpage>
               <lpage>169</lpage>
            </element-citation>
         </ref>
         <ref id="ref94">
            <element-citation publication-type="journal" id="cit94a">
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Habel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laughlin</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chambers</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Figuera-Losada</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>Synthesis, biological evaluation,
X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal
kinase (JNK) inhibitors</article-title>
               <source>J. Med. Chem.</source>
               <year>2010</year>
               <volume>53</volume>
               <fpage>419</fpage>
               <lpage>431</lpage>
            </element-citation>
            <mixed-citation publication-type="journal" id="cit94b"><comment>Corrections:</comment><source>J. Med. Chem.</source> <year>2010</year>, <volume>53</volume>, <fpage>1882</fpage>–<lpage>1882</lpage>.</mixed-citation>
         </ref>
         <ref id="ref95">
            <element-citation publication-type="journal" id="cit95">
               <name name-style="western">
                  <surname>Swahn</surname>
                  <given-names>B.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huerta</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kallin</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Malmstrom</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weigelt</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Viklund</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Womack</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xue</surname>
                  <given-names>Y. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Öhberg</surname>
                  <given-names>L.</given-names>
               </name>
               <article-title>Design and synthesis of 6-anilinoindazoles
as selective
inhibitors of c-Jun N-terminal kinase-3</article-title>
               <source>Bioorg.
Med. Chem. Lett.</source>
               <year>2005</year>
               <volume>15</volume>
               <fpage>5095</fpage>
               <lpage>5099</lpage>
            </element-citation>
         </ref>
         <ref id="ref96">
            <element-citation publication-type="journal" id="cit96">
               <name name-style="western">
                  <surname>Swahn</surname>
                  <given-names>B.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Xue</surname>
                  <given-names>Y. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arzel</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kallin</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Magnus</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Plobeck</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Viklund</surname>
                  <given-names>J.</given-names>
               </name>
               <article-title>Design and synthesis of 2′-anilino-4,4′-bipyridines
as selective inhibitors of c-Jun N-terminal kinase-3</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2006</year>
               <volume>16</volume>
               <fpage>1397</fpage>
               <lpage>1401</lpage>
            </element-citation>
         </ref>
         <ref id="ref97">
            <element-citation publication-type="journal" id="cit97">
               <name name-style="western">
                  <surname>Scapin</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>S. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lisnock</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Becker</surname>
                  <given-names>J. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>The structure
of JNK3 in complex with small molecule inhibitors: structural basis
for potency and selectivity</article-title>
               <source>Chem. Biol.</source>
               <year>2003</year>
               <volume>10</volume>
               <fpage>705</fpage>
               <lpage>712</lpage>
            </element-citation>
         </ref>
         <ref id="ref98">
            <element-citation publication-type="journal" id="cit98">
               <name name-style="western">
                  <surname>Karaman</surname>
                  <given-names>M. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herrgard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Treiber</surname>
                  <given-names>D. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gallant</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Atteridge</surname>
                  <given-names>C. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Campbell</surname>
                  <given-names>B. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chan</surname>
                  <given-names>K. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ciceri</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>M. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Edeen</surname>
                  <given-names>P. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Faraoni</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Floyd</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hunt</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lockhart</surname>
                  <given-names>D. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Milanov</surname>
                  <given-names>Z. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Morrison</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pallares</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Patel</surname>
                  <given-names>H. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pritchard</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wodicka</surname>
                  <given-names>L. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zarrinkar</surname>
                  <given-names>P. P.</given-names>
               </name>
               <article-title>A quantitative
analysis of kinase inhibitor selectivity</article-title>
               <source>Nat.
Biotechnol.</source>
               <year>2008</year>
               <volume>26</volume>
               <fpage>127</fpage>
               <lpage>132</lpage>
            </element-citation>
         </ref>
         <ref id="ref99">
            <element-citation publication-type="journal" id="cit99">
               <name name-style="western">
                  <surname>Dauer</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Przedborski</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Parkinson’s
disease: mechanisms and models</article-title>
               <source>Neuron</source>
               <year>2003</year>
               <volume>39</volume>
               <fpage>889</fpage>
               <lpage>909</lpage>
            </element-citation>
         </ref>
         <ref id="ref100">
            <element-citation publication-type="journal" id="cit100">
               <name name-style="western">
                  <surname>Jerussi</surname>
                  <given-names>T. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Glick</surname>
                  <given-names>S. D.</given-names>
               </name>
               <article-title>Drug-induced rotation
in rats without
lesionsbehavioral and neurochemical indexes of a normal asymmetry
in nigro-striatal function</article-title>
               <source>Psychopharmacology</source>
               <year>1976</year>
               <volume>47</volume>
               <fpage>249</fpage>
               <lpage>260</lpage>
            </element-citation>
         </ref>
         <ref id="ref101">
            <element-citation publication-type="journal" id="cit101">
               <name name-style="western">
                  <surname>Noël</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as
novel c-jun N-terminal kinase inhibitors</article-title>
               <source>Bioorg.
Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>2732</fpage>
               <lpage>2735</lpage>
            </element-citation>
         </ref>
         <ref id="ref102">
            <element-citation publication-type="journal" id="cit102">
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Z. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Canagarajah</surname>
                  <given-names>B. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boehm</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kassisa</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cobb</surname>
                  <given-names>M. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>P. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abdel-Meguid</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Adams</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goldsmith</surname>
                  <given-names>E. J.</given-names>
               </name>
               <article-title>Structural
basis of inhibitor selectivity
in MAP kinases</article-title>
               <source>Structure</source>
               <year>1998</year>
               <volume>6</volume>
               <fpage>1117</fpage>
               <lpage>1128</lpage>
            </element-citation>
         </ref>
         <ref id="ref103">
            <element-citation publication-type="journal" id="cit103">
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jiang</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Noël</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <article-title>Synthesis and SAR of novel quinazolines
as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>1719</fpage>
               <lpage>1723</lpage>
            </element-citation>
         </ref>
         <ref id="ref104">
            <mixed-citation publication-type="patent" id="cit104"><person-group person-group-type="allauthors"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lunney</surname><given-names>E. A.</given-names></name>; <name name-style="western"><surname>Planken</surname><given-names>S. P.</given-names></name></person-group> <article-title>Substituted 2-amino-fused heterocyclic
compounds as JNK modulators and their preparation, pharmaceutical
compositions and use in the treatment of diabetes and related diseases</article-title>. <patent>WO2007125405A2</patent>, <year>2007</year>.</mixed-citation>
         </ref>
         <ref id="ref105">
            <element-citation publication-type="journal" id="cit105">
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>Synthesis
and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>7072</fpage>
               <lpage>7075</lpage>
            </element-citation>
         </ref>
         <ref id="ref106">
            <element-citation publication-type="journal" id="cit106">
               <name name-style="western">
                  <surname>Song</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Noël</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Feurstein</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>Synthesis
and SAR of 2,4-diaminopyrimidines as potent c-jun N-terminal kinase
inhibitors</article-title>
               <source>MedChemComm</source>
               <year>2012</year>
               <volume>3</volume>
               <fpage>238</fpage>
               <lpage>243</lpage>
            </element-citation>
         </ref>
         <ref id="ref107">
            <element-citation publication-type="journal" id="cit107">
               <name name-style="western">
                  <surname>Halder</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>Y. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Merritt</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Spannuth</surname>
                  <given-names>W. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nick</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Honda</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamat</surname>
                  <given-names>A. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Han</surname>
                  <given-names>L. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>T. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lu</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tari’</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bornmann</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fernandez</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lopez-Berestein</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sood</surname>
                  <given-names>A. K.</given-names>
               </name>
               <article-title>Therapeutic efficacy of a novel focal adhesion kinase
inhibitor TAE226 in ovarian carcinoma</article-title>
               <source>Cancer
Res.</source>
               <year>2007</year>
               <volume>67</volume>
               <fpage>10976</fpage>
               <lpage>10983</lpage>
            </element-citation>
         </ref>
         <ref id="ref108">
            <mixed-citation publication-type="patent" id="cit108"><person-group person-group-type="allauthors"><name name-style="western"><surname>Garcia-Echeverria</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Kanazawa</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Kawahara</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Masuya</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Matsuura</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Miyake</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Ohmori</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Umemura</surname><given-names>I.</given-names></name></person-group> <article-title>Preparation
of novel 2,4-di­(phenylamino)­pyrimidines useful in the treatment of
neoplastic diseases, inflammatory and immune system disorders</article-title>. <patent>WO2004080980A1</patent>, <year>2004</year>.</mixed-citation>
         </ref>
         <ref id="ref109">
            <element-citation publication-type="journal" id="cit109">
               <name name-style="western">
                  <surname>Palmer</surname>
                  <given-names>W.
S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Alam</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arzeno</surname>
                  <given-names>H. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>K. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dunn</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goldstein</surname>
                  <given-names>D. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gong</surname>
                  <given-names>L. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goyal</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hermann</surname>
                  <given-names>J. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hogg</surname>
                  <given-names>J. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hsieh</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jahangir</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Janson</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kammlott</surname>
                  <given-names>R. U.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuglstatter</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lukacs</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Michoud</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reuter</surname>
                  <given-names>D. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shao</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Silva</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Trejo-Martin</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stein</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tan</surname>
                  <given-names>Y. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tivitmahaisoon</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tran</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weller</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <article-title>Development
of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase
profiling guided optimization of a 1,2,3-benzotriazole lead</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2013</year>
               <volume>23</volume>
               <fpage>1486</fpage>
               <lpage>1492</lpage>
            </element-citation>
         </ref>
         <ref id="ref110">
            <mixed-citation publication-type="patent" id="cit110"><person-group person-group-type="allauthors"><name name-style="western"><surname>Goldstein</surname><given-names>D. M.</given-names></name>; <name name-style="western"><surname>Gong</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Michoud</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Palmer</surname><given-names>W. S.</given-names></name>; <name name-style="western"><surname>Sidduri</surname><given-names>A.</given-names></name></person-group> <article-title>Preparation of
aminopyrimidinylbenzotriazoles as kinase modulators</article-title>. <patent>WO2008028860A1</patent>, <year>2008</year>.</mixed-citation>
         </ref>
         <ref id="ref111">
            <element-citation publication-type="journal" id="cit111">
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cameron</surname>
                  <given-names>M. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruiz</surname>
                  <given-names>C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P. V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Synthesis and SAR of
novel isoxazoles
as potent c-jun N-terminal kinase (JNK) inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2014</year>
               <volume>24</volume>
               <fpage>161</fpage>
               <lpage>164</lpage>
            </element-citation>
         </ref>
         <ref id="ref112">
            <element-citation publication-type="journal" id="cit112">
               <name name-style="western">
                  <surname>Young</surname>
                  <given-names>P. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>McLaughlin</surname>
                  <given-names>M. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kassis</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Doyle</surname>
                  <given-names>M. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>McNulty</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gallagher</surname>
                  <given-names>T. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fisher</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>McDonnell</surname>
                  <given-names>P. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carr</surname>
                  <given-names>S. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Huddleston</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Seibel</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Porter</surname>
                  <given-names>T. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Livi</surname>
                  <given-names>G. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Adams</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>J. C.</given-names>
               </name>
               <article-title>Pyridinyl imidazole
inhibitors of p38 mitogen-activated
protein kinase bind in the ATP site</article-title>
               <source>J. Biol.
Chem.</source>
               <year>1997</year>
               <volume>272</volume>
               <fpage>12116</fpage>
               <lpage>12121</lpage>
            </element-citation>
         </ref>
         <ref id="ref113">
            <element-citation publication-type="journal" id="cit113">
               <name name-style="western">
                  <surname>Peifer</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wagner</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laufer</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>New approaches
to the
treatment of inflammatory disorders small molecule inhibitors of p38
MAP kinase</article-title>
               <source>Curr. Top. Med. Chem.</source>
               <year>2006</year>
               <volume>6</volume>
               <fpage>113</fpage>
               <lpage>149</lpage>
            </element-citation>
         </ref>
         <ref id="ref114">
            <element-citation publication-type="journal" id="cit114">
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>M. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dominguez</surname>
                  <given-names>C.</given-names>
               </name>
               <article-title>MAP kinase
p38 inhibitors: clinical
results and an intimate look at their interactions with p38 alpha
protein</article-title>
               <source>Curr. Med. Chem.</source>
               <year>2005</year>
               <volume>12</volume>
               <fpage>2979</fpage>
               <lpage>2994</lpage>
            </element-citation>
         </ref>
         <ref id="ref115">
            <element-citation publication-type="journal" id="cit115">
               <name name-style="western">
                  <surname>Boulton</surname>
                  <given-names>A. J. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>A</surname>
                  <given-names>R.</given-names>
               </name>
               <article-title>The tautomerism of heteroaromatic
compounds with five-membered ringsI: 5-Hydroxyisoxazoles-isoxazol-5-ones</article-title>
               <source>Tetrahedron</source>
               <year>1961</year>
               <volume>12</volume>
               <fpage>41</fpage>
               <lpage>50</lpage>
            </element-citation>
         </ref>
         <ref id="ref116">
            <element-citation publication-type="journal" id="cit116">
               <name name-style="western">
                  <surname>Probst</surname>
                  <given-names>G. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bowers</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sealy</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Truong</surname>
                  <given-names>A. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hom</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Galemmo</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Konradi</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quincy</surname>
                  <given-names>D. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yao</surname>
                  <given-names>N. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toth</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Artis</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zmolek</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qin</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lorentzen</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nakamura</surname>
                  <given-names>D. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauer</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruslim</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chereau</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Anderson</surname>
                  <given-names>J. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bard</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Highly selective
c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like
pharmacokinetic properties prevent neurodegeneration</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>315</fpage>
               <lpage>319</lpage>
            </element-citation>
         </ref>
         <ref id="ref117">
            <element-citation publication-type="journal" id="cit117">
               <name name-style="western">
                  <surname>Neitz</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Konradi</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zmolek</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Qin</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lorentzen</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nakamura</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauer</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruslim</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chereau</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Anderson</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bard</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Highly selective
c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like
pharmacokinetic properties II. Central core replacement</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>3726</fpage>
               <lpage>3729</lpage>
            </element-citation>
         </ref>
         <ref id="ref118">
            <element-citation publication-type="journal" id="cit118">
               <name name-style="western">
                  <surname>Wogulis</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cunningham</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chilcote</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rydel</surname>
                  <given-names>R. E.</given-names>
               </name>
               <article-title>Nucleation-dependent
polymerization is an essential component of amyloid-mediated neuronal
cell death</article-title>
               <source>J. Neurosci.</source>
               <year>2005</year>
               <volume>25</volume>
               <fpage>1071</fpage>
               <lpage>1080</lpage>
            </element-citation>
         </ref>
         <ref id="ref119">
            <element-citation publication-type="journal" id="cit119">
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Malinin</surname>
                  <given-names>N. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rydel</surname>
                  <given-names>R. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>α2β1 and αVβ1
integrin signaling pathways mediate amyloid-β-induced neurotoxicity</article-title>
               <source>Neurobiol. Aging</source>
               <year>2007</year>
               <volume>28</volume>
               <fpage>226</fpage>
               <lpage>237</lpage>
            </element-citation>
         </ref>
         <ref id="ref120">
            <element-citation publication-type="journal" id="cit120">
               <name name-style="western">
                  <surname>Angell</surname>
                  <given-names>R. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Atkinson</surname>
                  <given-names>F. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>M. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chuang</surname>
                  <given-names>T. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Christopher</surname>
                  <given-names>J. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cichy-Knight</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dunn</surname>
                  <given-names>A. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hightower</surname>
                  <given-names>K. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Malkakorpi</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Musgrave</surname>
                  <given-names>J. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neu</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rowland</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shea</surname>
                  <given-names>R. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Somers</surname>
                  <given-names>D. O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Thomas</surname>
                  <given-names>S. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Thompson</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>R. L.</given-names>
               </name>
               <article-title><italic toggle="yes">N</italic>-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)­amides
as potent, selective, inhibitors of JNK2 and JNK3</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2007</year>
               <volume>17</volume>
               <fpage>1296</fpage>
               <lpage>1301</lpage>
            </element-citation>
         </ref>
         <ref id="ref121">
            <element-citation publication-type="journal" id="cit121">
               <name name-style="western">
                  <surname>Christopher</surname>
                  <given-names>J. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Atkinson</surname>
                  <given-names>F. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bax</surname>
                  <given-names>B. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>M. J. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Champigny</surname>
                  <given-names>A. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chuang</surname>
                  <given-names>T. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>E. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mosley</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Musgrave</surname>
                  <given-names>J. R.</given-names>
               </name>
               <article-title>1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2009</year>
               <volume>19</volume>
               <fpage>2230</fpage>
               <lpage>2234</lpage>
            </element-citation>
         </ref>
         <ref id="ref122">
            <element-citation publication-type="journal" id="cit122">
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>M. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>Y. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ahn</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>Y. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hah</surname>
                  <given-names>J. M.</given-names>
               </name>
               <article-title>Syntheses
and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole
derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective
effects</article-title>
               <source>Bioorg. Med. Chem.</source>
               <year>2013</year>
               <volume>21</volume>
               <fpage>2271</fpage>
               <lpage>2285</lpage>
            </element-citation>
         </ref>
         <ref id="ref123">
            <element-citation publication-type="journal" id="cit123">
               <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Habel</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Duckett</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ling</surname>
                  <given-names>Y. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koenig</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>He</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vojkovsky</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>LoGrasso</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kamenecka</surname>
                  <given-names>T. M.</given-names>
               </name>
               <article-title>Synthesis and SAR of piperazine amides
as novel c-jun N-terminal kinase (JNK) inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2009</year>
               <volume>19</volume>
               <fpage>3344</fpage>
               <lpage>3347</lpage>
            </element-citation>
         </ref>
         <ref id="ref124">
            <element-citation publication-type="journal" id="cit124">
               <name name-style="western">
                  <surname>Bowers</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Truong</surname>
                  <given-names>A. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neitz</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hom</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sealy</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Probst</surname>
                  <given-names>G. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quincy</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Peterson</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chan</surname>
                  <given-names>W. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Galemmo</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Konradi</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toth</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yao</surname>
                  <given-names>N. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Artis</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dryer</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Samant</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zmolek</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lorentzen</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goldbach</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tonn</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauer</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruslim</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bard</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Design and
synthesis of brain penetrant selective JNK inhibitors with improved
pharmacokinetic properties for the prevention of neurodegeneration</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>5521</fpage>
               <lpage>5527</lpage>
            </element-citation>
         </ref>
         <ref id="ref125">
            <element-citation publication-type="journal" id="cit125">
               <name name-style="western">
                  <surname>Bowers</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Truong</surname>
                  <given-names>A. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neitz</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neitzel</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Probst</surname>
                  <given-names>G. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hom</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Peterson</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Galemmo</surname>
                  <given-names>R. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Konradi</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toth</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yao</surname>
                  <given-names>N. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Artis</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brigham</surname>
                  <given-names>E. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauer</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ruslim</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bard</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Design and
synthesis of a novel, orally active, brain penetrant, tri-substituted
thiophene based JNK inhibitor</article-title>
               <source>Bioorg. Med.
Chem. Lett.</source>
               <year>2011</year>
               <volume>21</volume>
               <fpage>1838</fpage>
               <lpage>1843</lpage>
            </element-citation>
         </ref>
         <ref id="ref126">
            <element-citation publication-type="journal" id="cit126">
               <name name-style="western">
                  <surname>Hom</surname>
                  <given-names>R. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bowers</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sealy</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Truong</surname>
                  <given-names>A. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Probst</surname>
                  <given-names>G. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neitzel</surname>
                  <given-names>M. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Neitz</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fang</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brogley</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Konradi</surname>
                  <given-names>A. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sham</surname>
                  <given-names>H. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Toth</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pan</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yao</surname>
                  <given-names>N. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Artis</surname>
                  <given-names>D. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauer</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Powell</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bard</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yednock</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Griswold-Prenner</surname>
                  <given-names>I.</given-names>
               </name>
               <article-title>Design and
synthesis of disubstituted thiophene and thiazole based inhibitors
of JNK</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2010</year>
               <volume>20</volume>
               <fpage>7303</fpage>
               <lpage>7307</lpage>
            </element-citation>
         </ref>
         <ref id="ref127">
            <element-citation publication-type="journal" id="cit127">
               <name name-style="western">
                  <surname>De</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barile</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stebbins</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cellitti</surname>
                  <given-names>J. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Machleidt</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Carlson</surname>
                  <given-names>C. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dahl</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pellecchia</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Design, synthesis,
and structure–activity
relationship studies of thiophene-3-carboxamide derivatives as dual
inhibitors of the c-Jun N-terminal kinase</article-title>
               <source>Bioorg.
Med. Chem.</source>
               <year>2011</year>
               <volume>19</volume>
               <fpage>2582</fpage>
               <lpage>2588</lpage>
            </element-citation>
         </ref>
         <ref id="ref128">
            <element-citation publication-type="journal" id="cit128">
               <name name-style="western">
                  <surname>Gong</surname>
                  <given-names>L. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tan</surname>
                  <given-names>Y. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boice</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abbot</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>McCaleb</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Iyer</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zuo</surname>
                  <given-names>F. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dal Porto</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jin</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tran</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hsieh</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shao</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Reuter</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lukacs</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kammlott</surname>
                  <given-names>R. U.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuglstatter</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Goldstein</surname>
                  <given-names>D.</given-names>
               </name>
               <article-title>Discovery of a novel series of 4-quinolone JNK inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>22</volume>
               <fpage>7381</fpage>
               <lpage>7387</lpage>
            </element-citation>
         </ref>
         <ref id="ref129">
            <element-citation publication-type="journal" id="cit129">
               <name name-style="western">
                  <surname>Asano</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kitamura</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohra</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Aso</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Igata</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tamura</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kawamoto</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tanaka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sogabe</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Matsumoto</surname>
                  <given-names>S. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yamaguchi</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kimura</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Itoh</surname>
                  <given-names>F.</given-names>
               </name>
               <article-title>Discovery, synthesis and biological
evaluation of isoquinolones as novel and highly selective JNK inhibitors
(1)</article-title>
               <source>Bioorg. Med. Chem.</source>
               <year>2008</year>
               <volume>16</volume>
               <fpage>4715</fpage>
               <lpage>4732</lpage>
            </element-citation>
         </ref>
         <ref id="ref130">
            <element-citation publication-type="journal" id="cit130">
               <name name-style="western">
                  <surname>Asano</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kitamura</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohra</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Itoh</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kajino</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tamura</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kaneko</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ikeda</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Igata</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kawamoto</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sogabe</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Matsumoto</surname>
                  <given-names>S. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tanaka</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yamaguchi</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kimura</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fukumoto</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Discovery,
synthesis and biological evaluation of isoquinolones as novel and
highly selective JNK inhibitors (2)</article-title>
               <source>Bioorg.
Med. Chem.</source>
               <year>2008</year>
               <volume>16</volume>
               <fpage>4699</fpage>
               <lpage>4714</lpage>
            </element-citation>
         </ref>
         <ref id="ref131">
            <element-citation publication-type="journal" id="cit131">
               <name name-style="western">
                  <surname>Haynes</surname>
                  <given-names>N.-E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Scott</surname>
                  <given-names>N. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Janson</surname>
                  <given-names>C. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>J. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lukacs</surname>
                  <given-names>C. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Railkar</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tozzo</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Whittard</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>N. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cheung</surname>
                  <given-names>A. W.-H.</given-names>
               </name>
               <article-title>Identification
of an adamantyl azaquinolone JNK selective inhibitor</article-title>
               <source>ACS Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>3</volume>
               <fpage>764</fpage>
               <lpage>768</lpage>
            </element-citation>
         </ref>
         <ref id="ref132">
            <element-citation publication-type="journal" id="cit132">
               <name name-style="western">
                  <surname>Schepetkin</surname>
                  <given-names>I. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirpotina</surname>
                  <given-names>L. N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Khlebnikov</surname>
                  <given-names>A. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hanks</surname>
                  <given-names>T. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kochetkova</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pascual</surname>
                  <given-names>D. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jutila</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>M. T.</given-names>
               </name>
               <article-title>Identification and
characterization of a novel class
of c-Jun N-terminal kinase inhibitors</article-title>
               <source>Mol.
Pharmacol.</source>
               <year>2012</year>
               <volume>81</volume>
               <fpage>832</fpage>
               <lpage>845</lpage>
            </element-citation>
         </ref>
         <ref id="ref133">
            <element-citation publication-type="journal" id="cit133">
               <name name-style="western">
                  <surname>Bogoyevitch</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arthur</surname>
                  <given-names>P. G.</given-names>
               </name>
               <article-title>Inhibitors
of c-Jun N-terminal kinases-JuNK
no more?</article-title>
               <source>Biochim. Biophys. Acta, Proteins Proteomics</source>
               <year>2008</year>
               <volume>1784</volume>
               <fpage>76</fpage>
               <lpage>93</lpage>
            </element-citation>
         </ref>
         <ref id="ref134">
            <element-citation publication-type="journal" id="cit134">
               <name name-style="western">
                  <surname>Heo</surname>
                  <given-names>J. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Seo</surname>
                  <given-names>C. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>Y. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sung</surname>
                  <given-names>B. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>H. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>J. I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>S. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>J. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hwang</surname>
                  <given-names>K. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hyun</surname>
                  <given-names>Y. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeon</surname>
                  <given-names>Y. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ro</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cho</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>T. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>C. H.</given-names>
               </name>
               <article-title>Structural basis
for the selective inhibition of JNK1 by the scaffolding protein JIP1
and SP600125</article-title>
               <source>EMBO J.</source>
               <year>2004</year>
               <volume>23</volume>
               <fpage>2185</fpage>
               <lpage>2195</lpage>
            </element-citation>
         </ref>
         <ref id="ref135">
            <element-citation publication-type="journal" id="cit135">
               <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chang</surname>
                  <given-names>K. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilson</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tran</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zuo</surname>
                  <given-names>F. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Swinney</surname>
                  <given-names>D. C.</given-names>
               </name>
               <article-title>Kinetic characterization of human
JNK2 alpha 2 reaction mechanism using substrate competitive inhibitors</article-title>
               <source>Biochemistry</source>
               <year>2007</year>
               <volume>46</volume>
               <fpage>4775</fpage>
               <lpage>4784</lpage>
            </element-citation>
         </ref>
         <ref id="ref136">
            <element-citation publication-type="journal" id="cit136">
               <name name-style="western">
                  <surname>Borsello</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Clarke</surname>
                  <given-names>P. G. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hirt</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Vercelli</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Repici</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schorderet</surname>
                  <given-names>D. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bogousslavsky</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonny</surname>
                  <given-names>C.</given-names>
               </name>
               <article-title>A peptide inhibitor
of c-Jun N-terminal kinase protects against excitotoxicity
and cerebral ischemia</article-title>
               <source>Nat. Med.</source>
               <year>2003</year>
               <volume>9</volume>
               <fpage>1180</fpage>
               <lpage>1186</lpage>
            </element-citation>
         </ref>
         <ref id="ref137">
            <element-citation publication-type="journal" id="cit137">
               <name name-style="western">
                  <surname>Dinh</surname>
                  <given-names>C. T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Van de Water</surname>
                  <given-names>T. R.</given-names>
               </name>
               <article-title>Blocking
pro-cell-death signal pathways
to conserve hearing</article-title>
               <source>Audiol. Neurotol.</source>
               <year>2009</year>
               <volume>14</volume>
               <fpage>383</fpage>
               <lpage>392</lpage>
            </element-citation>
         </ref>
         <ref id="ref138">
            <element-citation publication-type="journal" id="cit138">
               <name name-style="western">
                  <surname>Reinecke</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Eminel</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dierck</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Roessner</surname>
                  <given-names>W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kersting</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chromik</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gavrilova</surname>
                  <given-names>O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Laukevicience</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Leuschner</surname>
                  <given-names>I.</given-names>
               </name>
               <name name-style="western">
                  <surname>Waetzig</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rosenstiel</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herdegen</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sina</surname>
                  <given-names>C.</given-names>
               </name>
               <article-title>The JNK inhibitor XG-102 protects
against TNBS-induced colitis</article-title>
               <source>PLoS One</source>
               <year>2012</year>
               <volume>7</volume>
               <fpage>e30985</fpage>
            </element-citation>
         </ref>
         <ref id="ref139">
            <element-citation publication-type="journal" id="cit139">
               <name name-style="western">
                  <surname>Sclip</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Antoniou</surname>
                  <given-names>X.</given-names>
               </name>
               <name name-style="western">
                  <surname>Colombo</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Camici</surname>
                  <given-names>G. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pozzi</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cardinetti</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Feligioni</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Veglianese</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bahlmann</surname>
                  <given-names>F. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cervo</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Balducci</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Costa</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tozzi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Calabresi</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Forloni</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Borsello</surname>
                  <given-names>T.</given-names>
               </name>
               <article-title>c-Jun N-terminal kinase regulates
soluble Aβ oligomers and cognitive impairment in AD mouse model</article-title>
               <source>J. Biol. Chem.</source>
               <year>2011</year>
               <volume>286</volume>
               <fpage>43871</fpage>
               <lpage>43880</lpage>
            </element-citation>
         </ref>
         <ref id="ref140">
            <element-citation publication-type="journal" id="cit140">
               <name name-style="western">
                  <surname>Touchard</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Omri</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Naud</surname>
                  <given-names>M.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Berdugo</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Deloche</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abadie</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jonet</surname>
                  <given-names>L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jeanny</surname>
                  <given-names>J.-C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Crisanti</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>de Kozak</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Combette</surname>
                  <given-names>J.-M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Behar-Cohen</surname>
                  <given-names>F.</given-names>
               </name>
               <article-title>A peptide
inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced
uveitis</article-title>
               <source>Invest. Ophthalmol. Visual Sci.</source>
               <year>2010</year>
               <volume>51</volume>
               <fpage>4683</fpage>
               <lpage>4693</lpage>
            </element-citation>
         </ref>
         <ref id="ref141">
            <element-citation publication-type="journal" id="cit141">
               <name name-style="western">
                  <surname>Wiegler</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonny</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Coquoz</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hirt</surname>
                  <given-names>L.</given-names>
               </name>
               <article-title>The JNK inhibitor
XG-102 protects from ischemic damage with delayed intravenous administration
also in the presence of recombinant tissue plasminogen activator</article-title>
               <source>Cerebrovasc. Dis.</source>
               <year>2008</year>
               <volume>26</volume>
               <fpage>360</fpage>
               <lpage>366</lpage>
            </element-citation>
         </ref>
         <ref id="ref142">
            <element-citation publication-type="journal" id="cit142">
               <name name-style="western">
                  <surname>Ngoei</surname>
                  <given-names>K. R. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Catimel</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Church</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lio</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dogovski</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Perugini</surname>
                  <given-names>M. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Watt</surname>
                  <given-names>P. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cheng</surname>
                  <given-names>H. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ng</surname>
                  <given-names>D. C. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bogoyevitch</surname>
                  <given-names>M. A.</given-names>
               </name>
               <article-title>Characterization of a novel JNK (c-Jun
N-terminal kinase) inhibitory peptide</article-title>
               <source>Biochem.
J.</source>
               <year>2011</year>
               <volume>434</volume>
               <fpage>399</fpage>
               <lpage>413</lpage>
            </element-citation>
         </ref>
         <ref id="ref143">
            <element-citation publication-type="journal" id="cit143">
               <name name-style="western">
                  <surname>Ngoei</surname>
                  <given-names>K.
R. W.</given-names>
               </name>
               <name name-style="western">
                  <surname>Catimel</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Milech</surname>
                  <given-names>N.</given-names>
               </name>
               <name name-style="western">
                  <surname>Watt</surname>
                  <given-names>P. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bogoyevitch</surname>
                  <given-names>M. A.</given-names>
               </name>
               <article-title>A novel
retro-inverso peptide is a preferential JNK
substrate-competitive inhibitor</article-title>
               <source>Int. J. Biochem.
Cell Biol.</source>
               <year>2013</year>
               <volume>45</volume>
               <fpage>1939</fpage>
               <lpage>1950</lpage>
            </element-citation>
         </ref>
         <ref id="ref144">
            <element-citation publication-type="journal" id="cit144">
               <name name-style="western">
                  <surname>Kaoud</surname>
                  <given-names>T.
S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mitra</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taliaferro</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cantrell</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Linse</surname>
                  <given-names>K. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Van Den
Berg</surname>
                  <given-names>C. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dalby</surname>
                  <given-names>K. N.</given-names>
               </name>
               <article-title>Development of JNK2-selective peptide
inhibitors that
inhibit breast cancer cell migration</article-title>
               <source>ACS Chem.
Biol.</source>
               <year>2011</year>
               <volume>6</volume>
               <fpage>658</fpage>
               <lpage>666</lpage>
            </element-citation>
         </ref>
         <ref id="ref145">
            <element-citation publication-type="journal" id="cit145">
               <name name-style="western">
                  <surname>Bonny</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Oberson</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Negri</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sauser</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Schorderet</surname>
                  <given-names>D. F.</given-names>
               </name>
               <article-title>Cell-permeable peptide inhibitors
of JNK novel blockers
of beta-cell death</article-title>
               <source>Diabetes</source>
               <year>2001</year>
               <volume>50</volume>
               <fpage>77</fpage>
               <lpage>82</lpage>
            </element-citation>
         </ref>
         <ref id="ref146">
            <element-citation publication-type="journal" id="cit146">
               <name name-style="western">
                  <surname>Kaoud</surname>
                  <given-names>T. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>C. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mitra</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tseng</surname>
                  <given-names>C. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jose</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taliaferro</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tuohetahuntila</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Devkota</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sammons</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shi</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hong</surname>
                  <given-names>J. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>P. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dalby</surname>
                  <given-names>K. N.</given-names>
               </name>
               <article-title>From in silico discovery
to intracellular activity: targeting JNK-protein interactions with
small molecules</article-title>
               <source>ACS Med. Chem. Lett.</source>
               <year>2012</year>
               <volume>3</volume>
               <fpage>721</fpage>
               <lpage>725</lpage>
            </element-citation>
         </ref>
         <ref id="ref147">
            <element-citation publication-type="journal" id="cit147">
               <name name-style="western">
                  <surname>Kaoud</surname>
                  <given-names>T. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Park</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mitra</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yan</surname>
                  <given-names>C. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tseng</surname>
                  <given-names>C. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shi</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jose</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Taliaferro</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ren</surname>
                  <given-names>P. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hong</surname>
                  <given-names>J. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dalby</surname>
                  <given-names>K. N.</given-names>
               </name>
               <article-title>Manipulating JNK
signaling with (−)-zuonin A</article-title>
               <source>ACS Chem.
Biol.</source>
               <year>2012</year>
               <volume>7</volume>
               <fpage>1873</fpage>
               <lpage>1883</lpage>
            </element-citation>
         </ref>
         <ref id="ref148">
            <element-citation publication-type="journal" id="cit148">
               <name name-style="western">
                  <surname>Stebbins</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>De</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pavlickova</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Machleidt</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L.-H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuntzen</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kitada</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Karin</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pellecchia</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Design and
characterization of a potent and selective dual ATP- and substrate-competitive
subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor</article-title>
               <source>J. Med. Chem.</source>
               <year>2011</year>
               <volume>54</volume>
               <fpage>6206</fpage>
               <lpage>6214</lpage>
            </element-citation>
         </ref>
         <ref id="ref149">
            <element-citation publication-type="journal" id="cit149">
               <name name-style="western">
                  <surname>Vazquez</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>De</surname>
                  <given-names>S. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Riel-Mehan</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Emdadi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cellitti</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Stebbins</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rega</surname>
                  <given-names>M. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pellecchia</surname>
                  <given-names>M.</given-names>
               </name>
               <article-title>Development of paramagnetic probes for molecular recognition
studies in protein kinases</article-title>
               <source>J. Med. Chem.</source>
               <year>2008</year>
               <volume>51</volume>
               <fpage>3460</fpage>
               <lpage>3465</lpage>
            </element-citation>
         </ref>
         <ref id="ref150">
            <element-citation publication-type="journal" id="cit150">
               <name name-style="western">
                  <surname>Prati</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Uliassi</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bolognesi</surname>
                  <given-names>M. L.</given-names>
               </name>
               <article-title>Two diseases,
one approach: multitarget drug discovery in Alzheimer’s and
neglected tropical diseases</article-title>
               <source>MedChemComm</source>
               <year>2014</year>
               <volume>5</volume>
               <fpage>853</fpage>
               <lpage>861</lpage>
            </element-citation>
         </ref>
         <ref id="ref151">
            <element-citation publication-type="journal" id="cit151">
               <name name-style="western">
                  <surname>Gilks</surname>
                  <given-names>W. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Abou-Sleiman</surname>
                  <given-names>P. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gandhi</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jain</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Singleton</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lees</surname>
                  <given-names>A. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Shaw</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bhatia</surname>
                  <given-names>K. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bonifati</surname>
                  <given-names>V.</given-names>
               </name>
               <name name-style="western">
                  <surname>Quinn</surname>
                  <given-names>N. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lynch</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Healy</surname>
                  <given-names>D. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Holton</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Revesz</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wood</surname>
                  <given-names>N. W.</given-names>
               </name>
               <article-title>Common LRRK2 mutation
in idiopathic Parkinson’s disease</article-title>
               <source>Lancet</source>
               <year>2005</year>
               <volume>365</volume>
               <fpage>415</fpage>
               <lpage>416</lpage>
            </element-citation>
         </ref>
         <ref id="ref152">
            <element-citation publication-type="journal" id="cit152">
               <name name-style="western">
                  <surname>Geldenhuys</surname>
                  <given-names>W. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Van der Schyf</surname>
                  <given-names>C. J.</given-names>
               </name>
               <article-title>Designing
drugs with multi-target
activity: the next step in the treatment of neurodegenerative disorders</article-title>
               <source>Expert Opin. Drug Discovery</source>
               <year>2013</year>
               <volume>8</volume>
               <fpage>115</fpage>
               <lpage>129</lpage>
            </element-citation>
         </ref>
         <ref id="ref153">
            <element-citation publication-type="journal" id="cit153">
               <name name-style="western">
                  <surname>Schubert</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Maher</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>An alternative approach to drug discovery
for Alzheimer’s disease dementia</article-title>
               <source>Future
Med. Chem.</source>
               <year>2012</year>
               <volume>4</volume>
               <fpage>1681</fpage>
               <lpage>1688</lpage>
            </element-citation>
         </ref>
         <ref id="ref154">
            <element-citation publication-type="journal" id="cit154">
               <name name-style="western">
                  <surname>Zimmermann</surname>
                  <given-names>G. R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lehar</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Keith</surname>
                  <given-names>C. T.</given-names>
               </name>
               <article-title>Multi-target therapeutics:
when the whole is greater than the sum of the parts</article-title>
               <source>Drug. Discovery Today</source>
               <year>2007</year>
               <volume>12</volume>
               <fpage>34</fpage>
               <lpage>42</lpage>
            </element-citation>
         </ref>
         <ref id="ref155">
            <element-citation publication-type="journal" id="cit155">
               <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Petter</surname>
                  <given-names>R. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Baillie</surname>
                  <given-names>T. A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Whitty</surname>
                  <given-names>A.</given-names>
               </name>
               <article-title>The resurgence
of covalent drugs</article-title>
               <source>Nat. Rev. Drug Discovery</source>
               <year>2011</year>
               <volume>10</volume>
               <fpage>307</fpage>
               <lpage>317</lpage>
            </element-citation>
         </ref>
         <ref id="ref156">
            <element-citation publication-type="journal" id="cit156">
               <name name-style="western">
                  <surname>Liu</surname>
                  <given-names>Q. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Sabnis</surname>
                  <given-names>Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>Z.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>T. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Buhrlage</surname>
                  <given-names>S. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jones</surname>
                  <given-names>L. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gray</surname>
                  <given-names>N. S.</given-names>
               </name>
               <article-title>Developing
irreversible
inhibitors of the protein kinase cysteinome</article-title>
               <source>Chem. Biol.</source>
               <year>2013</year>
               <volume>20</volume>
               <fpage>146</fpage>
               <lpage>159</lpage>
            </element-citation>
         </ref>
         <ref id="ref157">
            <element-citation publication-type="journal" id="cit157">
               <name name-style="western">
                  <surname>Sanderson</surname>
                  <given-names>K.</given-names>
               </name>
               <article-title>Irreversible kinase
inhibitors gain traction</article-title>
               <source>Nat. Rev. Drug Discovery</source>
               <year>2013</year>
               <volume>12</volume>
               <fpage>649</fpage>
               <lpage>651</lpage>
            </element-citation>
         </ref>
         <ref id="ref158">
            <element-citation publication-type="journal" id="cit158">
               <name name-style="western">
                  <surname>Genova</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Rijavec</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Barletta</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burrafato</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Biello</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Dal Bello</surname>
                  <given-names>M. G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Coco</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Truini</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Alama</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boccardo</surname>
                  <given-names>F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Grossi</surname>
                  <given-names>F.</given-names>
               </name>
               <article-title>Afatinib for the treatment
of advanced non-small-cell lung cancer</article-title>
               <source>Expert
Opin. Pharmacother.</source>
               <year>2014</year>
               <volume>15</volume>
               <fpage>889</fpage>
               <lpage>903</lpage>
            </element-citation>
         </ref>
         <ref id="ref159">
            <element-citation publication-type="journal" id="cit159">
               <name name-style="western">
                  <surname>Backes</surname>
                  <given-names>A. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zech</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Felber</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Klebl</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Müller</surname>
                  <given-names>G.</given-names>
               </name>
               <article-title>Small-molecule
inhibitors binding to protein kinase.
Part II: The novel pharmacophore approach of type II and type III
inhibition</article-title>
               <source>Expert Opin. Drug Discovery</source>
               <year>2008</year>
               <volume>3</volume>
               <fpage>1427</fpage>
               <lpage>1449</lpage>
            </element-citation>
         </ref>
         <ref id="ref160">
            <element-citation publication-type="journal" id="cit160">
               <name name-style="western">
                  <surname>Zimmermann</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Buchdunger</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mett</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Meyer</surname>
                  <given-names>T.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lydon</surname>
                  <given-names>N. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Traxler</surname>
                  <given-names>P.</given-names>
               </name>
               <article-title>Phenylamino-pyrimidine
(PAP)derivatives:
a new class of potent and highly selective PDGF-receptor autophosphorylation
inhibitors</article-title>
               <source>Bioorg. Med. Chem. Lett.</source>
               <year>1996</year>
               <volume>6</volume>
               <fpage>1221</fpage>
               <lpage>1226</lpage>
            </element-citation>
         </ref>
         <ref id="ref161">
            <element-citation publication-type="journal" id="cit161">
               <name name-style="western">
                  <surname>Patricelli</surname>
                  <given-names>M. P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nomanbhoy</surname>
                  <given-names>T. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>J. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Brown</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>J. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jagannathan</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Aban</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Okerberg</surname>
                  <given-names>E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Herring</surname>
                  <given-names>C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Nordin</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weissig</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>Q. K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>J. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gray</surname>
                  <given-names>N. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kozarich</surname>
                  <given-names>J. W.</given-names>
               </name>
               <article-title>In situ kinase profiling reveals
functionally relevant
properties of native kinases</article-title>
               <source>Chem. Biol.</source>
               <year>2011</year>
               <volume>18</volume>
               <fpage>699</fpage>
               <lpage>710</lpage>
            </element-citation>
         </ref>
         <ref id="ref162">
            <element-citation publication-type="journal" id="cit162">
               <name name-style="western">
                  <surname>Knapp</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Arruda</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Blagg</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Burley</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Drewry</surname>
                  <given-names>D. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Edwards</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Fabbro</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gillespie</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gray</surname>
                  <given-names>N. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kuster</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lackey</surname>
                  <given-names>K. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Mazzafera</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Tomkinson</surname>
                  <given-names>N. C. O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Willson</surname>
                  <given-names>T. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Workman</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zuercher</surname>
                  <given-names>W. J.</given-names>
               </name>
               <article-title>A public-private
partnership to unlock the untargeted kinome</article-title>
               <source>Nat. Chem. Biol.</source>
               <year>2013</year>
               <volume>9</volume>
               <fpage>3</fpage>
               <lpage>7</lpage>
            </element-citation>
         </ref>
         <ref id="ref163">
            <element-citation publication-type="journal" id="cit163">
               <name name-style="western">
                  <surname>Zimmermann</surname>
                  <given-names>M. O.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lange</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wilcken</surname>
                  <given-names>R.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cieslik</surname>
                  <given-names>M. B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Exner</surname>
                  <given-names>T. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Joerger</surname>
                  <given-names>A. C.</given-names>
               </name>
               <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>P.</given-names>
               </name>
               <name name-style="western">
                  <surname>Boeckler</surname>
                  <given-names>F. M.</given-names>
               </name>
               <article-title>Halogen-enriched
fragment libraries as chemical probes for harnessing halogen bonding
in fragment-based lead discovery</article-title>
               <source>Future Med.
Chem.</source>
               <year>2014</year>
               <volume>6</volume>
               <fpage>617</fpage>
               <lpage>639</lpage>
            </element-citation>
         </ref>
         <ref id="ref164">
            <element-citation publication-type="journal" id="cit164">
               <name name-style="western">
                  <surname>Gallo</surname>
                  <given-names>K.
A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>G. L.</given-names>
               </name>
               <article-title>Mixed-lineage
kinase control of JNK
and p38 MAPK pathways</article-title>
               <source>Nat. Rev. Mol. Cell.
Biol.</source>
               <year>2002</year>
               <volume>3</volume>
               <fpage>663</fpage>
               <lpage>672</lpage>
            </element-citation>
         </ref>
         <ref id="ref165">
            <element-citation publication-type="journal" id="cit165">
               <name name-style="western">
                  <surname>Hirai</surname>
                  <given-names>S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kawaguchi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Suenaga</surname>
                  <given-names>J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ono</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Cui</surname>
                  <given-names>D. F.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ohno</surname>
                  <given-names>S.</given-names>
               </name>
               <article-title>Expression
of MUK/DLK/ZPK, an activator
of the JNK pathway, in the nervous systems of the developing mouse
embryo</article-title>
               <source>Gene Expression Patterns</source>
               <year>2005</year>
               <volume>5</volume>
               <fpage>517</fpage>
               <lpage>523</lpage>
            </element-citation>
         </ref>
         <ref id="ref166">
            <element-citation publication-type="journal" id="cit166">
               <name name-style="western">
                  <surname>Ghosh</surname>
                  <given-names>A. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>B.</given-names>
               </name>
               <name name-style="western">
                  <surname>Pozniak</surname>
                  <given-names>C. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Watts</surname>
                  <given-names>R. J.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewcock</surname>
                  <given-names>J. W.</given-names>
               </name>
               <article-title>DLK induces developmental
neuronal
degeneration via selective regulation of proapoptotic JNK activity</article-title>
               <source>J. Cell Biol.</source>
               <year>2011</year>
               <volume>194</volume>
               <fpage>751</fpage>
               <lpage>764</lpage>
            </element-citation>
         </ref>
         <ref id="ref167">
            <element-citation publication-type="journal" id="cit167">
               <name name-style="western">
                  <surname>Pozniak</surname>
                  <given-names>C. D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ghosh</surname>
                  <given-names>A. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Gogineni</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Hanson</surname>
                  <given-names>J. E.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>S. H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Larson</surname>
                  <given-names>J. L.</given-names>
               </name>
               <name name-style="western">
                  <surname>Solanoy</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bustos</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Li</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ngu</surname>
                  <given-names>H.</given-names>
               </name>
               <name name-style="western">
                  <surname>Jubb</surname>
                  <given-names>A. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Ayalon</surname>
                  <given-names>G.</given-names>
               </name>
               <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>J. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Scearce-Levie</surname>
                  <given-names>K.</given-names>
               </name>
               <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>Q.</given-names>
               </name>
               <name name-style="western">
                  <surname>Weimer</surname>
                  <given-names>R. M.</given-names>
               </name>
               <name name-style="western">
                  <surname>Kirkpatrick</surname>
                  <given-names>D. S.</given-names>
               </name>
               <name name-style="western">
                  <surname>Lewcock</surname>
                  <given-names>J. W.</given-names>
               </name>
               <article-title>Dual leucine zipper kinase is required for excitotoxicity-induced
neuronal degeneration</article-title>
               <source>J. Exp. Med.</source>
               <year>2013</year>
               <volume>210</volume>
               <fpage>2553</fpage>
               <lpage>2567</lpage>
            </element-citation>
         </ref>
         <ref id="ref168">
            <element-citation publication-type="journal" id="cit168">
               <name name-style="western">
                  <surname>Tedeschi</surname>
                  <given-names>A.</given-names>
               </name>
               <name name-style="western">
                  <surname>Bradke</surname>
                  <given-names>F.</given-names>
               </name>
               <article-title>The DLK signalling
pathwaya
double-edged sword in neural development and regeneration</article-title>
               <source>EMBO Rep.</source>
               <year>2013</year>
               <volume>14</volume>
               <fpage>605</fpage>
               <lpage>614</lpage>
            </element-citation>
         </ref>
         <ref id="ref169">
            <element-citation publication-type="journal" id="cit169">
               <name name-style="western">
                  <surname>Ferraris</surname>
                  <given-names>D.</given-names>
               </name>
               <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>Z. Y.</given-names>
               </name>
               <name name-style="western">
                  <surname>Welsbie</surname>
                  <given-names>D.</given-names>
               </name>
               <article-title>Dual leucine zipper
kinase as a therapeutic target for neurodegenerative conditions</article-title>
               <source>Future Med. Chem.</source>
               <year>2013</year>
               <volume>5</volume>
               <fpage>1923</fpage>
               <lpage>1934</lpage>
            </element-citation>
         </ref>
      </ref-list>
   </back>
</article>
